Reasonably designed synthetic peptide shuttle agents for polypeptide load delivery to target eukaryotic cells, uses, methods and kits thereof

By designing a peptide shuttle agent containing cell penetration and endosomal leakage domains, the problem of low delivery efficiency of peptide load in eukaryotic cells is solved, and efficient delivery of peptide load to the cytosol and nucleus is achieved, suitable for the genome Editing and Cell Therapy.

CN118909050APending Publication Date: 2024-11-08FELDAN BIO INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410666609.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2017-08-01
Filing Date
2017-10-11
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The prior art is difficult to effectively deliver the polypeptide load from the extracellular space to the cytosol and/or nucleus of the target eukaryotic cells, resulting in inefficient transduction and safety issues.

Method used

A domain-based synthetic peptide shuttle agent is designed, including the cell penetration domain (CPD) and endosomal leakage domain (ELD), and utilizing histidine-rich domain, through machine learning and computer-aided Methods Optimize peptide sequences to improve the transduction efficiency and intracellular delivery capability of peptide load.

Benefits of technology

It significantly improves the transduction efficiency of the peptide load, enables it to effectively enter the cytosol and nucleus, avoids endosomal capture, enhances intracellular delivery capabilities, and reduces toxicity, suitable for genome editing and cell therapy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_5
    Figure SMS_5
  • Figure SMS_6
    Figure SMS_6
  • Figure SMS_7
    Figure SMS_7
Patent Text Reader

Abstract

The present specification relates to methods of delivering a polypeptide load from an extracellular space to the cytosol and / or nucleus of a target eukaryotic cell. The method comprises contacting the cell with a polypeptide load in the presence of a peptide shuttle agent at a concentration sufficient to increase the transduction efficiency of the polypeptide load. Also described herein are peptide shuttles that can be used to rationally design parameters of such synthetic peptide shuttles, satisfying one or more of these design parameters, and methods and compositions relating to the delivery of a variety of polypeptide loadings (e.g., transcription factors, antibodies, CRISPR-associated nuclease enzymes, and functional genome editing complexes) from an extracellular space to the cytosol and / or nucleus of a target eukaryotic cell using synthetic peptide shuttle agents. Also described are uses and targets of NK cells for genome editing for improving immunotherapy.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] The present application is a divisional application of the Chinese patent application No. 201780076076.4 (filing date: October 11, 2017, invention name: rationally designed synthetic peptide shuttles for delivering polypeptide loads from the extracellular space to the cytosol and / or nucleus of target eukaryotic cells, their uses, methods related thereto and kits). Technical Field

[0002] The present disclosure relates to synthetic peptide shuttles for delivering a variety of polypeptide cargoes from the extracellular space to the cytosol and / or nucleus of target eukaryotic cells. More specifically, the present disclosure relates to parameters useful in the rational design of such synthetic peptide shuttles. Background Art

[0003] Cellular delivery technologies for the transport of macromolecules into eukaryotic cells have a wide range of applications, especially in the biopharmaceutical industry. Although some soluble chemicals (e.g., small molecule drugs) can passively diffuse through the eukaryotic cell membrane, larger cargoes (e.g., biologics, polynucleotides, and peptides) require the assistance of shuttle agents to reach their intracellular targets.

[0004] Areas that could benefit from advances in cell delivery technology include the fields of genome editing and cell therapy, which have made great leaps forward in the past two decades. Interpreting the different growth factors and molecular cues that control cell expansion, differentiation, and reprogramming opens the door to many therapeutic possibilities for treating unmet medical needs. For example, inducing pluripotent stem cells directly from adult cells, direct cell conversion (transdifferentiation), and genome editing (zinc finger nucleases, TALEN, and CRISPR-related endonuclease technologies) are examples of methods that have been developed to maximize the value of cell therapy for clinical applications. Currently, the production of cells with high therapeutic activity generally requires ex vivo manipulation, mainly achieved through viral transduction, which raises important safety and economic issues for human applications. The ability to directly deliver active proteins such as transcription factors or artificial nucleases in these cells can advantageously avoid safety issues and regulatory barriers associated with more dangerous gene transfer methods. In particular, methods for directly delivering active genome editing complexes in immune cells to improve immunotherapy are highly desirable.

[0005] Protein transduction methods involving the direct fusion of recombinant protein cargo to cell-penetrating peptides (e.g., HIV transactivating protein TAT) require large amounts of recombinant protein and often fail to deliver cargo to the appropriate subcellular location, resulting in extensive endosomal capture and eventual degradation. Several endosomal membrane-destroying peptides have been developed in an attempt to promote the escape of endosomally captured cargo into the cytosol. However, many of these endosomal lytic peptides have been used to mitigate endosomal retention of cargo that has already been delivered intracellularly, and they themselves cannot assist in the initial steps of shuttling cargo across the plasma membrane within cells (Salomone et al., 2012; Salomone et al., 2013; Erazo-Oliveras et al., 2014; Fasoli et al., 2014).

[0006] In particular, Salomone et al., 2012 described the chimeric peptide CM18-TAT11, which is generated by the fusion of the Tat11 cell-penetrating motif with the CM18 hybrid (residues 1-7 of cecropin-A and residues 2-12 of melittin). The peptide was reported to be rapidly internalized by cells (due to its TAT ​​motif) and subsequently led to membrane destabilization of endocytic vesicles (due to the membrane-disrupting ability of the CM18 peptide). Although the peptide CM18-TAT11 fused to the fluorescent marker Atto-633 (molecular weight 774Da; 21% of the MW of the peptide) was reported to promote the escape of endosome-trapped TAT11-EGFP into the cytosol (see Salomone et al., 2012). Figure 3 ), CM18-TAT11 peptide (alone or in combination with Atto-633) is not shown as a shuttle agent that can increase the delivery of polypeptide load from the extracellular space to the cell-i.e., through the plasma membrane. In fact, Salomone et al., 2012 compared combined treatment (simultaneous treatment of TAT11-EGFP and CM18 TAT11-Atto-633) with time-shift treatment (i.e., incubating cells with TAT11-EGFP alone, fluorescence imaging, then incubating the same cells with CM18-TAT11-Atto-633 peptide alone, and performing fluorescence imaging again), and the authors reported that "both produced the same delivery results" (see Salomone et al., 2012, page 295, the last sentence of the first paragraph under the heading of "2.9 load delivery determination"). In other words, Salomone et al., 2012 described that peptide CM18 TAT11 (alone or in combination with Atto-633) has no effect on the delivery of polypeptide load from the extracellular space to the interior of the cell (i.e., protein transduction). Therefore, there remains a need for improved shuttle agents that can increase the transduction efficiency of polypeptide cargo and deliver the cargo to the cytosol and / or nucleus of target eukaryotic cells.

[0007] This specification refers to a number of documents, the contents of which are incorporated herein by reference in their entirety. Summary of the invention

[0008] Screening a variety of different peptides, the purpose is to identify polypeptide-based shuttle agents, which can deliver independent polypeptide loads intracellularly to the cytosol / nucleus of eukaryotic cells. On the one hand, these large-scale screening efforts have led to surprising discoveries, namely certain domain-based peptide shuttle agents improve the transduction efficiency of polypeptide loads in eukaryotic cells by increasing the number and / or ratio of cells that ultimately internalize polypeptide loads, and also enable the internalized load to enter the cytosol / nucleus compartment (thereby avoiding or reducing load endosome capture). These domain-based shuttle agents include an endosome leakage domain (ELD) operably connected to a cell penetration domain (CPD), and optionally one or more histidine-rich domains. On the other hand, the above-mentioned screening efforts also reveal that some peptides do not have or have low polypeptide load transduction activity, excessive toxicity and / or other undesirable properties (e.g., poor solubility and / or stability). These empirical data (positive and negative) are used herein to identify the physiochemical properties of successful, less successful and failed peptides, so as to obtain a set of design parameters that can rationally design and / or identify peptides with protein transduction activity.

[0009] Thus, the present description relates to methods for delivering a polypeptide cargo from the extracellular space to a target cell and / or the nucleus of a target eukaryotic cell by contacting the cell with the polypeptide cargo in the presence of a peptide shuttle agent as described herein, at a concentration sufficient to increase the transduction efficiency of the polypeptide cargo compared to the absence of the shuttle agent. More specifically, the present description relates to parameters that can be used to rationally design such synthetic peptide shuttle agents, peptide shuttle agents that satisfy one or more of these design parameters, and methods and compositions for delivering a variety of polypeptide cargoes from the extracellular space to the cytosol and / or nucleus of a target eukaryotic cell using synthetic peptide shuttle agents. The present description also relates to machine learning or computer-assisted methods that can be used to generate peptide variants that respect one or more of the design parameters described herein.

[0010] This specification also relates to co-transduction target polypeptide load and marker protein, as a means of identifying and / or enriching transduced cells. Surprisingly, it was found that a significantly high proportion of target eukaryotic cells successfully transduced with the target polypeptide load were successfully transduced with the marker protein. On the contrary, a significantly high proportion of cells not transduced with the target polypeptide load were not transduced with the marker protein. Separation of cells positive for the marker protein (e.g., by FACS) resulted in a significant increase in the proportion of cells successfully transduced with the target polypeptide load, and it was found that the correlation concentration depended on the cell population showing the highest. The fluorescence of the marker protein also tends to show the highest proportion of transduction with the target polypeptide load. It was also found that cells that were not successfully transduced after the first round of transduction with the target polypeptide load can be separated and re-transduced with the target polypeptide load in subsequent transduction cycles. Therefore, in some aspects, this specification relates to a method including co-transducing the target polypeptide load with a marker protein, wherein the marker protein can be used to separate or enrich cells transduced with the target polypeptide load. In some embodiments, this specification also relates to a method for repeated continuous transduction experiments performed on cells that were not successfully transduced with a marker protein after, for example, the first or previous transduction reaction. Such methods present an attractive approach to improve transduction efficiency in valuable cell populations (e.g., patient-derived cells for cell therapy) and / or cell populations that are inherently more difficult to transduce.

[0011] General Definitions

[0012] Headings and other identifiers, such as (a), (b), (i), (ii), etc., are provided merely to facilitate reading of the specification and claims. The use of headings or other identifiers in the specification or claims does not necessarily require that the steps or elements be performed in alphabetical or numerical order or in the order in which they are presented.

[0013] When used with the term "comprising" in the claims and / or the specification, the use of the word "a" or "an" can mean "one", but it is also consistent with the meaning of "one or more", "at least one" and "one or more than one".

[0014] The term "about" is used to indicate that a value includes the standard deviation of error for the device or method used to determine the value. In general, the term "about" means that a possible variation of up to 10% is specified. Thus, the term "about" encompasses a variation of 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10% of the value. Unless otherwise indicated, the use of the term "about" before a range applies to both ends of the range.

[0015] As used in this specification and claims, the words "comprising" (and any forms of comprising, such as "includes" and "including"), "having" (and any forms of having, such as "having" and "having"), "including" (and any forms of including, such as "including" and "including"), or "including" (and any forms of including, such as "including" and "including") are inclusive or open-ended and do not exclude additional, unrecited elements or method steps.

[0016] As used herein, "protein" or "polypeptide" or "peptide" refers to any peptide-linked chain of amino acids, which may or may not contain any type of modification (e.g., post-translational modifications such as acetylation, phosphorylation, glycosylation, sulfation, SUMOylation, prenylation, ubiquitination, etc.). For further clarity, protein / polypeptide / peptide modifications are contemplated as long as the modification does not destroy the protein transduction activity of the shuttle agents described herein.

[0017] As used herein, "domain" or "protein domain" generally refers to a part of a protein with a specific functionality or function. Some domains retain their function when separated from the rest of the protein and can therefore be used in a modular manner. The modular nature of many protein domains can provide flexibility in their placement in the shuttle agents of the present specification. However, some domains may perform better when designed at certain positions of the shuttle agent (e.g., at or between the N- or C-terminal regions). The position of the domain in its endogenous protein is sometimes an indication of where the domain should be designed in the shuttle agent and what type / length of linker should be used. In view of the present disclosure, a technician can use standard recombinant DNA technology to manipulate the position and / or number of domains within the shuttle agent of the present specification. In addition, the assays disclosed herein and other assays known in the art can be used to assess the functionality of each domain within the shuttle agent (e.g., their ability to promote cell penetration through the plasma membrane, endosomal escape and / or access to the cytosol). Standard methods can also be used to assess whether the domain of the shuttle agent affects the activity of the load to be delivered within the cell. In this regard, the expression "operably linked" as used herein refers to the ability of a domain to achieve its intended function (e.g., cell penetration, endosomal escape and / or subcellular targeting) in the context of the shuttle agent of the present specification. For greater clarity, the expression "operably linked" is intended to define a functional connection between two or more domains, without being limited to a specific order or distance between them.

[0018] As used herein, the term "synthetic" used in the term "synthetic peptide" or "synthetic polypeptide" means a non-naturally occurring molecule that can be produced in vitro (e.g., a molecule that is chemically synthesized and / or produced using recombinant DNA technology). The purity of various synthetic preparations can be evaluated by, for example, high performance liquid chromatography analysis and mass spectrometry. Chemical synthesis methods may be superior to cell expression systems (e.g., yeast or bacterial protein expression systems) because they may eliminate the need for extensive recombinant protein purification steps (e.g., required for clinical use). In contrast, longer synthetic polypeptides may be more complex and / or more expensive by chemical synthesis methods, and such polypeptides may be more advantageously produced using cell expression systems. In some embodiments, in contrast to expression from recombinant host cells, the peptides or shuttle agents in this specification may be chemically synthesized (e.g., solid phase or liquid phase peptide synthesis). In some embodiments, the peptides or shuttle agents of this specification may lack an N-terminal methionine residue. Those skilled in the art may adapt the synthetic peptides or shuttle agents of this specification to meet the specific needs of stability or other needs by using one or more modified amino acids (e.g., non-naturally occurring amino acids) or by chemically modifying the synthetic peptides or shuttle agents of this specification.

[0019] When used in the context of the shuttle agents described herein, the expression "polypeptide-based" is intended to distinguish the presently described shuttle agents from non-polypeptide or non-protein shuttle agents (e.g., lipid- or cationic polymer-based transduction agents), which are often associated with increased cytotoxicity and may not be suitable for use in human therapy.

[0020] As used herein, the term "independent" generally refers to molecules or agents that are not covalently bound to each other. For example, the expression "independent polypeptide cargo" means a polypeptide cargo delivered within a cell that is not covalently bound (e.g., not fused) to the shuttle agent of the present specification. In some aspects, having a shuttle agent that is independent of (not fused to) the polypeptide cargo may be advantageous because it provides increased shuttle agent versatility - for example, there is no need to redesign new fusion proteins for different polypeptide cargoes, and / or the ratio of shuttle agent to cargo can be easily changed (as opposed to being limited to a 1:1 ratio in the case of fusion proteins).

[0021] As used herein, the expression "is or is derived from" or "derived from" includes functional variants of a given protein domain (CPD or ELD), such as conservative amino acid substitutions, deletions, modifications and variants or functional derivatives, which do not abolish the activity of the protein domain.

[0022] Other objects, advantages and features of the present specification will become more apparent from a reading of the following non-restrictive description of specific embodiments thereof, which is given by way of example only with reference to the accompanying drawings. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] In the attached picture:

[0024] Figure 1 Typical results of a calcein endosomal escape assay, in which HEK293A cells were loaded with the fluorescent dye calcein ("100 μM calcein") and then treated (or not treated) with a shuttle agent that promotes calcein endosomal escape ("100 μM calcein + CM18-TAT 5 μM"). Panel A shows the results of the fluorescence microscopy experiment, while Panel B shows the results of the flow cytometry experiment.

[0025] Figure 2 Shown are the results of a calcein endosomal escape flow cytometric assay in which HeLa cells were loaded with calcein ("Calcein 100 μM") and then treated with increasing concentrations of the shuttle agent CM18-TAT-Cys (labeled "CM18-TAT").

[0026] Figure 3 and 4 The results of calcein endosomal escape flow cytometry assay are shown, in which HeLa cells ( Figure 3 ) or primary myoblasts ( Figure 4 ) were loaded with calcein ("Calcein 100 μM") and then treated with 5 μM or 8 μM of the shuttle agent CM18-TAT-Cys or CM18-penetrant-Cys (labeled as "CM18-TAT" and "CM18-penetrant," respectively).

[0027] Figure 5 The results of GFP transduction experiments observed by fluorescence microscopy are shown, in which GFP cargo protein was co-incubated with 0, 3 or 5 μM CM18-TAT-Cys (labeled as "CM18-TAT") and then exposed to HeLa cells. Cells were observed by bright field (upper panel) and fluorescence microscopy (lower panel).

[0028] Figure 6 shows the results of a GFP transduction efficiency experiment, where GFP load protein (10 μM) was co-incubated with different concentrations of CM18-TAT-Cys (labeled "CM18-TAT") prior to exposure to HeLa cells. Cells were evaluated by flow cytometry, and the percentage of fluorescent (GFP-positive) cells is shown in Figure A, and the corresponding cytotoxicity data are shown in Figure B.

[0029] Fig. 7 shows the results of GFP transduction efficiency experiments, wherein before exposure to HeLa cells, different concentrations of GFP load protein (10, 5 or 1 μM) were co-incubated with 5 μM CM18-TAT-Cys (Fig. A, labeled "CM18TAT") or 2.5 μM dCM18-TAT-Cys (Fig. B, labeled "dCM18TAT"). Cells were assessed by flow cytometry, and the percentage of fluorescent (GFP-positive) cells is shown.

[0030] Figure 8 and 9 Results of a GFP transduction efficiency experiment are shown, in which GFP cargo protein (10 μM) was co-incubated with different concentrations and combinations of CM18-TAT-Cys (labeled "CM18TAT"), CM18-penetrating peptide-Cys (labeled "CM18penetrating peptide"), and dimers of each (dCM18-TAT-Cys (labeled "dCM18TAT"), dCM18-penetrating peptide-Cys (labeled "dCM18penetrating peptide") prior to exposure to HeLa cells. Cells were evaluated by flow cytometry, and the percentage of fluorescent (GFP-positive) cells is shown.

[0031] Fig.10 Typical results of TAT-GFP transduction experiments are shown, wherein before being exposed to HeLa cells, TAT-GFP load protein (5 μM) and 3 μM CM18-TAT-Cys (labeled as "CM18-TAT") are co-incubated. Cells and GFP fluorescence are observed by bright field and fluorescence microscopy at 10 times and 40 times magnification. Arrows indicate the endosomal delivery of TAT-GFP in the absence of CM18-TAT-Cys and its nuclear delivery in the presence of CM18-TAT-Cys.

[0032] Figure 11 shows the result of TAT-GFP transduction efficiency experiment, wherein before being exposed to HeLa cells, TAT-GFP load protein (5 μM) was incubated with CM18-TAT-Cys (labeled as "CM18TAT") of different concentrations. Cells were assessed by flow cytometry, and the percentage of fluorescent (GFP-positive) cells was shown in Figure A, and the corresponding cytotoxicity data were shown in Figure B.

[0033] Fig.12 Show typical results of GFP-NLS transduction experiments, where GFP-NLS cargo protein (5 μM) was co-incubated with 5 μM CM18-TAT-Cys (labeled "CM18-TAT") before exposure to HeLa cells for 5 minutes. Cells and GFP fluorescence were observed by bright field and fluorescence microscopy at 10x, 20x, and 40x magnification. Arrows indicate the nuclear delivery region of GFP-NLS.

[0034] Figure 13 shows the results of a GFP-NLS transduction efficiency experiment, wherein before exposure to HeLa cells, GFP-NLS load protein (5 μM) was co-incubated with different concentrations of CM18-TAT-Cys (labeled "CM18TAT"). Cells were evaluated by flow cytometry, and the percentage of fluorescent (GFP-positive) cells is shown in Figure A, and the corresponding cytotoxicity data are shown in Figure B.

[0035] Fig.14 and 15 The results of the GFP-NLS transduction efficiency experiment are shown, wherein the GFP-NLS load protein (5 μM) was co-incubated with different concentrations and combinations of CM18-TAT (labeled as "CM18TAT"), CM18-penetrating peptide (labeled as "CM18 penetrating peptide"), and dimers of each (dCM18-TAT-Cys, dCM18-penetrating peptide-Cys; labeled as "dCM18TAT" and "dCM18 penetrating peptide", respectively) before exposure to HeLa cells. Cells were evaluated by flow cytometry, and the percentage of fluorescent (GFP-positive) cells is shown.

[0036] Fig.16 The results of GFP-NLS transduction efficiency experiments are shown, wherein GFP-NLS load protein (5 μM) was co-incubated with CM18-TAT-Cys alone (3.5 μM, labeled "CM18TAT") or with dCM18-penetrating peptide-Cys (1 μM, labeled "dCM18pen") for 5 minutes or 1 hour in pure DMEM medium ("DMEM") or DMEM medium containing 10% FBS ("FBS") before flow cytometry analysis. The percentage of fluorescent (GFP-positive) cells is shown. Cells treated with GFP-NLS without a shuttle agent or GFP-NLS ("control") and cells treated with GFP-NLS without a shuttle agent (GFP-NLS 5 μM) were used as controls.

[0037] Figure 17 shows the results of a GFP-NLS transduction efficiency experiment in which GFP-NLS load protein (5 μM) was co-incubated with or without 1 μM CM18-TAT-Cys (labeled "CM18TAT") prior to exposure to THP-1 cells. Cells were assessed by flow cytometry, and the percentage of fluorescent (GFP-positive) cells is shown in Figure A, and the corresponding cytotoxicity data are shown in Figure B.

[0038] Fig.18Shown are the results of a transduction efficiency experiment in which a FITC-labeled anti-tubulin antibody (0.5 μM) was co-incubated with 5 μM CM18-TAT-Cys (labeled "CM18-TAT") prior to exposure to HeLa cells. Functional antibody delivery was observed by bright field (20x) and fluorescence microscopy (20x and 40x), where fluorescent tubulin fibers were visible in the cytoplasm.

[0039] Figure 19 shows the results of FITC-labeled anti-tubulin antibody transduction efficiency experiments, wherein before being exposed to HeLa cells, antibody load protein (0.5 μM) and 3.5 μM CM18-TAT-Cys (labeled as "CM18TAT"), CM18-penetrating peptide-Cys (labeled as "CM18pen") or dCM18-penetrating peptide-Cys (labeled as "dCM18pen") or 3.5 μM CM18-TAT-Cys and 0.5 μM dCM18-penetrating peptide-Cys combination were incubated together. Cells were assessed by flow cytometry, and the percentage of fluorescent (GFP-positive) cells was shown in Figure A, and the corresponding cytotoxicity data were shown in Figure B.

[0040] Fig. 20 Shown are the results of a DNA transfection efficiency experiment in which DNA was transfected with Cy5 TM Dye-labeled plasmid DNA (pEGFP) was co-incubated with 0, 0.05, 0.5, or 5 μM CM18-TAT-Cys (labeled as “CM18-TAT”). Flow cytometric analysis allowed quantification of Cy5 TM emission (corresponding to intracellular delivery of DNA; y-axis) and GFP emission (corresponding to successful nuclear delivery of DNA; percentages indicated on each bar).

[0041] Figure 21 shows the results of a GFP-NLS transduction efficiency experiment, wherein before exposure to HeLa cells, GFP-NLS load protein (5 μM) was co-incubated with 1, 3 or 5 μM of CM18-TAT-Cys (labeled "CM18TAT"), His-CM18-TAT (labeled "His-CM18TAT"). Cells were evaluated by flow cytometry, and the percentage of fluorescent (GFP-positive) cells is shown in Figure A, and the corresponding cytotoxicity data are shown in Figure B.

[0042] Figure 22 shows the results of transduction efficiency experiments, wherein shuttle His-CM18-PTD4 was used to deliver GFP-NLS cargo protein in HeLa cells. GFP-NLS transduction efficiency was assessed by flow cytometry and the percentage of GFP fluorescent cells ("positive cells (%)") and corresponding cell viability data ("viability (%)") were displayed. Figure A shows a comparison of GFP-NLS transduction efficiencies using different transduction schemes (Scheme A vs. B). Figure B shows the effect of using different concentrations of shuttle His-CM18-PTD4 when using Scheme B.

[0043] Figures 23-26 are microscopic images showing the results of transduction experiments in which GFP-NLS (Figures 23, 24A, 24B, 25 and 26) or FITC-labeled anti-tubulin antibody ( Fig.24C and 24D ) Load protein was delivered intracellularly in HeLa cells using the shuttle His-CM18-PTD4. Bright field and fluorescence images of live cells are shown in Figures 23, 24 and 26. In Figure 25, cells were fixed, permeabilized and immunolabeled with anti-GFP antibody and fluorescent secondary antibody. White triangle windows indicate examples of co-labeled areas between nuclear (DAPI) and GFP-NLS signals. Fig.26 Images captured by confocal microscopy are shown.

[0044] Figure 27 shows microscopy images of a kinetic (time course) transduction experiment in HeLa cells, where the fluorescence of the GFP-NLS cargo protein was tracked 45, 75, 100 and 120 seconds after intracellular delivery using the shuttle His-CM18-PTD4. The diffuse cytoplasmic fluorescence pattern observed after 45 seconds (Panel A) gradually changed to a more concentrated nuclear pattern at 120 seconds (Panel D).

[0045] FIG28 shows microscopic images of a co-delivery transduction experiment in which two cargo proteins (GFP-NLS and mCherry TM Simultaneous intracellular delivery of GFP-NLS in HeLa cells by shuttling His-CM18-PTD4. Cells and fluorescence signals were observed by (A) bright field and (B) fluorescence microscopy. White triangle windows indicate nuclei (DAPI) and GFP-NLS or mCherry TM Examples of co-labeled regions between .

[0046] Figure 29 shows the results of GFP-NLS transduction efficiency experiments in HeLa cells using different shuttle agents or single domain / control peptides. GFP-NLS transduction efficiency was assessed by flow cytometry and GFP fluorescent cell percentages ("positive cells (%)") and corresponding cell viability data ("viability (%)") were displayed in Figures A, B, DG and I. In Figures A and DF, cells were exposed to load / shuttle agents for 10 seconds. In Figure I, cells were exposed to load / shuttle agents for 1 minute. In Figures B, C, G and H, cells were exposed to load / shuttle agents for 1, 2 or 5 minutes. "Relative fluorescence intensity (FL1-A)" or "signal intensity" corresponds to the average value of all fluorescence intensities of each cell with GFP fluorescence signal from GFP-NLS fluorescent protein after delivery with shuttle agents. Figure D shows the results of control experiments, in which only single domain peptides (ELD or CDP) or peptide His-PTD4 (His-CPD) were used for GFP-NLS transduction instead of multi-domain shuttle agents.

[0047] Figure 30 shows microscopic images of HeLa cells transduced with GFP-NLS using shuttle agents (A) TAT-KALA, (B) His-CM18-PTD4, (C) His-C(LLKK)3C-PTD4, (D) PTD4-KALA, (E) EB1-PTD4, and (F) His-CM18-PTD4-His. The inset in the bottom row shows the results of the corresponding flow cytometry analysis, indicating the percentage of cells exhibiting GFP fluorescence.

[0048] Fig.31 Results of transduction efficiency experiments are shown, in which the shuttle His-CM18-PTD4 was used to deliver GFP-NLS cargo intracellularly in THP-1 cells using different protocols (Protocol A vs. C). GFP-NLS transduction efficiency was assessed by flow cytometry and the percentage of GFP fluorescent cells ("Positive Cells (%)") and corresponding cell viability data ("Viability (%)") are shown. "Control" corresponds to THP-1 cells exposed to GFP-NLS cargo in the absence of the shuttle agent.

[0049] Figure 32 shows microscope images of THP-1 cells transduced with GFP-NLS load protein using shuttle His-CM18-PTD4. Images taken at 4x, 10x and 40x magnification are shown in Figures A-C, respectively. The white triangle window in Figure C indicates an example of a co-labeled region between cells (bright field) and GFP-NLS fluorescence. Figure D shows the results of the corresponding flow cytometry analysis, indicating the percentage of cells presenting GFP fluorescence.

[0050] Figure 33 shows microscopy images of THP-1 cells transduced with GFP-NLS cargo protein using shuttle His-CM18-PTD4. White triangular windows indicate examples of co-labeled areas between cells (bright field; panels A and B) and GFP-NLS fluorescence (panels C and D).

[0051] Figure 34 shows the results of the GFP-NLS transduction efficiency experiment using shuttle TAT-KALA, His-CM18-PTD4 or His-C (LLKK) 3C-PTD4 in THP-1 cells. Load protein / shuttle agent was exposed to THP-1 cells for 15, 30, 60 or 120 seconds. The GFP-NLS transduction efficiency was assessed by flow cytometry and the percentage of GFP fluorescent cells ("positive cells (%)") and corresponding cell viability data ("vitality (%)") were shown in Figure A. In Figure B, "Relative fluorescence intensity (FL1-A)" corresponds to the mean value of all fluorescence intensities of each cell with GFP fluorescence signal from the GFP-NLS fluorescent protein after being delivered with a shuttle agent.

[0052] Figure 35 shows the results of transduction efficiency experiments, in which THP-1 cells were exposed to GFP-NLS load for 2.5 hours every day in the presence of shuttle agents. His-CM18-PTD4 was used in Figure AE and His-C(LLKK)3C-PTD4 was used in Figure F. The GFP-NLS transduction efficiency was determined by flow cytometry on the 1st and 3rd days, and the results were expressed as the percentage of GFP fluorescent cells ("Positive cells (%)") and the corresponding cell viability data ("Vitality (%)") in Figure AC and F. For cells exposed to the His-CM18-PTD4 shuttle agent, Figure D shows the metabolic activity index of THP-1 cells after 1, 2, 4 and 24h, and Figure E shows the metabolic activity index of THP-1 cells after 1-4 days.

[0053] Fig.36 Shown is a comparison of the GFP-NLS transduction efficiency of the shuttle His-CM18-PTD4 in various cell types (e.g. adherent and suspension, as well as cell lines and primary cells) as measured by flow cytometry. The results are expressed as the percentage of GFP fluorescent cells ("Positive Cells (%)") and the corresponding cell viability data ("Viability (%)").

[0054] Figure 37 shows fluorescence microscopy images of different types of cells (AH) transduced with GFP-NLS payload using shuttle His-CM18-PTD4. GFP fluorescence was observed at 10x magnification by fluorescence microscopy. Parallel flow cytometry experimental results (viability and percentage of GFP fluorescent cells) are also provided in the inset.

[0055] Figure 38 shows fluorescence microscopy images of primary human myoblasts transduced with GFP-NLS using shuttle His-CM18-PTD4. Cells were fixed and permeabilized before immunolabeling GFP-NLS with anti-GFP antibody and fluorescent secondary antibody. Immunolabeled GFP is shown in Figure A, and the image overlaps with the nuclear (DAPI) labeling in Figure B.

[0056] Figure 39 shows a schematic diagram (A, B and C) and sample fluorescence images (D and E) of a transfection plasmid replacement assay for evaluating the activity of intracellular delivered CRISPR / Cas9-NLS complexes. (A) On day 1, cells were transfected with a plasmid encoding the fluorescent protein mCherry TM Cells were transfected with expression plasmids for mCherry and GFP, with a stop codon separating their two open reading frames. Transfection of cells with the expression plasmid resulted in mCherryTM expression only (D). The CRISPR / Cas9-NLS complex, which had been designed / programmed to cleave the plasmid DNA at the stop codon, was then delivered intracellularly to the mCherry expression plasmid. TM Transfected cells produce double-stranded cleavage of plasmid DNA at the stop codon (B). In a subset of cells, random nonhomologous DNA repair of the cleaved plasmid occurs and results in the removal of the stop codon (C), thereby eliminating GFP expression and fluorescence (E). White triangle windows indicate mCherry TM Examples of co-labeled regions of GFP and GFP fluorescence.

[0057] Figure 40 shows the expression of mCherry TM Fluorescence microscopy images of HeLa cells expressing GFP and CRISPR / Cas9-NLS mediated cleavage of plasmid replacement DNA. In Figures AD, HeLa cells were co-transfected with three plasmids: a plasmid replacement as described in the overview of Figure 39, and two other expression plasmids encoding Cas9-NLS protein and crRNA / tracrRNA, respectively. CRISPR / Cas9-mediated cleavage of the plasmid replacement at the stop codon and subsequent DNA repair by the cell allows GFP (Figures B and D) as well as mCherry TM In Figures EH, HeLa cells were transfected with plasmid surrogates using the shuttle His-CM18-PTD4 and subsequently transduced with an active CRISPR / Cas9-NLS complex. CRISPR / Cas9-mediated cleavage of the plasmid surrogates at the stop codon and subsequent DNA repair by the cells allowed the expression of GFP (Figures F and H) as well as mCherry TM (Figures E and G) expression.

[0058] Fig.41AShow the product of DNA cleavage assay (T7E1 assay) separated by agarose gel electrophoresis, which is used to measure the cleavage of CRISPR / Cas9-mediated cell genomic DNA. HeLa cells were transduced with a CRISPR-Cas9-NLS complex programmed to cleave the PPIB gene. The appearance of cleavage products in white boxes 1 and 2 indicates cleavage of the PPIB gene by a CRISPR-Cas9-NLS complex (which uses shuttle His-C (LLKK) 3C-PTD4 (lane B) or intracellular delivery of a lipid transfection agent (lane D) used as a positive control). The cleavage product is not present in the negative control (lanes A and C).

[0059] Fig.41B Shown are products of a DNA cleavage assay (T7E1 assay) separated by agarose gel electrophoresis, which is used to measure CRISPR / Cas9-mediated cleavage of cellular genomic DNA (PPIB DNA sequence). The left panel shows the cleavage products of the PPIB DNA sequence amplified by the CRISPR / Cas9 complex after delivery of the complex with the shuttle agent His-CM18-PTD4 in HeLa cells. The right panel shows the DNA sequence amplified before the T7E1 digestion procedure as a negative control.

[0060] Fig.41C Shown are products of a DNA cleavage assay (T7E1 assay) separated by agarose gel electrophoresis, which is used to measure CRISPR / Cas9-mediated cleavage of cellular genomic DNA (PPIB DNA sequence). The left panel shows the amplified PPIB DNA sequence after incubation of HeLa cells with Cas9 / RNA complexes in the presence of a lipid transfection agent (DharmaFect TM Transfection reagent #T-20XX-01) (positive control). The right panel shows the amplified DNA sequence before the T7E1 digestion procedure as a negative control. Figure 42-44 The transcriptional activity of THP-1 cells transduced with the transcription factor HOXB4 using different concentrations of the shuttle His-CM18-PTD4 and different load / shuttle agent exposure times is shown. Successful intranuclear delivery of HOXB4 was determined by monitoring the mRNA levels of the target gene by real-time PCR, and the results were normalized to those in the negative control (HOXB4 without the shuttle agent) and expressed as "folds over the control" (left side bar graph). Total cellular RNA (ng / μL) was quantified and used as a marker of cell viability (right side bar graph). Or “control” means “no treatment”; “TF” means “transcription factor only”; “FS” means “shuttle agent only”.

[0061] Figure 45 shows fluorescence microscopy images of HeLa cells transduced with wild-type HOXB4 cargo using the shuttle His-CM18-PTD4. After 30 minutes of incubation to allow transduced HOXB4-WT to accumulate in the nucleus, cells were fixed, permeabilized and labeled with primary anti-HOXB4 monoclonal antibody and fluorescent secondary antibody (panels B and D). Nuclei were labeled with DAPI (panels A and C). White triangular windows indicate examples of co-labeled areas between nuclei and HOXB4 - compare A vs. B (x20 magnification) and C vs. D (x40 magnification).

[0062] Figure 46 shows the products of DNA cleavage assays separated by agarose gel electrophoresis, which are used to measure CRISPR / Cas9-mediated cleavage of cellular genomic DNA (HPTR sequence) after intracellular delivery of complexes with different shuttle agents. Figure A shows the results of using the following shuttle agents in HeLa cells: His-CM18-PTD4, His-CM18-PTD4-His and His-C(LLKK)3C-PTD4. Figure B shows the results of using His-CM18-PTD4-His and His-CM18-L2-PTD4 in Jurkat cells. The negative control (lane 4 in Figures A and B) shows the HPTR DNA sequence amplified after incubation of cells with CRISPR / Cas9 complexes without the presence of shuttle agents. The positive control (lane 5 in Figures A and B) shows the HPTR DNA sequence amplified after incubation of cells with CRISPR / Cas9 complexes in the presence of commercially available lipid transfection agents.

[0063] Fig.47 The transcriptional activity of THP-1 cells transduced with the transcription factor HOXB4 using the shuttle agents His-CM18-PTD4, TAT-KALA, EB1-PTD4, His-C(LLKK)3C-PTD4 and His-CM18-PTD4-His is shown. The successful intranuclear delivery of HOXB4 is determined by monitoring the mRNA levels of the target gene by real-time PCR, and the results are normalized to those in the negative control (HOXB4 without shuttle agent) and expressed as "multiples over the control" (left side bar graph). Total cellular RNA (ng / μL) is quantified and used as a marker of cell viability (right side bar graph). Or “control” means “no treatment”; “TF” means “transcription factor only”; “FS” means “shuttle agent only”.

[0064] Fig.48In vivo GFP-NLS delivery in rat parietal cortex by His-CM18-PTD4 is shown. In brief, GFP-NLS (20 μM) was injected into the parietal cortex of rats for 10 minutes in the presence of shuttle agent His-CM18-PTD4 (20 μM). Ventral rat brain slices were collected and analyzed by fluorescence microscopy at (A) 4x, (C) 10x and (D) 20x magnification. The injection site is located in the deepest layer of the parietal cortex (PCx). In the presence of His-CM18-PTD4 shuttle agent, GFP-NLS diffuses in the nuclei of PCx, corpus callosum (Cc) and striatum (Str) (white curve marks the limit between brain structures). Figure B shows the stereoscopic coordinates of the injection site (black arrow) from the rat brain atlas of Franklin and Paxinos. Injection of GFP-NLS in the presence of His-CM18-PTD4 was performed in the left part of the brain, and a negative control (injection of GFP-NLS alone) was performed in the contralateral part. The black circles and black lines in panel B show the areas observed in the fluorescent images (A, C, and D).

[0065] Fig.49A and 49B The helical wheel (left) and the "open cylinder" (right) of the peptides FSD5 and VSVG PTD4 are shown, respectively. The geometry of each amino acid residue corresponds to its biochemical properties (i.e., hydrophobicity, charge, or hydrophilicity) based on the residue side chain. One of the main differences between the two open cylinder representations of FSD5 and VSVG-PTD4 is the presence of a highly hydrophobic core in FSD5 (in Fig.49A , left and right), which is absent in VSVG PTD4. Fig.49A and 49B The cylinders in the lower middle panel represent a simplified form of the open cylindrical representation in the right panel, where: “H” represents a high hydrophobic surface area; “h” represents a low hydrophobic surface area; “+” represents a positively charged residue; and “h” represents a hydrophilic residue.

[0066] Figures 49C-49F Predicted three-dimensional models of the structures of peptides FSD5, FSD18, VSVG PTD4 and FSD44 are shown, respectively.

[0067] Figure 49G Display peptides His-CM18-PTD4; EB1-PTD4; His-C(LLKK) 3 Multiple sequence alignment of C-PTD4; FSD5; FSD10; FSD19; FSD20; FSD21; FSD44; FSD46; and FSD63, along with the “identity” score for each residue position. For the purpose of alignment, the histidine-rich domain was voluntarily excluded.

[0068] Figures 50A-50C Shown are microscopy images of live HeLa cells successfully transduced by the shuttle agent FSD5, with fluorescently labeled antibodies as cargo. Fig.50A Goat anti-rabbit IgG H&L (Alexa Fluor 500, 500 ng / ml) visualized at 20x magnification by bright field (upper panel) and fluorescence microscopy (lower panel) are shown. 594) Cytoplasmic transduction of antibodies. Fig.50B and 50C Goat anti-mouse IgG H&L (Alexa Fluor) visualized at 10x and 20x magnification by bright field (upper panel) and fluorescence microscopy (lower panel), respectively, are shown. 488) Cytoplasmic transduction of antibodies.

[0069] Fig.50D The results of a transduction experiment are shown in which an anti-NUP98 antibody that recognizes an antigen in the perinuclear membrane was transduced into HeLa cells using the shuttle agent FSD19. After transduction, the HeLa cells were fixed, permeabilized, and stained with a fluorescent (Alexa Fluor) TM 488) secondary antibody (left panel) and Hoechst nuclear staining (right panel). The upper and lower panels represent images taken at 20x and 40x magnification, respectively.

[0070] Figures 51A-51F The results of genome editing experiments are shown, in which CRISPR / Cas9-NLS genome editing complexes were transduced into different cell types (HeLa, NK cells, NIC-H196 cells, HCC-78 cells and REC-1 cells). Different shuttle peptides (FSD5, FSD8, FSD10, FSD18) and successful genome editing were verified by genomic DNA cleavage assays. The CRISPR / Cas9-NLS complex consists of recombinant Cas9-NLS, which is complexed with crRNA / tracrRNA designed to cut HPRT genomic DNA sequences. Successful genome editing was observed by detecting genomic DNA cleavage products (thick solid arrows) compared to uncut genomic target genes (thin dashed arrows). Negative controls (-ctrl") are from transduction experiments performed in the absence of any shuttle peptide. The relative signal intensities of the cleavage product bands were quantified directly on the gel using imaging software. The sum of all bands in a given lane corresponds to 100% of the signal, and the italicized values ​​at the bottom of each lane are the sum of the relative signals (%) of only the two cleavage product bands (thick solid arrows).

[0071] Figure 51GCleavage of the targeted HPRT genomic sequence by the CRISPR / Cas9-NLS complex transduced by FSD5 in the absence ("No Template") or presence ("+500ng") of a short DNA template (72 bp) is shown. The thin dashed arrow indicates the band corresponding to the target gene, and the thick solid arrow indicates the band corresponding to the CRISPR / Cas9-NLS-mediated cleavage product of the target gene, indicating successful transduction of a fully functional genome editing complex in the presence and absence of a DNA template. The italicized values ​​at the bottom of each lane are the sum of the relative signals (%) of only the two cleavage product bands (thick solid arrows). Fig.51H Shows the use of primer pairs specific for short DNA templates Figure 51G The results of PCR amplification of samples showed that the DNA template sequence was inserted into the genome (see Fig.51H ).

[0072] Fig.51I Cleavage of the targeted HPRT genomic sequence by the CRISPR / Cas9-NLS complex transduced by FSD5 in the absence ("No Template") or presence ("+500ng") of a long linear DNA template (1631 bp) is shown. The thin dashed arrow indicates the band corresponding to the target gene, and the thick solid arrow indicates the band corresponding to the CRISPR / Cas9-NLS-mediated cleavage product of the target gene, indicating successful transduction of a fully functional genome editing complex in the presence and absence of a DNA template. The italicized values ​​at the bottom of each lane are the sum of the relative signals (%) of only the two cleavage product bands (thick solid arrows). Fig.51J The use of primers designed to amplify the genomic cleavage site is shown. Fig.51I PCR amplification results for a sample. Genomic insertion of the long DNA template sequence can be seen by the presence of larger bands in the "+500ng" (faint) and "+1000ng" (darker) lanes - see Fig.51J Arrow in the.

[0073] Figure 51K and 51L shows that after PCR amplification and agarose gel electrophoresis separation, in HeLa ( Figure 51K ) and NK cells ( Figure 51L) in the absence ("-ctrl") or presence of the shuttle agent FSD18. The thin dashed arrow indicates the band corresponding to the target gene, and the thick solid arrow indicates the band corresponding to the CRISPR / Cpf1-NLS-mediated cleavage product of the target gene, which indicates the successful transduction of the fully functional genome editing complex. The relative signal intensity of each different band was quantified directly on the gel using imaging software. The sum of all bands in a given lane corresponds to 100% of the signal, and the italicized numerical value at the bottom of each lane is the sum of the relative signals (%) of only the two cleavage product bands (thick solid arrows). Transfection was performed using the lipofectamine-based transfection reagent CRISPRMAX TM No genomic DNA cleavage was observed upon transduction of the CRISPR / Cpf1-NLS genome editing complex.

[0074] Figures 52A-52E Shown are the results of the following separation by agarose gel electrophoresis in the absence ("-ctrl") or presence of the shuttle agents FSD10, FSD18, FSD19, FSD21, FSD23 or FSD43 used at different concentrations, exposure times and in different cell types: THP-1 ( Fig.52A );NK( Fig.52B -D) and HeLa( Fig.52E ) with CRISPR / Cas9-NLS and crRNA / tracrRNA or with CRISPR / Cpf1-NLS and a single guide RNA to cut the target genomic B2M DNA sequence. The cells were incubated with the CRISPR / Cpf1 complex and the FSD shuttle agent at the specified time and concentration. The thin dotted arrows represent the bands corresponding to the target gene, and the thick solid arrows represent the bands corresponding to the CRISPR system-mediated cleavage products of the target gene, indicating the successful transduction of the fully functional CRISPR / Cas9 NLS genome editing complex. The relative signal intensity of each different band was quantified directly on the gel using imaging software. The sum of all bands in a given lane corresponds to 100% of the signal, and the italic values ​​at the bottom of each lane are the sum of the relative signals (%) of only two cleavage product bands (thick solid arrows).

[0075] Figures 52F-52I Shown are the results of the following separation by agarose gel electrophoresis in the absence ("-ctrl") or presence of the shuttle agents FSD10, FSD18, FSD19 or FSD23 used at different concentrations, exposure times and in different cell types: NK ( Fig.52F -G);THP-1( Fig.52H ) and primary myoblasts ( Fig.52I) using CRISPR / Cpf1-NLS and a single guide crRNA to cleave the target genomic GSK3 ( Fig.52F ), CBLB( Figure 52G ) and DNMT1( Fig.52H -I) DNA sequence results. Cells were incubated with CRISPR / Cpf1 complexes and FSD at the indicated time and concentration. Thin dashed arrows indicate bands corresponding to target genes, and thick solid arrows indicate bands corresponding to CRISPR system-mediated cleavage products of these target genes, indicating successful transduction of fully functional CRISPR / Cpf1 NLS genome editing complexes.

[0076] Figures 52J-52N Shown are the results of the experiments in the absence (“-ctrl”) or presence of the shuttle agents FSD10, FSD21, FSD22 or FSD23 used at different concentrations, exposure times and in NK cells ( Figures 52F-52G ) and NK-92 cells ( Fig.52H ) with CRISPR / Cpf1-NLS and a single guide crRNA to cleave the target genomic NKG2A DNA sequence. The cells were incubated with the CRISPR / Cpf1 complex for the specified incubation time and concentration. The thin dotted arrows represent the bands corresponding to the target gene, and the thick solid arrows represent the bands corresponding to the CRISPR system-mediated cleavage products of the target gene, indicating the successful transduction of a fully functional CRISPR / Cpf1 NLS genome editing complex.

[0077] Figures 53A-53C Results are shown for cleavage of target genomic HPRT, DNMT1, and B2M DNA sequences using the CRISPR system. Two genomic HPRT and DNMT1 sequences were targeted in HeLa cells using CRISPR / Cas9-NLS and CRISPR / Cpf1-NLS genome editing complexes designed for these purposes transduced with the shuttle peptide FSD18. Fig.53A )DNA sequence or two DNA loci on exon 2 of genome B2M ( Fig.53B ). After separation by agarose gel electrophoresis, two DNA loci on genomic B2M exon 2 were targeted in NK cells with CRISPR / Cpf1-NLS and a single guide crRNA-1, crRNA-2, or both in the absence (“-ctrl”) or presence of the shuttle agents FSD10, FSD21, or FSD23 used at different concentrations, exposure times ( Fig.53C). The thin dashed arrows indicate the bands corresponding to the target gene, and the thick solid arrows indicate the bands corresponding to the CRISPR / Cpf1-mediated cleavage products in the presence of crRNA-1 or crRNA2 or both (crRNA1+2) targeting B2M exon 2, indicating the successful transduction of a fully functional CRISPR / Cpf1 NLS genome editing complex.

[0078] Figures 54A-54D Shown are the results of a flow cytometry assay in which T cells were treated with increasing concentrations of the shuttle agent FSD21 ( Fig.54B 8 μM, Fig.54C 10 μM, Fig.54D 12 μM in ), 1.33 μM of CRISPR / Cpf1-NLS system and 2 μM single guide crRNA treatment targeting B2M genomic DNA sequence. 72 hours after treatment, HLA positive and HLA negative (B2M knockout) cells were identified by using APC-labeled mouse anti-human HLA-ABC antibody. The left-shifted cell population indicates the successful inactivation of cell surface HLA receptors, which is caused by the inactivation of the B2M gene.

[0079] Figures 55A-55D Shown are the results of a flow cytometry assay in which T cells were treated with increasing concentrations of the shuttle agent FSD18 ( Fig.55B 8 μM, Fig.55C 10 μM, Fig.55D 12μM), 1.33μM CRISPR / Cpf1-NLS system and 2μM single guide crRNA targeting B2MDNA sequence were processed. 72 hours after treatment, HLA positive and HLA negative (B2M knockout) cells were identified by using APC-labeled mouse anti-human HLA-ABC antibody. The left-shifted cell population indicates the successful inactivation of cell surface HLA receptors, which is caused by the inactivation of the B2M gene.

[0080] Figures 56A-56E Shown are the results of a flow cytometry assay in which THP-1 cells were treated with a mixture of 1.33 μM CRISPR / Cpf1-NLS system, 2 μM one or three guide crRNAs each targeting a different site within the B2M genomic DNA sequence, and 3 μM FSD18 ( Figures 56B-56E ) or not processed (“unprocessed”, Fig.56A ). 48 hours after treatment, the untreated cells ( Fig.56A ), cells treated with crRNA E ( Fig.56B ), cells treated with crRNA G ( Fig.56C ), cells treated with crRNA J ( Fig.56D ) and cells treated with crRNA E+G+J ( Fig.56E ) APC-labeled mouse anti-human HLA-ABC antibody was used to identify HLA-positive and HLA-negative (B2M knockout) cells. The left-shifted cell population indicates successful inactivation of cell surface HLA receptors due to inactivation of the B2M gene.

[0081] Fig.57A and 57B Results of experiments are shown in which NK-92 cells were genome edited to determine whether inactivation of the endogenous NKG2A gene could increase its ability to kill target HeLa cells. Briefly, NK-92 cells were transduced with a CRISPR / Cpf1-NLS genome editing complex designed to cleave the NKG2A gene using the shuttle agent peptide FSD23. After transduction, NK-92 cells were immunolabeled with a phycoerythrin (PE)-labeled anti-NKG2A antibody and then analyzed by flow cytometry, as shown in Figure 2. Fig.57A As shown, to verify the successful inactivation of NKG2A. As a control, unlabeled wild-type NK-92 cells ("unlabeled WT cells") had no antibody signal, and labeled wild-type NK-92 cells ("labeled WT cells") had a complete immune labeling signal. For NKG2A-KO NK-92 cells, two cell populations (peaks) were observed: one with complete knockout of NKG2A receptor expression on the cell surface ("complete NKG2A KO cells"), and the other cell population partially lacked expression ("partial NKG2A KO cells"). Fig.57B Results of a cytotoxicity assay are shown, in which target HeLa cells previously loaded with an intracellular fluorescent dye (calcein) were exposed to wild-type (solid line) or genome-edited NKG2A-KO (dashed line) effector NK-92 cells at different effector:target ratios (E:T ratios). Cytotoxicity was assessed by the relative release of intracellular calcein into the extracellular space resulting from cell membrane disruption of target HeLa cells (% cell cleavage").

[0082] Figures 58A-58F Shown are the results of a flow cytometry assay in which T cells were treated with a mixture of GFP-NLS, a CRISPR / Cpf1-NLS complex designed to cleave the B2M genomic DNA sequence, and the shuttle agent FSD18 ( Figures 58A-58F ) or not processed (“unprocessed”, Fig.58A ). Fig.58B and 58C The results of two-dimensional flow cytometric analysis based on GFP fluorescence (x-axis) and cell surface HLA expression (y-axis) after 5 hours of treatment are shown. Fig.58E ) and GFP positive fraction ( Fig.58F) of cells by fluorescence activated cell sorting ( Fig.58D ) resulted in an increase in the proportion of genome-edited (HLA-negative) cells to 29.7% of the GFP-positive fraction ( Fig.58F ). Each cell fraction was then subjected to a standard T7E1 cleavage assay followed by agarose gel electrophoresis to assess the effectiveness of genome editing. The results are shown in Figure 58G In the figure, the thin dotted arrows indicate the bands corresponding to the target genes, and the thick solid arrows indicate the bands corresponding to the cleavage products mediated by the CRISPR system of the target genes. The values ​​at the bottom of lanes 2, 3, and 4 correspond to the relative signal intensity (%) of the cleavage product bands (solid arrows) in the lanes.

[0083] Figures 59A-59E Shown are the results of a flow cytometry assay in which T cells were treated with a mixture of GFP-NLS, a CRISPR / Cpf1-NLS complex designed to cleave the endogenous B2M gene, and the shuttle agent FSD18 ( Figures 59C-59E ) or not processed (“unprocessed”, Fig.59A and 59B ). Fig.59A and 59B Results are shown for “untreated” negative control cells that were not exposed to peptide shuttles, GFP, and CRISPR / Cpf1 and analyzed by flow cytometry for GFP fluorescence ( Fig.59A ) and cell surface HLA expression ( Fig.59B ). T cells were co-transduced with both GFP-NLS and CRISPR / Cpf1 via peptide FSD18, and the resulting GFP fluorescence distribution is shown in Fig.59C . Fig.59C The two gates shown in the figure represent the cell fraction considered to be GFP positive ("GFP+"; 93.2%; solid gate) and the cell subfraction considered to exhibit high GFP fluorescence ("GFP high"; 33.1%; dashed gate). Fig.59E ) were compared to fluorescence-activated cell sorting to quantify cell surface HLA expression levels in cells considered GFP-positive ( Fig.59D The above co-transduction experiment was repeated using 12 μM or 15 μM FSD18, and then fluorescence activated cells were sorted into GFP positive and GFP negative cell fractions. A standard T7E1 cleavage assay was performed on each fraction, and different samples were subjected to agarose gel electrophoresis.

[0084] FIG60 shows the results of flow cytometry analysis in which T cells were first transduced with the peptide FSD18 and loaded with GFP-NLS ( Fig.60B ) or not (“untreated”, Fig.60AThe first transduction resulted in a GFP-NLS transduction efficiency of 55.4% ( Fig.60B ). Fluorescence activated cell sorting was performed after the first transduction to isolate GFP-negative cells ( Fig.60C ), and the GFP-negative cell population was transduced a second time with GFP-NLS using peptide FSD18. The results of this second transduction are shown in Fig.60D In this study, the GFP-NLS transduction efficiency was found to be 60.6%.

[0085] Sequence Listing

[0086] This application contains a sequence listing in computer readable form, which was created on October 10, 2017 and is approximately 5 MB in size. The computer readable form is incorporated herein by reference.

[0087]

[0088] DETAILED DESCRIPTION

[0089] Large-scale screening efforts have led to the discovery that domain-based peptide shuttle agents comprising an endosomal leakage domain (ELD) operably linked to a cell penetrating domain (CPD), and optionally one or more histidine-rich domains, can increase the transduction efficiency of independent polypeptide cargoes in eukaryotic cells, allowing cargoes to enter the cytosol / nuclear compartment (e.g., see Examples 1-15). In contrast, the above screening efforts have also revealed that some peptides have no or low polypeptide cargo transduction capacity, excessive toxicity and / or other undesirable properties (e.g., poor solubility and / or stability).

[0090] Based on these empirical data (both positive and negative), the amino acid sequences and properties of successful, less successful, and failed peptides were compared in order to better understand the physicochemical properties shared by the more successful shuttle agents. This comparison involved two main approaches: first, manual stratification of the different screened peptides according to their transduction performance based on our ENCODE biosignature data; and second, a more simplified “transduction score” approach that only considers the transduction efficiency and cytotoxicity of different peptides for a given peptide load and cell line.

[0091] For manual stratification, the screened peptides were individually evaluated based on their transduction performance, taking into account, for example, their solubility / stability / ease of synthesis; their ability to promote the escape of endosomally trapped calcein (e.g., see Example 2); their ability to deliver one or more types of independent polypeptide cargo intracellularly by flow cytometry in different types of cells and cell lines (e.g., primary, immortalized, adherent, suspension, etc.) and under different transduction protocols (e.g., see Examples 3-6 and 8-15); their ability to deliver polypeptide cargo to the cytosol and / or nucleus by fluorescence microscopy (e.g., for fluorescently labeled cargo), increase in transcriptional activity (e.g., transcription factor cargo), or genome editing capacity (e.g., for nuclease cargo or genome editing complexes such as CRISPR / Cas9 or CRISPR / Cpf1) (e.g., see Examples 3-6 and 8-15), as well as toxicity to different types of cells and cell lines (e.g., primary, immortalized, adherent, suspension) under different transduction protocols.

[0092] For the "transduction score" method, each peptide is assigned a score corresponding to a given cell line and fluorescently labeled polypeptide load, which combines transduction efficiency and cytotoxicity data into a single numerical value. The transduction score is calculated by simply multiplying the highest percent transduction efficiency observed by flow cytometry for a given peptide, load, and cell type by the percent cell viability of the peptide in the tested cell line. Peptides are then sorted according to their transduction score as a screening tool to stratify peptides into successful, less successful, or failed shuttle agents.

[0093] The above manual curation and "transduction score" based analysis revealed many parameters that successful region-based shuttle agents generally share (see, e.g., Example A). These parameters were then successfully used to manually design new peptide shuttle agents with polypeptide cargo transduction activity that lacked and / or were not based on known putative CPDs and / or ELDs (see, e.g., Example B). Furthermore, it was observed that peptides that met the most design parameters generally had the highest transduction scores, while peptides that met the fewest number of design parameters generally had the lowest transduction scores.

[0094] The design parameters described herein were further validated by testing multiple synthetic peptides whose amino acid sequences were generated using a machine learning algorithm (e.g., see Example C.1) that had been "trained" using transduction efficiency and cytotoxicity data for domain-based peptides (but not the design parameters described herein). Interestingly, the peptides generated by the machine learning algorithm that exhibited the highest transduction scores were generally peptides that met all of the design parameters described herein, thereby confirming their use in actively designing and / or predicting the transduction activity of new peptide shuttles (e.g., tailored to specific polypeptide loads and / or cell types). In addition, computer-assisted random peptide sequence generation followed by descriptor filtering was used to generate a list of 10,000 peptide variants that covered nearly all of the design parameters described herein (see Example C.2).

[0095] It is shown herein that rationally designed peptide shuttles promote the escape of endosomally trapped fluorescent dyes, indicating endosomolytic activity (see, e.g., Example D). In addition, it is shown herein that rationally designed peptide shuttles can transduce various polypeptide cargoes (e.g., fluorescent proteins, transcription factors, antibodies, and entire CRISPR-associated genome editing complexes with or without DNA templates) in different cell types (adherent and suspended) (see, e.g., Example EG).

[0096] Rational design parameters and peptide shuttles

[0097] In some aspects, the specification relates to a method for delivering a polypeptide cargo from the extracellular space to the cytosol and / or nucleus of a target eukaryotic cell. The method comprises contacting the target eukaryotic cell with the polypeptide cargo in the presence of a shuttle agent at a concentration sufficient to increase the transduction efficiency of the polypeptide cargo compared to the absence of the shuttle agent. In some aspects, the shuttle agent relates to a peptide that satisfies one or more of the following parameters.

[0098] (1) In some embodiments, the shuttle agent is a peptide having a length of at least 20 amino acids. For example, the peptide may comprise a minimum length of 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 amino acid residues and a maximum length of 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145 or 150 amino acid residues. In some embodiments, shorter peptides (e.g., in the range of 20-50 amino acids) may be particularly advantageous because they can be more easily synthesized and purified by chemical synthesis methods, which may be more suitable for clinical use (in contrast to recombinant proteins, which must be purified from cell expression systems). Although the numbers and ranges in this specification are generally listed as multiples of 5, this specification should not be limited thereto. For example, the maximum length described in this specification should be understood to also include lengths of 56, 57, 58...61, 62, etc., and the non-enumeration here is only for the sake of brevity. The same reasoning applies to the % identity listed here.

[0099] (2) In some embodiments, the peptide shuttle agent comprises an amphipathic α-helical motif. As used herein, unless otherwise indicated, the expression "α-helical motif" or "α-helix" refers to a right-handed coiled or helical conformation (helix) with a rotation angle of 100 degrees between consecutive amino acids and / or an α-helix with 3.6 residues per turn. As used herein, the expression "comprising an α-helical motif" or "amphipathic α-helical motif" and the like refer to the prediction of the three-dimensional conformation of the peptide (or peptide segment) of the present specification. When adopted in a biological context based on the primary amino acid sequence of the peptide, regardless of whether the peptide actually adopts the conformation when used as a shuttle agent in a cell. In addition, the peptide of the present specification may contain one or more α-helical motifs at different positions of the peptide. For example, the shuttle agent FSD5 is predicted to adopt an α-helix throughout its length (see Fig.49C ), while the shuttle agent FSD18 is predicted to consist of two separate α-helices towards the N- and C-terminal regions of the peptide (see Fig.49D ). In some embodiments, it is predicted that the shuttle agents of the present specification do not contain a β-sheet motif, such as Fig.49E and 49F Methods for predicting the presence of α-helices and β-sheets in proteins and peptides are well known in the art. For example, one such method is based on using PEP-FOLD TM3D modeling of , which is an online resource for de novo peptide structure prediction (http: / / bioserv.rpbs.univ-paris-diderot.fr / services / PEP-FOLD / ) (Lamiable et al., 2016; Shen et al., 2014; Thévenet et al., 2012). Other methods for predicting the presence of α-helices in peptides and proteins are known and readily available to the skilled person.

[0100] As used herein, the expression "amphipathic" refers to a peptide having both hydrophobic and hydrophilic elements (e.g., based on the side chains of the amino acids comprising the peptide). For example, the expression "amphipathic alpha-helix" or "amphipathic alpha-helical motif" refers to a peptide predicted to adopt an alpha-helical motif having a non-polar hydrophobic face and a polar hydrophilic face based on the properties of the amino acid side chains that form the helix.

[0101] (3) In some embodiments, the peptide shuttle agent of the present specification comprises an amphipathic α-helical motif having a positively charged hydrophilic outer surface, such as an outer surface rich in R and / or K residues. As used herein, the expression "positively charged hydrophilic outer surface" means that based on the α-helical wheel projection, there are at least three lysine (K) and / or arginine (R) residues clustered on one side of the amphipathic α-helical motif (see, for example, Fig.49A , left). Various programs can be used to prepare such spiral wheel projections, such as the online spiral wheel projection tool available at http: / / rzlab.ucr.edu / scripts / wheel / wheel.cgi. In some embodiments, an amphipathic α-helical motif can comprise a positively charged hydrophilic outer surface, an α-helix based on a rotation angle of 100 degrees between consecutive amino acids and / or an α-helix with 3.6 residues per turn, comprising: (a) at least two, three or four adjacent positively charged K and / or R residues in a spiral wheel projection; and / or (b) a six adjacent residue segment comprising three to five K and / or R residues in a spiral wheel projection.

[0102] In some embodiments, the peptide shuttle agent of the present specification comprises an amphipathic α-helical motif comprising a hydrophobic outer surface, based on an α-helix with a rotation angle of 100 degrees between consecutive amino acids and / or an α-helix with 3.6 residues per turn, the hydrophobic outer surface comprising: (a) at least two adjacent L residues when projected on the helical wheel; and / or (b) a stretch of ten adjacent residues comprising at least five hydrophobic residues selected from the following L, I, F, V, W and M when projected on the helical wheel.

[0103] (4) In some embodiments, the peptide shuttle agents of the present specification comprise an amphipathic α-helical motif having a highly hydrophobic core composed of spatially adjacent highly hydrophobic residues (e.g., L, I, F, V, W, and / or M). In some embodiments, based on an open cylindrical representation of an α-helix with 3.6 residues per turn, the highly hydrophobic core may be composed of spatially adjacent L, I, F, V, W, and / or M amino acids, representing 12 to 50% of the amino acids of the peptide, excluding any histidine-rich domains (see below) when calculating, such as Fig.49A As shown in the figure on the right. In some embodiments, the high hydrophobic core can be composed of spatially adjacent L, I, F, V, W and / or M amino acids, representing 12.5%, 13%, 13.5%, 14%, 14.5%, 15%, 15.5%, 16%, 16.5%, 17%, 17.5%, 18%, 18.5%, 19%, 19.5% or 20%, to 25%, 30%, 35%, 40% or 45% of the amino acids of the peptide. More specifically, the high hydrophobic core parameter can be calculated by first arranging the amino acids of the peptide in an open cylindrical representation and then depicting the region of continuous high hydrophobic residues (L, I, F, V, W, M), such as Fig.49A The number of highly hydrophobic residues contained in this delineated highly hydrophobic core is then divided by the total amino acid length of the peptide, excluding any histidine-rich domains (e.g., N- and / or C-terminal histidine-rich domains). For example, Fig.49A For the peptide shown in , there are 8 residues in the depicted high hydrophobic core, and there are 25 residues in total in the peptide (excluding the terminal 12 histidines). Therefore, the high hydrophobic core is 32% (8 / 25).

[0104] (5) Hydrophobic moment refers to a measure of the amphipathicity of a helix, peptide or part thereof and is calculated by summing the hydrophobicity loads of the amino acid side chains (Eisenberg et al., 1982). An online tool for calculating the hydrophobic moment of polypeptides is available from:

[0105] http: / / rzlab.ucr.edu / scripts / wheel / wheel.cgi. A high hydrophobic moment indicates strong amphiphilicity, while a low hydrophobic moment indicates poor amphiphilicity. In some embodiments, the peptide shuttle agent of the present specification may consist of or comprise a peptide or α-helical domain having a hydrophobic moment (μ) of 3.5 to 11. In some embodiments, the shuttle agent may be a peptide comprising an amphipathic α-helical motif having a hydrophobic moment of 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8 , 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0 and an upper limit of 9.5, 9.6, 9.7, 9.8, 9.9, 10.0, 10.1, 10.2, 10.3, 10.4, 10.5, 10.6, 10.7, 10.8, 10.9 or 11.0. In some embodiments, the shuttling agent can have a hydrophobic moment between a lower limit of 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0 and an upper limit of 9.5, 9.6, 9.7, 9.8, 9.9, 10.0, 10.1, 10.2, 10.3, 10.4 or 10.5. In some embodiments, any histidine-rich domain that may be present in the peptide is excluded when calculating the hydrophobic moment.

[0106] (6) In some embodiments, the peptide shuttle agents of the present disclosure may have a predicted net charge of at least +4 at physiological pH, calculated from the side chains of K, R, D, and E residues. For example, the net charge of the peptide may be at least +5, +6, +7, at least +8, at least +9, at least +10, at least +11, at least +12, at least +13, at least +14, or at least +15 at physiological pH. These positive charges are generally conferred by the greater presence of positively charged lysine and / or arginine residues, as opposed to negatively charged aspartic acid and / or glutamic acid residues.

[0107] (7) In some embodiments, the peptide shuttle agents of the present specification may have a predicted isoelectric point (pI) of 8 to 13, preferably 10 to 13. Programs and methods for calculating and / or measuring the isoelectric point of a peptide or protein are known in the art. For example, the pI can be calculated using the Prot Param software available from: http: / / web.expasy.org / protparam /

[0108] (8) In some embodiments, the peptide shuttle agent of the present specification may be composed of 35 to 65% hydrophobic residues (A, C, G, I, L, M, F, P, W, Y, V). In specific embodiments, the peptide shuttle agent may be composed of any combination of 36% to 64%, 37% to 63%, 38% to 62%, 39% to 61% or 40% to 60% amino acids: A, C, G, I, L, M, F, P, W, Y and V.

[0109] (9) In some embodiments, the peptide shuttle agent of the present specification may be composed of 0 to 30% neutral hydrophilic residues (N, Q, S, T). In specific embodiments, the peptide shuttle agent may be composed of 1% to 29%, 2% to 28%, 3% to 27%, 4% to 26%, 5% to 25%, 6% to 24%, 7% to 23%, 8% to 22%, 9% to 21% or 10% to 20% of any combination of amino acids: N, Q, S and T.

[0110] (10) In some embodiments, the peptide shuttle agent of the present specification may be composed of 35 to 85% of amino acids A, L, K and / or R. In specific embodiments, the peptide shuttle agent may be composed of any combination of 36% to 80%, 37% to 75%, 38% to 70%, 39% to 65%, or 40% to 60% of amino acids: A, L, K or R.

[0111] (11) In some embodiments, the peptide shuttle agent of the present specification may be composed of 15 to 45% of amino acids A and / or L, provided that at least 5% L is present in the peptide. In specific embodiments, the peptide shuttle agent may be composed of any combination of 15% to 40%, 20% to 40%, 20% to 35%, or 20% to 30% of amino acids: A and L, provided that at least 5% L is present in the peptide.

[0112] (12) In some embodiments, the peptide shuttle agent of the present specification may be composed of 20% to 45% of amino acids K and / or R. In specific embodiments, the peptide shuttle agent may be composed of any combination of amino acids: K and R, 20% to 40%, 20% to 35%, or 20% to 30%.

[0113] (13) In some embodiments, the peptide shuttle agent of the present specification may be composed of 0 to 10% of amino acids D and / or E. In a specific embodiment, the peptide shuttle agent may be composed of any combination of amino acids D and E at 5% to 10%.

[0114] (14) In some embodiments, the absolute difference between the percentage of A and / or L and the percentage of K and / or R in the peptide shuttle agent may be less than or equal to 10%. In specific embodiments, the absolute difference between the percentage of A and / or L and the percentage of K and / or R in the peptide shuttle agent may be less than or equal to 9%, 8%, 7%, 6% or 5%.

[0115] (15) In some embodiments, the peptide shuttle agent of the present specification may be composed of 10% to 45% of the amino acids Q, Y, W, P, I, S, G, V, F, E, D, C, M, N, T or H (i.e., not A, L, K or R). In specific embodiments, the peptide shuttle agent may be composed of any combination of 15% to 40%, 20% to 35% or 20% to 30% of the amino acids: Q, Y, W, P, I, S, G, V, F, E, D, C, M, N, T and H.

[0116] In some embodiments, the peptide shuttle agents of the present specification involve at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least nine, at least ten, at least eleven, at least twelve, thirteen, at least fourteen or all of the parameters (1) to (15) described herein. In specific embodiments, the peptide shuttle agents of the present specification involve all of the parameters (1) to (3), and at least six, at least seven, at least eight, at least nine, at least ten, at least eleven or all of the parameters (4) to (15) described herein.

[0117] In some embodiments, when the peptide shuttle agent of the present specification comprises only one histidine-rich domain, the residues of one histidine-rich domain may be included in the calculation / evaluation of parameters (1) to (15) described herein. In some embodiments, when the peptide shuttle agent of the present specification comprises more than one histidine-rich domain, the residues of only one histidine-rich domain may be included in the calculation / evaluation of parameters (1) to (15) described herein. For example, when the peptide shuttle agent of the present specification comprises two histidine-rich domains: a first histidine-rich domain toward the N-terminus and a second histidine-rich domain toward the C-terminus, only the first histidine-rich domain may be included in the calculation / evaluation of parameters (1) to (15) described herein.

[0118] In some embodiments, machine learning or computer-aided design methods can be implemented to generate peptides involving one or more parameters (1) to (15) described herein. Some parameters, such as parameters (1) and (5)-(15), may be more suitable for implementation in computer-aided design methods, while structural parameters, such as parameters (2), (3), and (4), may be more suitable for manual design methods. Therefore, in some embodiments, peptides involving one or more parameters (1) to (15) can be generated by combining computer-aided and manual design methods. For example, multiple sequence alignment analysis of the various peptides shown herein (and other peptides) that act as effective shuttle agents revealed the presence of some consensus sequences - i.e., alternating patterns of hydrophobic, cationic, hydrophilic, alanine and glycine amino acids that are commonly found. The presence of these consensus sequences may result in peptides involving structural parameters (2), (3), and (4) (i.e., amphipathic α-helix formation, positively charged faces, and a 12%-50% highly hydrophobic core). Therefore, these and other consensus sequences can be used in machine learning and / or computer-aided design methods to generate peptides involving one or more parameters (1)-(15).

[0119] Thus, in some embodiments, the peptide shuttle agents described herein may comprise or consist of the following amino acid sequence:

[0120] (a) [X1]-[X2]-[Linker]-[X3]-[X4] (Formula 1);

[0121] (b) [X1]-[X2]-[Linker]-[X4]-[X3] (Formula 2);

[0122] (c) [X2]-[X1]-[Linker]-[X3]-[X4] (Formula 3);

[0123] (d) [X2]-[X1]-[Linker]-[X4]-[X3] (Formula 4);

[0124] (e) [X3]-[X4]-[Linker]-[X1]-[X2] (Formula 5);

[0125] (f) [X3]-[X4]-[Linker]-[X2]-[X1] (Formula 6);

[0126] (g) [X4]-[X3]-[Linker]-[X1]-[X2] (Formula 7); or

[0127] (h) [X4]-[X3]-[Connector]-[X2]-[X1] (Formula 8)

[0128] in:

[0129] [X1] is selected from: 2[Φ]-1[+]-2[Φ]-1[ζ]-1[+]-; 2[Φ]-1[+]-2[Φ]-2[+]-;

[0130] 1[+]-1[Φ]-1[+]-2[Φ]-1[ζ]-1[+]-; and 1[+]-1[Φ]-1[+]-2[Φ]-2[+]-;

[0131] [X2] is selected from: -2[Φ]-1[+]-2[Φ]-2[ζ]-; -2[Φ]-1[+]-2[Φ]-2[+]-;

[0132] -2[Φ]-1[+]-2[Φ]-1[+]-1[ζ]-; -2[Φ]-1[+]-2[Φ]-1[ζ]-1[+]-; -2[Φ]-2[+]-1[Φ]-2[+]-;

[0133] -2[Φ]-2[+]-1[Φ]-2[ζ]-; -2[Φ]-2[+]-1[Φ]-1[+]-1[ζ]-; and -2[Φ]-2[+]-1[Φ]-1[ζ]-1[+]-;

[0134] [X3] is selected from: -4[+]-A-; -3[+]-G-A-; -3[+]-A-A-; -2[+]-1[Φ]-1[+]-A-; -2[+]-1[Φ]-G-A-;

[0135] -2[+]-1[Φ]-A-A-; or -2[+]-A-1[+]-A; -2[+]-A-G-A; -2[+]-A-A-A-; -1[Φ]-3[+]-A-; -1[Φ]-2[+]-G-A-; -1[Φ]-2[+]-A-A-; -1[Φ]-1[+]-1[Φ]-1[+]-A; -1[Φ]-1[+]-1[Φ]-G-A; -1[Φ]-1[+]-1[Φ]-A-A;

[0136] -1[Φ]-1[+]-A-1[+]-A; -1[Φ]-1[+]-A-G-A; -1[Φ]-1[+]-A-A-A; -A-1[+]-A-1[+]-A; -A-1[+]-A-G-A; and -A-1[+]-A-A-A;

[0137] [X4] is selected from: -1[ζ]-2A-1[+]-A; -1[ζ]-2A-2[+]; -1[+]-2A-1[+]-A; -1[ζ]-2A-1[+]-1[ζ]-A-1[+]; -1[ζ]-A-1[ζ]-A-1[+]; -2[+]-A-2[+]; -2[+]-A-1[+]-A; -2[+]-A-1[+]-1[ζ]-A-1[+];

[0138] -2[+]-1[ζ]-A-1[+]; -1[+]-1[ζ]-A-1[+]-A; -1[+]-1[ζ]-A-2[+]; -1[+]-1[ζ]-A-1[+]-1[ζ]-A-1[+]; -1[+]-2[ζ]-A-1[+]; -1[+]-2[ζ]-2[+]; -1[+]-2[ζ]-1[+]-A; -1[+]-2[ζ]-1[+]-1[ζ]-A-1[+];

[0139] -1[+]-2[ζ]-1[ζ]-A-1[+]; -3[ζ]-2[+]; -3[ζ]-1[+]-A; -3[ζ]-1[+]-1[ζ]-A-1[+];

[0140] -1[ζ]-2A-1[+]-A; -1[ζ]-2A-2[+]; -1[ζ]-2A-1[+]-1[ζ]-A-1[+]; -2[+]-A-1[+]-A;

[0141] -2[+]-1[ζ]-1[+]-A; -1[+]-1[ζ]-A-1[+]-A; -1[+]-2A-1[+]-1[ζ]-A-1[+]; and -1[ζ]-A-1[ζ]-A-1[+]; and

[0142] [Linker] is selected from: -Gn-; -Sn-; -(GnSn)n-; -(GnSn)nGn-; -(GnSn)nSn-; -(GnSn)nGn(GnSn)n-; and

[0143] (GnSn)nSn(GnSn)n-;

[0144] wherein: [Φ] is an amino acid, which is: Leu, Phe, Trp, Ile, Met, Tyr or Val; [+] is an amino acid, which is: Lys or Arg; [ζ] is an amino acid, which is: Gln, Asn, Thr or Ser; A is the amino acid Ala; G is the amino acid Gly; S is the amino acid Ser;

[0145] and n is an integer from 1 to 20, 1 to 19, 1 to 18, 1 to 17, 1 to 16, 1 to 15, 1 to 14, 1 to 13, 1 to 12, 1 to 11, 1 to 10, 1 to 9, 1 to 8, 1 to 7, 1 to 6, 1 to 5, 1 to 1-4 or 1 to 3.

[0146] In some embodiments, the peptide shuttle agent of the present specification may comprise or consist of any one of the amino acid sequences of SEQ ID NOs: 104, 105, 107, 108, 110-131, 133-135, 138, 140, 142, 145, 148, 151, 152, 169-242 and 243-10 242. In some embodiments, the peptide shuttle agent of the present specification may comprise the amino acid sequence motif of SEQ ID NOs: 158 and / or 159, which are found in each of the peptides FSD5, FSD16, FSD18, FSD19, FSD20, FSD22 and FSD23. In some embodiments, the peptide shuttle agent of the present specification may comprise the amino acid sequence motif of SEQ ID NO: 158 operably linked to the amino acid sequence motif of SEQ ID NO: 159. In some embodiments, the peptide shuttle agent of the present specification may comprise a peptide that is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95% identical to any one of the amino acid sequences of SEQ ID NOs: 104, 105, 107, 108, 110-131, 133-135, 138, 140, 142, 145, 148, 151, 152, 169-242 and 243-10 242, or a functional variant of SEQ ID NOs: 104, 105, 107, 108, 110-131, 133-135, 138, 140, 142, 145, 148, 151, 152, 169-242 and 243-10 242, or consists of the same. As used herein, "functional variant" refers to a peptide having polypeptide cargo transduction activity, which differs from a reference peptide by one or more conservative amino acid substitutions. As used herein, "conservative amino acid substitutions" are amino acid substitutions in which one amino acid residue is replaced by another amino acid residue having a similar side chain. Families of amino acid residues having similar side chains are well defined in the art, including basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), non-polar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), β-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine).

[0147] In some embodiments, the peptide shuttle agent of the present specification may comprise any one of the amino acid sequences of SEQ ID NOs: 57-59, 66-72 or 82-102, or a functional variant having at least 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94% or 95% identity with any one of SEQ ID NOs: 57-59, 66-72 or 82-102, or consist thereof. In some embodiments, the peptide shuttle agent of the present specification does not comprise one or more of any one of the amino acid sequences of SEQ ID NOs: 57-59, 66-72 or 82-102.

[0148] In some embodiments, the shuttle agent of the present specification may comprise an oligomer (e.g., dimer, trimer, etc.) of a peptide described herein. Such an oligomer may be constructed by covalently binding the same or different types of shuttle agent monomers (e.g., using disulfide bonds to introduce cysteine ​​residues into the monomer sequence). In some embodiments, the shuttle agent of the present specification may comprise an N-terminal and / or C-terminal cysteine ​​residue.

[0149] Histidine-rich domain

[0150] In some embodiments, the peptide shuttle agent of the present specification may further comprise one or more histidine-rich domains. In some embodiments, the histidine-rich domain may be a stretch of at least 2, at least 3, at least 4, at least 5 or at least 6 amino acids containing at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85% or at least 90% histidine residues. In some embodiments, the histidine-rich domain may comprise at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8 or at least 9 consecutive histidine residues. Without being bound by theory, the histidine-rich domain in the shuttle agent may act as a proton sponge in the endosome by protonating its imidazole group under the acidic conditions of the endosome, providing another mechanism for endosomal membrane instability, thereby further promoting the ability of endosomally captured cargo to enter the cytosol. In some embodiments, the histidine-rich domain may be located at or towards the N- and / or C-terminus of the peptide shuttle agent.

[0151] Connectors

[0152] In some embodiments, the peptide shuttle agents of the present specification may include one or more suitable linkers (e.g., flexible polypeptide linkers). In some embodiments, such linkers can separate two or more amphipathic α-helical motifs (e.g., see Fig.49D In some embodiments, a linker can be used to separate two or more domains (CPD, ELD or histidine-rich domain) from each other. In some embodiments, a linker can be formed by adding a small hydrophobic amino acid sequence (e.g., glycine) with no rotation potential and a polar serine residue that imparts stability and flexibility. The linker can be soft and allow regional movement of the shuttle agent. In some embodiments, proline can be avoided because they can add significant conformational rigidity. In some embodiments, the linker can be a serine / glycine-rich linker (e.g., GGS, GGSGGGS, GGSGGGSGGGS, etc.). In some embodiments, the use of a shuttle agent containing a suitable linker can facilitate the delivery of independent polypeptide cargoes to suspended cells rather than adherent cells. In some embodiments, the linker can comprise or consist of the following:

[0153] -Gn-; -Sn-; -(GnSn)n-; -(GnSn)nGn-; -(GnSn)nSn-; -(GnSn)nGn(GnSn)n-; or (GnSn)nSn(GnSn)n-, wherein G is the amino acid Gly; S is the amino acid Ser; and n is an integer from 1 to 5.

[0154] Endosomal leakage domain (ELD)

[0155] In some aspects, the peptide shuttle agent of the present specification may include an endosomal leakage domain (ELD) for promoting endosomal escape and entry into the cytoplasmic compartment. As used herein, the expression "endosomal leakage domain" refers to an amino acid sequence that gives the macromolecule captured by the endosomal access to the cytoplasmic compartment. Without being limited by theory, the endosomal leakage domain is a short sequence (often derived from viral or bacterial peptides) that is believed to induce the destabilization of the endosomal membrane and the release of the contents in the body to the cytoplasm. As used herein, the expression "endosomal lytic peptide" is intended to refer to the peptide of this common class with endosomal membrane destabilization characteristics. Therefore, in some embodiments, the synthetic peptide or polypeptide-based shuttle agent of the present invention may include an ELD that is an endosomal lytic peptide. The activity of this peptide can be evaluated, for example, using the calcein endosomal escape assay described in Example 2.

[0156] In some embodiments, the ELD can be a peptide that destroys the membrane at acidic pH, such as a pH-dependent membrane active peptide (PMAP) or a pH-dependent cleavage peptide. For example, the peptides GALA and INF-7 are amphipathic peptides that form alpha helices when the pH decreases and changes the charge they contain. More specifically, without being limited by theory, it is shown that ELDs such as GALA induce endosomal leakage by forming pores and flipping of membrane lipids after the conformational change due to pH decrease (Kakudo, Chaki et al., 2004, Li, Nicol et al., 2004). On the contrary, it is shown that ELDs such as INF-7 induce endosomal leakage by accumulating in the endosomal membrane and destabilizing the endosomal membrane (El-Sayed, Futaki et al., 2009). Therefore, during the maturation of the endosomal body, the change in peptide conformation is caused by the decrease in pH and it destabilizes the endosomal membrane, resulting in the release of endosomal contents. It is believed that the same principle applies to toxin A of Pseudomonas (Varkouhi, Scholte et al., 2011). After the pH drops, the conformation of the toxin translocation domain changes, allowing it to insert into the endosomal membrane, where it forms a hole (London 1992, O'Keefe 1992). This ultimately facilitates the destabilization of the endosomal body and the translocation of the complex to the endosomal body. The above-mentioned ELD is included in the ELD of this specification and other endosomal leakage mechanisms whose mechanism of action is not exhaustively defined.

[0157] In some embodiments, the ELD can be an antimicrobial peptide (AMP) such as a linear cationic alpha-helical antimicrobial peptide (AMP). Due to their ability to interact strongly with bacterial membranes, these peptides play a key role in the innate immune response. Without being limited by theory, it is believed that these peptides are disordered in aqueous solutions, but adopt an alpha-helical secondary structure in a hydrophobic environment. The latter conformation is believed to contribute to its typical concentration-dependent membrane-destructive properties. When accumulated in endosomes at certain concentrations, some antimicrobial peptides may induce endosomal leakage.

[0158] In some embodiments, the ELD can be an antimicrobial peptide (AMP) such as a cecropin-A / melitin hybrid (CM series) peptide. Such peptides are considered to be among the smallest and most effective AMP-derived peptides with membrane-damaging capabilities. Cecropins are a family of antimicrobial peptides that have membrane-perturbing capabilities against both Gram-positive and Gram-negative bacteria. Cecropin A (CA), the first antimicrobial peptide identified, consists of 37 amino acids with a linear structure. Melitin (M), a 26 amino acid peptide, is a cell membrane cleavage factor found in honey bee venom. Cecropin-melitin hybrid peptides have been shown to produce short, effective antibiotic peptides without cytotoxicity (i.e., non-hemolytic) to eukaryotic cells, a property that is ideal in any antimicrobial agent. These chimeric peptides construct a variety of combinations of the hydrophilic N-terminal domain of cecropin A and the hydrophobic N-terminal domain of melittin, and have been tested on bacterial model systems. Two 26-mers, CA(1-13)M(1-13) and CA(1-8)M(1-18) (Boman et al., 1989) have been shown to demonstrate broad spectrum and improved potency of natural bactericidal peptide A without the cytotoxic effects of melittin.

[0159] In an effort to generate shorter CM series peptides, the authors of Andreu et al., 1992, constructed hybrid peptides such as a 26-mer (CA(1-8)M(1-18)) and combined it with a 20-mer (CA(1-8)M(1-12)), an 18-mer (CA(1-8)M(1-10)) and six 15-mers (CA(1-7)M(1-8), CA(1-7)M(2-9), CA(1-7)M(3-10), CA(1-7)M(4-11), CA(1-7 )M(5-12) and CA(1-7)M(6-13)) were compared. The 20- and 18-mers maintained similar activity to CA(1-8)M(1-18). Of the six 15-mers, CA(1-7)M(1-8) showed the first antibacterial activity, but the other five showed similar antibiotic potency without hemolysis compared to the 26-mer. Thus, in some embodiments, the synthetic peptides or polypeptide-based shuttle agents of the present invention may comprise an ELD that is or is derived from a variant of the CM series peptides, such as those described above.

[0160] In some embodiments, the ELD can be a cecropin-A fused to residues 2-12 of melittin (YGRKKRRQRRR).

[0161] The CM series peptide CM18, composed of residues 1-7 of (KWKLFKKIGAVLKVLTTG), [C(1–7)M(2–12)]. When fused to the cell-penetrating peptide TAT, CM18 was shown to independently cross the plasma membrane and destabilize the endosomal membrane, allowing some endosomally trapped complexes to be released into the cytoplasm (Salomone et al., 2012). However, in some of the authors' experiments, the use of the CM18-TAT11 peptide fused to a fluorophore raised uncertainty about the contribution of the peptide over the fluorophore, as the fluorophore itself has been shown to contribute to endosomal lysis—for example, via photochemical disruption of the endosomal membrane (Erazo-Oliveras et al., 2014).

[0162] In some embodiments, the ELD may be CM18 having an amino acid sequence of SEQ ID NO: 1 having endosomolytic activity, or a variant thereof having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 85%, 90%, 91%, 92%, 93%, 94% or 95% identity with SEQ ID NO: 1.

[0163] In some embodiments, the ELD may be a peptide derived from the N-terminus of the HA2 subunit of influenza hemagglutinin (HA), which may also cause destabilization of the endosomal membrane when accumulated in endosomes.

[0164] In some embodiments, the synthetic peptide or polypeptide-based shuttle agent of the present invention may comprise an ELD that is or is derived from the ELDs described in Table I, or a variant thereof having endosomal escape activity and / or pH-dependent membrane disruptive activity.

[0165] Table I: Examples of endosomal leakage domains

[0166]

[0167]

[0168]

[0169] In some embodiments, the shuttle agent of the present invention may include one or more ELDs or one or more types of ELDs. More specifically, it may include at least 2, at least 3, at least 4, at least 5 or more ELDs. In some embodiments, the shuttle agent may include 1-10 ELDs, 1-9 ELDs, 1-8 ELDs, 1-7 ELDs, 1-6 ELDs, 1-5 ELDs, 1-4 ELDs, 1-3 ELDs, etc.

[0170] In some embodiments, the order or placement of the ELD relative to other domains within the shuttle agents of the invention may be varied so long as the shuttling ability of the shuttle agent is retained.

[0171] In some embodiments, the ELD may be a variant or fragment of any of those listed in Table I and having endosomolytic activity. In some embodiments, the ELD may comprise an amino acid sequence of any of SEQ ID NOs: 1-15, 63, or 64, or a sequence that is at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 85%, 90%, 91%, 92%, 93%, 94%, or 95% identical to any of SEQ ID NOs: 1-15, 63, or 64, or consist of the same, and have endosomolytic activity.

[0172] In some embodiments, the shuttle agent of the present description does not comprise one or more of any one of the amino acid sequences of SEQ ID NOs: 1-15, 63 or 64.

[0173] Cell Penetrating Domain (CPD)

[0174] In some aspects, the shuttle agents of the present invention may comprise a cell penetrating domain (CPD). As used herein, the expression "cell penetrating domain" refers to an amino acid sequence that confers the ability of a macromolecule (eg, a peptide or protein) comprising a CPD to be transduced into a cell.

[0175] In some embodiments, CPD can be (or can be derived from) a cell-penetrating peptide or a protein transduction domain of a cell-penetrating peptide. Cell-penetrating peptides can function as carriers to successfully deliver a variety of loads (e.g., polynucleotides, polypeptides, small molecule compounds or other macromolecules / otherwise impermeable membrane compounds) into cells. Cell-penetrating peptides often include short peptides rich in basic amino acids, which, once fused to a macromolecule (or otherwise operably connected), mediate its internalization into cells (Shaw, Catchpole et al., 2008). The first cell-penetrating peptide was identified by analyzing the cell-penetrating ability of HIV-1 transcription cis-activating factor (Tat) protein (Green and Loewenstein 1988, Vives, Brodin et al., 1997). The protein comprises a short hydrophilic amino acid sequence, referred to as "TAT", which promotes its insertion into the plasma membrane and forms a hole. Since this discovery, a variety of other cell-penetrating peptides have been described. In this regard, in some embodiments, CPD can be a cell-penetrating peptide as listed in Table II, or a variant thereof having cell-penetrating peptide activity.

[0176] Table II: Examples of cell penetrating peptides

[0177]

[0178] Not limited by theory, it is believed that cell penetrating peptides interact with the plasma membrane before passing through by pinocytosis or endocytosis. In the case of TAT peptides, it is believed that its hydrophilic nature and charge promote its insertion into the plasma membrane and form holes (Herce and Garcia 2007). The alpha helical motif in hydrophobic peptides (such as SP) is also believed to form holes in the plasma membrane (Veach, Liu et al., 2004).

[0179] In some embodiments, the shuttle agent of the present invention may comprise one or more CPDs or one or more types of CPDs. More specifically, it may comprise at least 2, at least 3, at least 4, or at least 5 or more CPDs. In some embodiments, the shuttle agent may comprise 1-10 CPDs, 1-6 CPDs, 1-5 CPDs, 1-4 CPDs, 1-3 CPDs, etc.

[0180] In some embodiments, the CPD may be a TAT having an amino acid sequence of SEQ ID NO: 17, or a variant thereof having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81% 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94% or 95% identity to SEQ ID NO: 17 and having cell penetrating activity; or a membrane-penetrating peptide having an amino acid sequence of SEQ ID NO: 18, or a variant thereof having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81% 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94% or 95% identity to SEQ ID NO: 18 and having cell penetrating activity. IDNO: 18 having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81% 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94% or 95% identity and variants thereof having cell penetrating activity.

[0181] In some embodiments, the CPD can be a PTD4 having an amino acid sequence of SEQ ID NO:65, or a variant thereof having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81% 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94% or 95% identity to SEQ ID NO:65.

[0182] In some embodiments, the order or placement of the CPD relative to other domains (ELD, histidine-rich domain) within the shuttle agents of the invention may be varied as long as the shuttling ability of the shuttle agent is retained.

[0183] In some embodiments, the CPD may be a variant or fragment of any of those listed in Table II and having cell penetrating activity. In some embodiments, the CPD may comprise an amino acid sequence of any of SEQ ID NOs: 16-27 or 65, or a sequence that is at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 85%, 90%, 91%, 92%, 93%, 94% or 95% identical to any of SEQ ID NOs: 16-27 or 65 and having cell penetrating activity, or consist of the same.

[0184] In some embodiments, the shuttle agent of the present specification does not comprise any of the amino acid sequences in SEQ ID NO: 16-27 or 65.

[0185] load

[0186] In some aspects, the peptide shuttle agents of the present specification can be used to deliver a polypeptide cargo (e.g., an independent polypeptide cargo) from the extracellular space to the cytosol and / or nucleus of a target eukaryotic cell, wherein the concentration of the synthetic peptide shuttle agent used is sufficient to improve the transduction efficiency of the polypeptide cargo compared to the absence of the synthetic peptide shuttle agent. In some embodiments, the polypeptide cargo can be fused with one or more CPDs to further promote intracellular delivery. In some embodiments, the CPD fused with the polypeptide cargo can be the same or different from the CPD that can be present in the shuttle agent of the present specification. Such fusion proteins can be constructed using standard recombinant techniques. In some embodiments, an independent polypeptide cargo can be fused, compounded, or covalently bound to a second biologically active cargo (e.g., a biologically active polypeptide or compound). Alternatively or simultaneously, the polypeptide cargo can include a subcellular targeting domain.

[0187] In some embodiments, the polypeptide load must be delivered to the nucleus for it to implement its expected biological effect. One such example is when the load is a polypeptide intended for nuclear delivery (e.g., a transcription factor). In this regard, research on the translocation mechanism of viral DNA has enabled the identification of nuclear localization signals (NLS). The NLS sequence is recognized by proteins (import proteins α and β), which act as transporters and translocation regulators across the nuclear membrane. NLS is generally rich in charged amino acids such as arginine, histidine, and lysine, giving a positive charge, which is partially responsible for its recognition by the import protein. Therefore, in some embodiments, the polypeptide load may include an NLS that promotes nuclear delivery, such as one or more NLS listed in Table III, or a variant thereof with nuclear targeting activity. Of course, it should be understood that in some embodiments, the polypeptide load may include its native NLS.

[0188] Table III: Nuclear localization signals

[0189]

[0190]

[0191]

[0192] Once delivered to the cytoplasm, the recombinant protein is exposed to the protein transport system of the eukaryotic cell. In fact, all proteins are synthesized in the cytoplasm of the cell and then redistributed to their final subcellular location by a small amino acid sequence-based transport system recognized by the shuttle protein (Karniely and Pines 2005, Stojanovski, Bohnert et al., 2012). In addition to NLS, other localization sequences can mediate subcellular targeting to a variety of organelles after intracellular delivery of the polypeptide cargo of the present invention. Therefore, in some embodiments, the polypeptide cargo of the present invention may include a subcellular localization signal for promoting shuttle agents and compound delivery to specific organelles, such as one or more sequences listed in Table IV, or variants thereof having corresponding subcellular targeting activity.

[0193] Table IV: Subcellular localization signals

[0194]

[0195] In some embodiments, the cargo can be a biologically active compound, such as a biologically active (recombinant) polypeptide (e.g., a transcription factor, a cytokine, or a nuclease) for intracellular delivery. As used herein, the expression "biological activity" refers to the ability of a compound to mediate structural, regulatory, and / or biochemical function when introduced into a target cell.

[0196] In some embodiments, the cargo can be a recombinant polypeptide for nuclear delivery, such as a transcription factor. In some embodiments, the transcription factor can be HOXB4 (Lu, Feng et al., 2007), NUP98-HOXA9 (Takeda, Goolsby et al., 2006), Oct3 / 4, Sox2, Sox9, Klf4, c-Myc (Takahashi and Yamanaka 2006), MyoD (Sung, Mun et al., 2013), Pdx1, Ngn3 and MafA (Akinci, Banga et al., 2012), Blimp-1 (Lin, Chou et al., 2013), Eomes, T-bet (Gordon, Chaix et al., 2012), FOXO3A (Warr, Binnewies et al., 2013), NF-YA (Dolfini, Minuzzo et al., 2012), SALL4 (Aguila, Liao ...5 (Aguila, Liao et al., 2013), NF-YA (Dolfini, Minuzzo et al., 2012), SALL6 (Aguila, Liao et al., 2013), NF-YA (Dolfini, Minuzzo et al., 2012), SALL7 (Aguila, Liao et al., 2013), NF-YA (Dolfini, Minuzzo et al., 2012), SALL8 (Aguila, Liao et al., 2013), NF-YA (Dolfini, Minuzzo et al., 2012), SALL9 (A , 2011), ISL1 (Fonoudi, Yeganeh et al., 2013), FoxA1 (Tan, Xie et al., 2010), Nanog, Esrrb, Lin28 (Buganim et al., 2014), HIF1-alpha (Lord-Dufour et al., 2009), Hlf, Runx1t1, Pbx1, Lmo2, Zfp37, Prdm5 (Riddell et al., 2014), or Bcl-6 (Ichii, Sakamoto et al., 2004).

[0197] In some embodiments, the load can be a recombinant polypeptide for nuclear delivery, such as a nuclease for genome editing technology. In some embodiments, the nuclease can be an RNA-guided endonuclease, a CRISPR endonuclease, a type I CRISPR endonuclease, a type II CRISPR endonuclease, a type III CRISPR endonuclease, a type IV CRISPR endonuclease, a type V CRISPR endonuclease, a type VI CRISPR endonuclease, CRISPR-associated protein 9 (Cas9), Cpf1 (Zetsche et al., 2015), CasX and / or CasY (Burstein et al., 2016), a zinc finger nuclease (ZFN), a transcription activator-like effector nuclease (TALEN) (Cox et al., 2015), a homing endonuclease, a meganuclease, a DNA-guided nuclease such as Natronobacterium gregoryi Argonaute (NgAgo; Gao et al., 2016), or any combination thereof. In some embodiments, the nuclease can be a catalytically dead endonuclease, such as a catalytically dead CRISPR-associated protein 9 (dCas9), dCpf1, dCasX, dCasY, or any combination thereof. Other nucleases not explicitly mentioned here may still be encompassed in the present invention. In some embodiments, the nuclease can be fused to a nuclear localization signal (e.g., Cas9-NLS; Cpf1-NLS; ZFN-NLS; TALEN-NLS). In some embodiments, the nuclease can be complexed with a nucleic acid (e.g., one or more guide RNAs, crRNAs, tracrRNAs, or both crRNAs and tracrRNAs). In some embodiments, the nuclease may have DNA or RNA binding activity, but may lack the ability to cut DNA.

[0198] In some embodiments, the shuttle agents of the invention can be used for intracellular delivery (e.g., nuclear delivery) of one or more CRISPR endonucleases, such as one or more CRISPR endonucleases described below.

[0199] Type I and its subtypes A, B, C, D, E, F and I, including their respective Cas1, Cas2, Cas3, Cas4, Cas6, Cas7 and Cas8 proteins, and the hallmark homologs and subunits of these Cas proteins include Cse1, Cse2, Cas7, Cas5 and Cas6e subunits in Escherichia coli (IE type) and Csy1, Csy2, Csy3 and Cas6f in Pseudomonas aeruginosa (IF type) (Wiedenheft et al., 2011; Makarova et al., 2011). Type II and its subtypes A, B, C, including their respective Cas1, Cas2 and Cas9 proteins, and the hallmark homologs and subunits of these Cas proteins include the Csn complex (Makarova et al., 2011). Type III and its subtypes A, B and MTH326-like modules include their respective Cas1, Cas2, Cas6 and Cas10 proteins, and hallmark homologs and subunits of these Cas proteins including Csm and CMR complexes (Makarova et al., 2011). Type V represents the Csf3 family of Cas proteins. Members of this family show close CRISPR repeats in Acidithiobacillus ferrooxidans ATCC23270, Azoarcus sp. (strain EbN1) and Rhodoferaxferrireducens (strain DSM 15236 / ATCC BAA-621 / T118). In the latter two species, CRISPR / Cas loci were found on plasmids. Type V and its subtypes have only recently been discovered and include Cpf1, C2c1 and C2c3. Type VI includes the enzyme C2c2, which is reported to have little homology to known sequences.

[0200] In some embodiments, the shuttle agents of the present invention can be used in combination with one or more of the above-described nucleases, endonucleases, RNA-guided endonucleases, CRISPR endonucleases for a variety of applications, such as those described herein. The CRISPR system interacts with its respective nucleic acid, such as DNA binding, RNA binding, helicase and nuclease motifs (Makarova et al., 2011; Barrangou & Marraffini, 2014). The CRISPR system can be used for different genome editing applications, including:

[0201] Cas-mediated genome editing methods that perform non-homologous end joining (NHEJ) and / or homology-directed recombination (HDR) (Cong et al., 2013);

[0202] Catalytically dead Cas (dCas) when bound to a promoter sequence, one or more gRNAs, and RNA polymerase (with or without a complex with other protein partners) can inhibit and / or activate transcription initiation (Bikard et al., 2013);

[0203] Catalytically dead Cas (dCas) that can also be combined with different functional protein domains as a way to bring about enzymatic activity at specific sites in the genome, including transcriptional repression, transcriptional activation, chromatin remodeling, fluorescent reporters, histone modifications, recombinase systems acetylation, methylation, ubiquitination, phosphorylation, SUMOylation, ribosylation, and citrullination (Gilbert et al., 2013).

[0204] Those of ordinary skill in the art will appreciate that the shuttle agents of the present invention, although exemplified in this embodiment with Cas9 and Cpf1, can be used with other nucleases described herein. Therefore, the present specification includes nucleases such as Cpf1, Cas9 and variants of these nucleases or other nucleases. It should be understood that in one aspect, the present specification can broadly cover any payload with nuclease activity, such as RNA-guided endonucleases, or variants thereof (e.g., those that can bind DNA or RNA, but have lost their nuclease activity; or those fused to transcription factors).

[0205] In some embodiments, the polypeptide load can be a cytokine, such as a chemokine, an interferon, an interleukin, a lymphokine, or a tumor necrosis factor. In some embodiments, the polypeptide load can be a hormone or a growth factor. In some embodiments, the load can be an antibody (e.g., a labeled antibody, a therapeutic antibody, an anti-apoptotic antibody, an antibody that recognizes an intracellular antigen). In some embodiments, the load can be a detectable marker (a fluorescent polypeptide or a reporter enzyme) for intracellular delivery, such as for research and / or diagnostic purposes.

[0206] In some embodiments, the load can be a globular protein or a fibrous protein. In some embodiments, the load can have a molecular weight of about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50 to about 150, 200, 250, 300, 350, 400, 450, 500 kDa or more. In some embodiments, the load can have a molecular weight of about 20 to 200 kDa.

[0207] In some embodiments, the polypeptide cargo can be a peptide cargo, such as a peptide that recognizes an intracellular molecule.

[0208] In some embodiments, the polypeptide cargo may be an enzyme and / or an enzyme inhibitor.

[0209] In some embodiments, the peptide shuttle agents of the present specification can be used to deliver polypeptide cargo from the extracellular space to the cytosol and / or nucleus of different types of target eukaryotic cells, wherein the concentration of the synthetic peptide shuttle agent used is sufficient to increase the transduction efficiency of the polypeptide cargo compared to the absence of the synthetic peptide shuttle agent. The target eukaryotic cell can be an animal cell, a mammalian cell or a human cell. In some embodiments, the target eukaryotic cell can be a stem cell (e.g., an embryonic stem cell, a pluripotent stem cell, an induced pluripotent stem cell, a neural stem cell, a mesenchymal stem cell, a hematopoietic stem cell, a peripheral blood stem cell), a primary cell (e.g., a myoblast, a fibroblast) or an immune cell (e.g., a NK cell, a T cell, a dendritic cell, an antigen presenting cell). It should be understood that cells that are generally resistant or unsuitable for protein transduction may be interesting candidates for the synthetic peptide or polypeptide-based shuttle agents of the present specification.

[0210] Non-toxic metabolizable shuttle agent

[0211] In some embodiments, the shuttle agent of the present specification can be non-toxic to the intended target eukaryotic cells at concentrations up to 50 μM, 45 μM, 40 μM, 35 μM, 30 μM, 25 μM, 20 μM, 15 μM, 10 μM, 9 μM, 8 μM, 7 μM, 6 μM, 5 μM, 4 μM, 3 μM, 2 μM, 1 μM, 0.5 μM, 0.1 μM or 0.05 μM. The cytotoxicity of the shuttle agent of the present specification can be measured using any suitable method. In addition, the transduction protocol (e.g., the concentration of the shuttle and / or load used, the shuttle / load exposure time, the exposure in the presence or absence of serum) can be adjusted to reduce or minimize the toxicity of the shuttle agent, and / or improve / maximize the transfection efficiency.

[0212] In some embodiments, the shuttle agent of the present specification can be easily metabolized by the expected target eukaryotic cell. For example, the shuttle agent can be composed entirely or substantially of a peptide or polypeptide, wherein the target eukaryotic cell has a cellular mechanism for metabolism / degradation. In fact, it is expected that the intracellular half-life of the synthetic peptide and polypeptide-based shuttle agents of the present specification is much lower than the half-life of foreign organic compounds such as fluorophores. However, fluorophores may be toxic and must be studied before clinical safe use (Alford et al., 2009). In some embodiments, the shuttle agent of the present specification can be applied to clinical practice. In some embodiments, the shuttle agent of the present specification can avoid the use of domains or compounds whose toxicity is uncertain or not excluded.

[0213] mixture

[0214] In some embodiments, the present description relates to compositions comprising a mixture of at least 2, at least 3, at least 4, or at least 5 different types of synthetic peptides or polypeptide-based shuttle agents as defined herein. In some embodiments, combining different types of synthetic peptides or peptide shuttle agents (e.g., different shuttle agents comprising different types of domains) can provide increased versatility for delivering different polypeptide cargoes within a cell. In addition, without being bound by theory, combining lower concentrations of different types of shuttle agents can help reduce cytotoxicity associated with using a single type of shuttle agent (e.g., at higher concentrations).

[0215] Methods, kits, uses and cells

[0216] In some embodiments, the specification relates to a method for delivering a polypeptide cargo from the extracellular space to the cytosol and / or nucleus of a target eukaryotic cell. The method comprises contacting the target eukaryotic cell with the polypeptide cargo in the presence of a shuttle agent at a concentration sufficient to increase the transduction efficiency of the polypeptide cargo compared to the absence of the shuttle agent. In some embodiments, contacting the target eukaryotic cell with the polypeptide cargo in the presence of a shuttle agent results in an increase in the transduction efficiency of the polypeptide cargo by at least 10 times, 20 times, 30 times, 40 times, 50 times, or 100 times compared to the absence of the shuttle agent.

[0217] In some embodiments, the present specification relates to a method for increasing the transduction efficiency of a polypeptide load to the cytosol of a target eukaryotic cell. As used herein, the expression "increasing transduction efficiency" refers to the ability of the shuttle agent of the present specification to improve the percentage or proportion of the target cell population to which the target load (e.g., polypeptide load) is delivered. Passing through the plasma membrane intracellularly. Immunofluorescence microscopy, flow cytometry, and other suitable methods can be used to assess the efficiency of load transduction. In some embodiments, the shuttle agent of the present specification can achieve a transduction efficiency of at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80% or 85%, for example, as measured by immunofluorescence microscopy, flow cytometry, FACS, and other suitable methods. In some embodiments, the shuttle agents of the disclosure can achieve one of the above transduction efficiencies together with a desired cell viability of at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95%, as measured, for example, by the assay described in Example 3.3a or by another suitable assay known in the art.

[0218] In addition to increasing the target cell transduction efficiency, the shuttle agent of the present specification can promote the delivery of the target load (e.g., polypeptide load) to the cytosol of the target cell. In this regard, it may be challenging to use peptides to effectively deliver the extracellular load to the cytosol of the target cell, because the load is often captured in the intracellular endosome after passing through the plasma membrane, which may limit its intracellular availability and may cause its final metabolic degradation. For example, it is reported that the use of the protein transduction domain from HIV-1 Tat protein causes the load to be isolated in large quantities into intracellular vesicles. In some aspects, the shuttle agent of the present specification can promote the ability of the load captured by the endosomal to escape from the endosomal and enter the cytoplasmic compartment. In this regard, the expression of "to the cytosol" in the phrase "increasing the transduction efficiency of the independent polypeptide load to the cytosol" is intended to indicate that the shuttle agent of the present specification allows the target load delivered in the cell to escape from the endosomal capture and enter the cytosolic compartment. After the target load enters the cytosol, it can be subsequently targeted to various subcellular compartments (e.g., nucleus, nucleolus, mitochondria, peroxisomes). In some embodiments, the expression "to the cytosol" is therefore intended to include not only cytosol delivery, but also delivery to other subcellular compartments that first require loading into the cytosol compartment.

[0219] In some embodiments, the methods of the present specification are in vitro methods. In other embodiments, the methods of the present specification are in vivo methods.

[0220] In some embodiments, the methods of the present specification may include contacting a target eukaryotic cell with a shuttle agent, or a composition as defined herein and a polypeptide cargo. In some embodiments, the shuttle agent or composition may be pre-incubated with the polypeptide cargo to form a mixture before exposing the target eukaryotic cell to the mixture. In some embodiments, the type of shuttle agent may be selected based on the amino acid sequence of the polypeptide cargo to be delivered within the cell. In other embodiments, the type of shuttle agent may be selected to take into account the amino acid sequence of the polypeptide cargo to be delivered within the cell, the cell type, the tissue type, etc.

[0221] In some embodiments, the method may include multiple treatments of the target cells with the shuttle agent or composition (e.g., 1, 2, 3, 4 or more times per day, and / or on a predetermined schedule). In such cases, lower concentrations of the shuttle agent or composition may be desirable (e.g., to reduce toxicity). In some embodiments, the cells may be suspension cells or adherent cells. In some embodiments, one skilled in the art will be able to adapt the teachings of this specification using different combinations of shuttle agents, domains, uses, and methods to suit the specific needs of delivering a polypeptide cargo to a specific cell with a desired viability.

[0222] In some embodiments, the methods of the present disclosure can be applied to methods for intracellular delivery of polypeptide cargo to cells in vivo. These methods can be accomplished by parenteral administration or direct injection into a tissue, organ or system.

[0223] In some embodiments, the shuttle agent or composition and the polypeptide cargo can be exposed to the target cell in the presence or absence of serum. In some embodiments, the method can be suitable for clinical or therapeutic use.

[0224] In some embodiments, the present description relates to a kit for delivering a polypeptide cargo from the extracellular space to the cytosol and / or nucleus of a target eukaryotic cell. In some embodiments, the present description relates to a kit for increasing the transduction efficiency of a polypeptide cargo to the cytosol of a target eukaryotic cell. The kit may comprise a shuttle agent or a composition as defined herein and a suitable container.

[0225] In some embodiments, the target eukaryotic cell can be an animal cell, a mammalian cell or a human cell. In some embodiments, the target eukaryotic cell can be a stem cell (e.g., embryonic stem cell, pluripotent stem cell, induced pluripotent stem cell, neural stem cell, mesenchymal stem cell, hematopoietic stem cell, peripheral blood stem cell), a primary cell (e.g., myoblast, fibroblast) or an immune cell (e.g., NK cell, T cell, dendritic cell, antigen presenting cell). In some embodiments, the present specification relates to isolated cells, which contain a shuttle agent based on a synthetic peptide or polypeptide as defined herein. In some embodiments, the cell can be a protein-induced pluripotent stem cell. It should be understood that cells that are generally resistant or unsuitable for protein transduction may be interesting candidates for the synthetic peptide or polypeptide-based shuttle agent of the present specification.

[0226] In some embodiments, the description relates to a method for producing a synthetic peptide shuttle agent that delivers a polypeptide cargo from the extracellular space to the cytosol and / or nucleus of a target eukaryotic cell, the method comprising synthesizing a peptide that is:

[0227] (1) A peptide of at least 20 amino acids in length comprising:

[0228] (2) an amphipathic α-helical motif with a positively charged hydrophilic outer surface, and

[0229] (3) Hydrophobic outer surface,

[0230] Among them, at least five of the following parameters (4) to (15) are involved:

[0231] (4) based on an open cylindrical representation of an α-helix with 3.6 residues per turn, the hydrophobic outer surface contains a highly hydrophobic core composed of spatially adjacent L, I, F, V, W, and / or M amino acids representing 12% to 50% of the amino acids of the peptide;

[0232] (5) The hydrophobic moment (μ) of the peptide is 3.5 to 11;

[0233] (6) The predicted net charge of the peptide at physiological pH is at least +4;

[0234] (7) the isoelectric point (pI) of the peptide is between 8 and 13;

[0235] (8) The peptide consists of 35% to 65% of any combination of the amino acids A, C, G, I, L, M, F, P, W, Y, and V;

[0236] (9) The peptide consists of any combination of 0% to 30% of the amino acids: N, Q, S and T;

[0237] (10) The peptide consists of 35% to 85% of any combination of amino acids: A, L, K or R;

[0238] (11) a peptide consisting of 15% to 45% of any combination of amino acids: A and L, provided that at least 5% of L is present in the peptide;

[0239] (12) The peptide consists of 20% to 45% of any combination of amino acids: K and R;

[0240] (13) The peptide consists of 0% to 10% of any combination of amino acids: D and E;

[0241] (14) the difference between the percentage of A and L residues in the peptide (%A+L) and the percentage of K and R residues in the peptide (%K+R) is less than or equal to 10%; and

[0242] (15) The peptide consists of any combination of 10% to 45% of the amino acids: Q, Y, W, P, I, S, G, V, F, E, D, C, M, N, T and H.

[0243] In some embodiments, the present description relates to a method for identifying a shuttle agent that delivers a polypeptide cargo from the extracellular space to the cytosol and / or nucleus of a target eukaryotic cell, the method comprising: (a) synthesizing a peptide, which is a peptide as defined herein; (b) contacting a target eukaryotic cell with a polypeptide cargo in the presence of the peptide; (c) measuring the transduction efficiency of the polypeptide cargo in the target eukaryotic cell; and (d) when an increase in the transduction efficiency of the polypeptide cargo in the target eukaryotic cell is observed, identifying the peptide as a shuttle agent that transduces the polypeptide cargo.

[0244] In some embodiments, the present specification relates to a genome editing system comprising: (a) a shuttle agent as defined herein; (b) a CRISPR-associated nuclease; and (c) one or more guide RNAs. In some embodiments, the genome editing system may further comprise a linear DNA template for controlling genome editing.

[0245] Genome editing for improved cell therapy

[0246] In some embodiments, the shuttle agents, synthetic peptides, compositions and methods described herein can be used to transduce genome editing complexes (e.g., CRISPR-based genome editing complexes) to genetically engineer cells to improve cell therapy compared to native cells or untreated cells. These improvements may include, for example, reducing the immunogenicity of engineered cells and / or improving the activity / efficacy of engineered cells.

[0247] Particularly attractive immune cells for genome engineering can be natural killer (NK) cells because they have the natural ability to identify and kill tumor cells. Therefore, in some embodiments, this specification relates to shuttle agents, synthetic peptides, compositions and methods described herein for transducing genome editing complexes (e.g., genome editing complexes based on CRISPR) to genetically engineer NK (or other immune cells benefiting from the same modification) to improve cell-based immunotherapy. For example, this specification may relate to intracellular delivery of one or more genome editing complexes based on CRISPR, and the genome editing complexes include targeting CBLB gene, c-CBL gene, GSK3 gene, ILT2 gene, CISH gene, NKG2a gene, B2M gene or any combination thereof Guide RNA and / or linear DNA template. As described below, such gene targets can enhance NK-mediated cytotoxicity after knockout.

[0248] 1. NKG2A (KLRC1, CD159A, killer cell lectin-like receptor C1)

[0249] CD94 / NKG2A acts as an MHC class I-specific NK inhibitory receptor (Braud et al., 1998; Lee et al., 1998). bright CD16 dim NKG2A is expressed by a subset of NK cells (about 10% of peripheral NK cells), which generally have low cytotoxicity (Cooper et al., 2001; Poli et al., 2009). The NKG2A ligand is a non-classical MHC class I HLA-E molecule expressed on every human cell. Recognition of HLA-E by the NKG2A receptor is part of the "self-tolerance" mechanism (also involving KIR receptors), leading to negative regulation of NK cell cytotoxicity (Lee et al., 1998).

[0250] There is clinical evidence for the role of nonclassical HLA class I, primarily HLA-E and HLA-G (see ILT-2 targets), in evading immune surveillance, leading to higher cancer recurrence and reduced overall survival after surgery (de Kruijf et al., 2010; Levy et al., 2008; Ye et al., 2007a; Yie et al., 2007b; Yie et al., 2007c; Yie et al., 2007d; Guo et al., 2015; Ishigami et al., 2015; Zhen et al., 2013). The use of NKG2A-KO NK cells during adoptive cell therapy can counteract the presence of HLA-E molecules (membrane-bound or soluble) in the tumor microenvironment. In addition, NK cells expanded from K562 feeder cells expressing IL15 or IL21 resulted in a high percentage of NKG2A pos Cells (Denman et al., 2012), and it may be necessary to knock out this inhibitory receptor during the expansion process. In addition, the results in Example G.9 demonstrated that NKG2A-KO NK92 cells have significantly higher cytotoxicity against IFN-γ treated HeLa cells.

[0251] 2. ILT2 (Ig-like transcript 2 gene)

[0252] ILT2 is an inhibitory receptor expressed on several immune cells, including NK cells (Kirwan et al., 2005). The ligand of this receptor is the HLA-G molecule, which is naturally expressed only in the thymus and trophoblasts. However, many tumors acquire the ability to express HLA-G to escape attack by immune cells through inhibition of ILT2 receptor activation. In fact, NKL ILT2- Cells are more effective than parental NKL against K562 cells overexpressing HLA-G (Wu et al., 2015). In addition, overexpression of HLA-G in OVCAR-3 cancer cells impairs NK cell-mediated cytotoxicity (Lin et al., 2007). As for HLA-E, expression of HLA-G on cancer cells is generally associated with poor prognosis.

[0253] 3. c-Cbl and Cbl-b (Casitas B lineage lymphoma oncogene family).

[0254] These genes (from Casitas B-lineage lymphoma proto-oncogenes, Cbl family) encode E3 ligases that function in protein ubiquitination pathways (regulation of cellular protein content). E3 ligases catalyze the formation of a covalent bond between Ub (ubiquitin protein) and specific lysine residues on target proteins (more than several thousand E3 ligases in mammals). Cbl family members are involved in the negative regulation of signaling by receptor tyrosine kinases on immune cells by binding and ubiquitinating phosphorylated receptors and adaptors (Liu et al., 2014; Utz-Nicoladoni, 2015). One demonstrated that c-cbl and Cbl-b ubiquitinated the phosphorylated LAT adaptor. Phosphorylation of LAT upon NK cell activation requires the recruitment of other mediators, in particular PLC-γ and siRNA-mediated knockdown of c-cbl and Cbl-b increased NK cell activity against B-cell lymphoma 721.221-Cw4 (Matalon et al., 2016).

[0255] Others have identified TAM (Tyro3, ​​Axl, Mer) receptors as targets for Cbl-b ubiquitination (Paolino et al., 2014). However, given that TAM receptors negatively regulate NK cells, Cbl-b knockout should be associated with a decrease in NK cell activity. Therefore, TAM receptors can be considered a good target for enhancing NK cells, but it is not possible to knock them out through Cbl-b.

[0256] In vivo studies have shown that Cbl-b- / - mice are protected from the growth of primary tumors (Loeser et al., 2007). In addition, NK cells isolated from these mice have increased proliferation and IFN-γ production upon activation (Paolino et al., 2014).

[0257] 4. GSK3B (glycogen synthase kinase β)

[0258] GSK3b is a Ser / Thr kinase involved in several cellular functions such as proliferation, apoptosis, inflammatory responses, stress, etc. (Patel et al., 2017). Inhibition of GSK3b in NK cells (using a small inhibitor) resulted in increased cytotoxicity against AML (OCI-AML3) (possibly through IFN-g, TNF-α production, 2B4 stimulation and upregulation of LFA-1) (Parameswaran et al., 2016; Aoukaty et al., 2005). We recently demonstrated that the GSK3β inhibitor SB216763 enhanced the cytotoxic activity of NK92 against HeLa cells (data not shown). This effect was increased by co-incubation with IL-15.

[0259] 5.CISH (cytokine-induced SH2-containing protein)

[0260] CIS protein is a member of the inhibitor of cytokine signaling (SOCS) protein, which binds to phosphorylated JAK and inhibits the JAK-STAT signaling pathway. Recently, Cish- / - mice demonstrated that CIS is a key inhibitor of IL15 signaling in NK cells (Delconte et al., 2016). After IL15 exposure, these cells have a prolonged IL15 response, increased IFN-g production and increased cytotoxic potential. In addition, there is a clear relationship between IL15 responsiveness and NKG2D-dependent cytotoxicity (Horng et al., 2007).

[0261] In clinical trials, co-injection of cytokines, such as IL2 and IL15, is strongly recommended during adoptive NK cell therapy to maintain NK cell activity. However, such co-injection can cause severe side effects in patients. The use of IL15-allergic NK cells (CISH knockout) would be beneficial for treatment.

[0262] In some embodiments, the B2M gene (component of MHC class I molecule) encoding β2 microglobulin (B2M) can significantly reduce the immunogenicity of each cell expressing MHC class I. In other aspects, the genome of NK cells can be delivered as described herein after genome editing system. More specifically, the cytotoxicity of NK cells can be improved after delivery of genome editing system targeting specific putative targets, which can enhance NK-mediated cytotoxicity, such as NKG2A, ILT2, c-Cbl, Cbl-b, GSK3B and CISH genes.

[0263] Co-transduction with target peptide cargo and marker protein

[0264] This article and PCT patent application publication number WO / 2016 / 161516 have demonstrated the ability of domain-based and rationally designed peptide shuttle agents to co-transduce two different polypeptide loads into a target eukaryotic cell population. Example 1 of this specification shows that co-transduction of a target polypeptide load (e.g., CRISPR-endonuclease) and an independent marker protein (e.g., GFP) in a target eukaryotic cell population may not necessarily improve the overall transfection efficiency of the target polypeptide load. However, it was surprisingly found that a significantly high proportion of target eukaryotic cells successfully transduced with a target polypeptide load were successfully transduced with a marker protein. On the contrary, a significantly high proportion of cells that were not transduced with a target polypeptide load were not transduced with a marker protein. Separation of cells positive for marker proteins (e.g., by FACS) resulted in a significant increase in the proportion of cells successfully transduced with a target polypeptide load, and it was found that the correlation concentration depended on the cell population that showed the highest. The fluorescence of the marker protein also showed the highest proportion of transduction with the target polypeptide load.

[0265] In some aspects, the present specification relates to a method for enriching eukaryotic cells transduced with a target polypeptide cargo. The method may include: (a) co-transducing a target eukaryotic cell population with a target polypeptide cargo and a marker protein; and (b) separating or concentrating eukaryotic cells transduced with a marker protein, thereby enriching eukaryotic cells transduced with a target polypeptide cargo.

[0266] In some embodiments, the marker protein may not be covalently bound to the target polypeptide cargo (e.g., the marker protein is independent of the target polypeptide cargo), the marker protein may be covalently bound to the target polypeptide cargo, the marker protein may be non-covalently bound to the target polypeptide cargo (e.g., electrostatic and / or conformational binding through protein domain-protein domain interactions), or the marker protein may be covalently bound to the target polypeptide cargo via a cleavable linker (e.g., a linker peptide comprising an enzyme cleavage site, such as an enzyme expressed in endosomes, lysosomes, or cytosol). In some embodiments, the intracellular concentration of the transduced marker protein may be positively correlated with the intracellular concentration of the transduced target polypeptide cargo.

[0267] In some embodiments, the marker protein may comprise a detectable label. As used herein, a "detectable label" refers to a molecule or particle that enables one skilled in the art to identify and separate cells comprising a label from cells lacking the label. In some embodiments, the marker protein may be a fluorescent protein, a fluorescently labeled protein, a bioluminescent protein, an isotope-labeled protein, a magnetically labeled protein, or another detectable label that can separate cells containing the marker protein from cells lacking the marker protein, or can separate cells based on the level of the marker protein in the cell.

[0268] In some embodiments, eukaryotic cells transduced with a marker protein can be isolated or concentrated using flow cytometry, fluorescence activated cell sorting (FACS), magnetic activated cell sorting (MACS), or other known cell separation / sorting techniques. Isolating or enriching successfully transduced cells may be particularly advantageous, for example, for polypeptide cargoes, such as functional CRISPR-based genome editing complexes, which may be associated with relatively low transduction efficiencies.

[0269] It is also surprisingly disclosed herein in Example 1 that cells that were not successfully transduced after a first round of transduction with a polypeptide of interest cargo can be isolated and re-transduced with a polypeptide of interest cargo in a subsequent transduction cycle. These results suggest that cells that were not successfully transduced after a first round of transduction with a polypeptide of interest cargo are not necessarily refractory to subsequent transductions.

[0270] In some embodiments, the present specification relates to a method for enriching eukaryotic cells transduced with a target polypeptide load, the method comprising: (a) co-transducing a target eukaryotic cell population with a target polypeptide load and a marker protein; and (b) separating eukaryotic cells transduced with a marker protein from cells lacking the marker protein, thereby producing a marker protein-positive cell population and a marker protein-negative cell population. In some embodiments, steps (a) and (b) can be repeated one or more times on a marker protein-negative cell population, on a marker protein-positive cell population, or on a marker protein-negative and marker protein-positive cell population. In some embodiments, the method for enriching eukaryotic cells transduced with a target polypeptide load can be automated, for example, by separating cells that are negative for marker protein transduction and re-transducing a marker protein-negative cell population.

[0271] In some embodiments, the present description relates to a method for enriching eukaryotic cells transduced with a target polypeptide cargo, the method comprising: (a) co-transducing a target eukaryotic cell population with a target polypeptide cargo and a marker protein; and (b) separating eukaryotic cells transduced with the marker protein based on the intracellular concentration of the marker protein.

[0272] In some embodiments, a marker protein described herein can be a protein that stimulates cell proliferation (eg, a growth factor or transcription factor), a protein that stimulates cell differentiation, a protein that promotes cell survival, an anti-apoptotic protein, or a protein with another biological activity.

[0273] In some embodiments, the target polypeptide cargo and marker protein can be co-transduced by contacting the target eukaryotic cell with the polypeptide cargo and marker protein in the presence of a peptide transduction agent, wherein the concentration of the peptide transduction agent present is sufficient to improve the transduction efficiency of the polypeptide cargo and marker protein compared to the absence of the peptide transduction agent. In some embodiments, the peptide transduction agent can be an endosomal lytic peptide. In some embodiments, the peptide transduction agent is or comprises a domain-based peptide shuttle agent in PCT Patent Application Publication No. WO / 2016 / 161516 and / or US 9,738,687, or a rationally designed peptide shuttle agent as defined herein. In some embodiments, the aforementioned domain-based peptide shuttle agent can be a synthetic peptide comprising an endosomal leakage domain (ELD) operably linked to a cell penetrating domain (CPD), or an ELD operably linked to a histidine-rich domain and a CPD. In some embodiments, the aforementioned domain-based peptide shuttle agents: (a) comprise a minimum length of 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 amino acid residues and a maximum length of 35, 40, 45, 50, 55, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145 or 150 amino acid residues; (b) have a predicted net charge of at least +4, +5, +6, +7, +8, +9, +10, +11, +12, +13, +14 or +15 at physiological pH; (c) are soluble in aqueous solution; or (d) any combination of (a) to (c). In some embodiments, ELD, CPD, histidine-rich domain, linker domain are as defined herein. In some embodiments, the target eukaryotic cell comprises or consists of an animal cell, a mammalian cell, a human cell, a stem cell, a primary cell, an immune cell, a T cell, a NK cell, a dendritic cell, or other types or subtypes of cells.

[0274] In some embodiments, the target polypeptide cargo can be: (i) a polypeptide cargo as defined herein; and / or (ii) one or more CRISPR-associated nucleases alone or with one or more corresponding guide RNAs and / or linear DNA templates as defined herein.

[0275] Terms

[0276] In some embodiments, this specification may refer to the following clauses:

[0277] 1. A method for delivering a polypeptide cargo from the extracellular space to the cytosol and / or nucleus of a target eukaryotic cell, the method comprising contacting the target eukaryotic cell with the polypeptide cargo in the presence of a shuttle agent, wherein the concentration of the shuttle agent is sufficient to increase the transduction efficiency of the polypeptide cargo compared to the absence of the shuttle agent, wherein the shuttle agent is:

[0278] (1) A peptide of at least 20 amino acids in length comprising:

[0279] (2) an amphipathic α-helical motif with a positively charged hydrophilic outer surface, and

[0280] (3) Hydrophobic outer surface,

[0281] Among them, at least five of the following parameters (4) to (15) are involved:

[0282] (4) based on an open cylindrical representation of an α-helix with 3.6 residues per turn, the hydrophobic outer surface contains a highly hydrophobic core composed of spatially adjacent L, I, F, V, W, and / or M amino acids representing 12% to 50% of the amino acids of the peptide;

[0283] (5) The hydrophobic moment (μ) of the peptide is 3.5 to 11;

[0284] (6) The predicted net charge of the peptide at physiological pH is at least +4;

[0285] (7) the isoelectric point (pI) of the peptide is between 8 and 13;

[0286] (8) The peptide consists of 35% to 65% of any combination of the amino acids A, C, G, I, L, M, F, P, W, Y, and V;

[0287] (9) The peptide consists of any combination of 0% to 30% of the amino acids: N, Q, S and T;

[0288] (10) The peptide consists of 35% to 85% of any combination of amino acids: A, L, K or R;

[0289] (11) a peptide consisting of 15% to 45% of any combination of amino acids: A and L, provided that at least 5% of L is present in the peptide;

[0290] (12) The peptide consists of 20% to 45% of any combination of amino acids: K and R;

[0291] (13) The peptide consists of 0% to 10% of any combination of amino acids: D and E;

[0292] (14) the difference between the percentage of A and L residues in the peptide (%A+L) and the percentage of K and R residues in the peptide (%K+R) is less than or equal to 10%; and

[0293] (15) The peptide consists of any combination of 10% to 45% of the amino acids: Q, Y, W, P, I, S, G, V, F, E, D, C, M, N, T and H.

[0294] 2. The method of clause 1, wherein the shuttling agent is involved in at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, or all of the parameters (4) to (15).

[0295] 3. The method of clause 1 or 2, wherein:

[0296] (i) the shuttle agent is a peptide having a minimum length of 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 amino acids and a maximum length of 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145 or 150 amino acids;

[0297] (ii) the hydrophobic moment (μ) of the amphipathic α-helical motif is between a lower limit of 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0 and an upper limit of 9.5, 9.6, 9.7, 9.8, 9.9, 10.0, 10.1, 10.2, 10.3, 10.4, 10.5, 10.6, 10.7, 10.8, 10.9 or 11.0;

[0298] (iii) the amphipathic α-helical motif comprises a positively charged hydrophilic outer surface, based on an α-helix with a rotation angle of 100 degrees between consecutive amino acids and / or an α-helix with 3.6 residues per turn, wherein the hydrophilic outer surface comprises: (a) at least two, three or four adjacent positively charged K and / or R residues in helical wheel projection; and / or (b) a six adjacent residue stretch comprising three to five K and / or R residues in helical wheel projection;

[0299] (iv) the amphipathic α-helical motif comprises a hydrophobic outer surface, based on an α-helix with a rotation angle of 100 degrees between consecutive amino acids and / or an α-helix with 3.6 residues per turn, wherein the hydrophobic outer surface comprises: (a) at least two adjacent L residues when projected in the helical wheel; and / or (b) a stretch of ten adjacent residues when projected in the helical wheel comprising at least five hydrophobic residues selected from the group consisting of: L, I, F, V, W and M;

[0300] (v) the hydrophobic outer surface comprises a highly hydrophobic core composed of spatially adjacent L, I, F, V, W and / or M amino acids representing 12.5%, 13%, 13.5%, 14%, 14.5%, 15%, 15.5%, 16%, 16.5%, 17%, 17.5%, 18%, 18.5%, 19%, 19.5% or 20% to 25%, 30%, 35%, 40% or 45% of the amino acids of the peptide;

[0301] (vi) the hydrophobic moment (μ) of the peptide is between 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0 and 9.5, 9.6, 9.7, 9.8, 9.9, 10.0, 10.1, 10.2, 10.3, 10.4 or 10.5;

[0302] (vii) the peptide has a predicted net charge of +4, +5, +6, +7, +8, +9, +10, +11, +12, +13, +14 or +15;

[0303] (viii) the peptide has a predicted pi of 10-13; or

[0304] (ix) Any combination of (i) to (viii).

[0305] 4. The method of any one of clauses 1 to 3, wherein the shuttling agent is related to at least one, at least two, at least three, at least four, at least five, at least six or all of the following parameters:

[0306] (8) The peptide consists of any combination of 36% to 64%, 37% to 63%, 38% to 62%, 39% to 61%, or 40% to 60% of the amino acids A, C, G, I, L, M, F, P, W, Y, and V;

[0307] (9) Peptides consisting of 1% to 29%, 2% to 28%, 3% to 27%, 4% to 26%, 5% to 25%, 6% to 24%, 7% to 23%, 8% to 22%, 9% to 21% or 10% to 20% of any combination of the amino acids: N, Q, S and T;

[0308] (10) Peptides consisting of any combination of 36% to 80%, 37% to 75%, 38% to 70%, 39% to 65% or 40% to 60% amino acids: A, L, K or R;

[0309] (11) Peptides consisting of 15% to 40%, 20% to 40%, 20% to 35% or 20% to 30% of any combination of amino acids: A and L;

[0310] (12) The peptide consists of 20% to 40%, 20% to 35%, or 20% to 30% of any combination of amino acids: K and R;

[0311] (13) The peptide consists of 5% to 10% of any combination of amino acids: D and E;

[0312] (14) the difference between the percentage of A and L residues in the peptide (%A+L) and the percentage of K and R residues in the peptide (%K+R) is less than or equal to 9%, 8%, 7%, 6% or 5%; and

[0313] (15) The peptide consists of any combination of 15% to 40%, 20% to 35% or 20% to 30% of the amino acids Q, Y, W, P, I, S, G, V, F, E, D, C, M, N, T and H.

[0314] 5. The method of any one of clauses 1 to 4, wherein the peptide comprises a histidine-rich domain.

[0315] 6. The method of clause 5, wherein the histidine-rich domain is:

[0316] (i) positioned towards the N-terminus of the peptide and / or towards the C-terminus of the peptide;

[0317] (ii) is a stretch of at least 3, at least 4, at least 5 or at least 6 amino acids comprising at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85% or at least 90% histidine residues; and / or comprises at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8 or at least 9 consecutive histidine residues; or

[0318] (iii) Both (i) and (ii).

[0319] 7. The method of any one of clauses 1 to 6, wherein the peptide comprises a flexible linker domain rich in serine and / or glycine residues.

[0320] 8. The method of any one of clauses 1 to 7, wherein the peptide comprises or consists of the following amino acid sequence:

[0321] (a) [X1]-[X2]-[Linker]-[X3]-[X4] (Formula 1);

[0322] (b) [X1]-[X2]-[Linker]-[X4]-[X3] (Formula 2);

[0323] (c) [X2]-[X1]-[Linker]-[X3]-[X4] (Formula 3);

[0324] (d) [X2]-[X1]-[Linker]-[X4]-[X3] (Formula 4);

[0325] (e) [X3]-[X4]-[Linker]-[X1]-[X2] (Formula 5);

[0326] (f) [X3]-[X4]-[Linker]-[X2]-[X1] (Formula 6);

[0327] (g) [X4]-[X3]-[Linker]-[X1]-[X2] (Formula 7); or

[0328] (h) [X4]-[X3]-[Linker]-[X2]-[X1] (Formula 8),

[0329] in:

[0330] [X1] is selected from: 2[Φ]-1[+]-2[Φ]-1[ζ]-1[+]-; 2[Φ]-1[+]-2[Φ]-2[+]-;

[0331] 1[+]-1[Φ]-1[+]-2[Φ]-1[ζ]-1[+]-; and 1[+]-1[Φ]-1[+]-2[Φ]-2[+]-;

[0332] [X2] is selected from: -2[Φ]-1[+]-2[Φ]-2[ζ]-; -2[Φ]-1[+]-2[Φ]-2[+]-;

[0333] -2[Φ]-1[+]-2[Φ]-1[+]-1[ζ]-;-2[Φ]-1[+]-2[Φ]-1[ζ]-1[+]-;-2[Φ]-2[+]-1[Φ]-2[+]-;

[0334] -2[Φ]-2[+]-1[Φ]-2[ζ]-; -2[Φ]-2[+]-1[Φ]-1[+]-1[ζ]-; and -2[Φ]-2[+]-1[Φ]-1[ζ]-1[+]-;

[0335] [X3] is selected from: -4[+]-A-; -3[+]-G-A-; -3[+]-A-A-; -2[+]-1[Φ]-1[+]-A-; -2[+]-1[Φ]-G-A-;

[0336] -2[+]-1[Φ]-A-A-; or -2[+]-A-1[+]-A; -2[+]-A-G-A; -2[+]-A-A-A-; -1[Φ]-3[+]-A-; -1[Φ]-2[+]-G-A-; -1[Φ]-2[+]-A-A-; -1[Φ]-1[+]-1[Φ]-1[+]-A; -1[Φ]-1[+]-1[Φ]-G-A; -1[Φ]-1[+]-1[Φ]-A-A;

[0337] -1[Φ]-1[+]-A-1[+]-A; -1[Φ]-1[+]-A-G-A; -1[Φ]-1[+]-A-A-A; -A-1[+]-A-1[+]-A; -A-1[+]-A-G-A; and -A-1[+]-A-A-A;

[0338] [X4] is selected from: -1[ζ]-2A-1[+]-A; -1[ζ]-2A-2[+]; -1[+]-2A-1[+]-A; -1[ζ]-2A-1[+]-1[ζ]-A-1[+]; -1[ζ]-A-1[ζ]-A-1[+]; -2[+]-A-2[+]; -2[+]-A-1[+]-A; -2[+]-A-1[+]-1[ζ]-A-1[+];

[0339] -2[+]-1[ζ]-A-1[+]; -1[+]-1[ζ]-A-1[+]-A; -1[+]-1[ζ]-A-2[+]; -1[+]-1[ζ]-A-1[+]-1[ζ]-A-1[+]; -1[+]-2[ζ]-A-1[+]; -1[+]-2[ζ]-2[+]; -1[+]-2[ζ]-1[+]-A; -1[+]-2[ζ]-1[+]-1[ζ]-A-1[+];

[0340] -1[+]-2[ζ]-1[ζ]-A-1[+]; -3[ζ]-2[+]; -3[ζ]-1[+]-A; -3[ζ]-1[+]-1[ζ]-A-1[+];

[0341] -1[ζ]-2A-1[+]-A; -1[ζ]-2A-2[+]; -1[ζ]-2A-1[+]-1[ζ]-A-1[+]; -2[+]-A-1[+]-A;

[0342] -2[+]-1[ζ]-1[+]-A; -1[+]-1[ζ]-A-1[+]-A; -1[+]-2A-1[+]-1[ζ]-A-1[+]; and -1[ζ]-A-1[ζ]-A-1[+]; and

[0343] [Linker] is selected from: -Gn-; -Sn-; -(GnSn)n-; -(GnSn)nGn-; -(GnSn)nSn-; -(GnSn)nGn(GnSn)n-; and

[0344] (GnSn)nSn(GnSn)n-;

[0345] in:

[0346] [Φ] is an amino acid which is: Leu, Phe, Trp, Ile, Met, Tyr or Val;

[0347] [+] is an amino acid, which is: Lys or Arg;

[0348] [ζ] is an amino acid which is: Gln, Asn, Thr or Ser;

[0349] A is the amino acid Ala;

[0350] G is the amino acid Gly;

[0351] S is the amino acid Ser; and

[0352] n is an integer of 1 to 20, 1 to 19, 1 to 18, 1 to 17, 1 to 16, 1 to 14, 1 to 13, 1 to 12, 1 to 11, 1 to 10, 1 to 9, 1 to 8, 1 to 7, 1 to 6, 1 to 5, 1 to 1-4 or 1 to 3.

[0353] 9. The method of any one of clauses 1 to 8, wherein:

[0354] (i) the peptide is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95% identical to the amino acid sequence of any one of SEQ ID NOs: 104, 105, 107, 108, 110-131, 133-135, 138, 140, 142, 145, 148, 151, 152, 169-242 and 243-10 242; or the peptide comprises or consists of a functional variant of any one of SEQ ID NOs: 104, 105, 107, 108, 110-131, 133-135, 138, 140, 142, 145, 148, 151, 152, 169-242 and 243-10 242;

[0355] (ii) the peptide:

[0356] (a) comprising or consisting of the amino acid sequence of any one of SEQ ID NOs: 104, 105, 107, 108, 110-131, 133-135, 138, 140, 142, 145, 148, 151, 152, 169-242 and 243-10 242;

[0357] (b) comprising the amino acid sequence motif of SEQ ID NO: 158 and / or 159; or

[0358] (c) comprising the amino acid sequence motif of SEQ ID NO: 158 operably linked to the amino acid sequence motif of SEQ ID NO: 159; or

[0359] (iii) Both (i) and (ii).

[0360] 10. The method of any one of clauses 1 to 9, wherein the peptide comprises an endosomal leakage domain (ELD) and / or a cell penetrating domain (CPD).

[0361] 11. The method of clause 10, wherein:

[0362] (i) The ELD is or is derived from: an endosomolytic peptide; an antimicrobial peptide (AMP); a linear cationic α-helical antimicrobial peptide; a cecropin-A / melittin hybrid (CM series) peptide; a pH-dependent membrane active peptide (PAMP); a peptide amphiphile; a peptide derived from the N-terminus of the HA2 subunit of influenza hemagglutinin (HA); CM18; a diphtheria toxin T domain (DT); GALA; pea; INF-7; LAH4; the human genome project; H5WYG; HA2; EB1; VSVG; Pseudomonas toxin; melittin; KALA; JST-1; C(LLKK) 3 C; G(LLKK) 3 G; or any combination thereof;

[0363] (ii) the CPD is or is derived from: a cell penetrating peptide or a protein transduction domain derived from a cell penetrating peptide; TAT; PTD4; Antennapedia; PVEC; M918; PEP-1; PEP-2; Xentry; arginine stretch; transport protein; SYNB1; SYNB3; or any combination thereof; or (iii) both (i) and (ii).

[0364] 12. The method of clause 10 or 11, wherein the peptide comprises:

[0365] (a) ELD comprising the amino acid sequence of any one of SEQ ID NOs: 1-15, 63 or 64, or a variant or fragment thereof having endosomolytic activity;

[0366] (b) a CPD comprising the amino acid sequence of any one of SEQ ID NOs: 16-27 or 65, or a variant or fragment thereof having cell penetrating activity; or

[0367] (c) Both (a) and (b).

[0368] 13. The method of any one of clauses 10 to 12, wherein:

[0369] (i) The peptide comprises an ELD which is CM18, KALA or C(LLKK) having an amino acid sequence of SEQ ID NO: 1, 14 or 63 3 C, or a variant thereof having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95% identity to SEQ ID NO: 1, 14 or 63 and having endosomolytic activity;

[0370] (ii) wherein the peptide comprises a CPD which is TAT ​​or PTD4 having an amino acid sequence of SEQ ID NO: 17 or 65, or a variant thereof having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95% identity to SEQ ID NO: 17 or 65 and having cell penetrating activity; or

[0371] (iii) Both (i) and (ii).

[0372] 14. The method of any one of clauses 1 to 9, wherein the peptide comprises the amino acid sequence of any one of SEQ ID NOs: 57-59, 66-72 or 82-102, or a functional variant thereof having at least 85%, 90% or 95% identity with any one of SEQ ID NOs: 57-59, 66-72 or 82-102.

[0373] 15. The method of any one of clauses 1 to 14, wherein:

[0374] (i) the shuttle agent can be completely metabolized by the target eukaryotic cell; and / or

[0375] (ii) contacting the target eukaryotic cells with the polypeptide cargo in the presence of said concentration of the shuttling agent results in at least a 10-fold, 20-fold, 30-fold, 40-fold, 50-fold or 100-fold increase in the transduction efficiency of said polypeptide cargo compared to the absence of said shuttling agent.

[0376] 16. The method of any one of clauses 1 to 15 which is an in vitro method.

[0377] 17. A synthetic peptide shuttle agent which is a peptide as defined in any one of clauses 1 to 15.

[0378] 18. The synthetic peptide of clause 17, which is a peptide of 20 to 100 amino acids in length comprising the amino acid sequence of any one of SEQ ID NOs: 104, 105, 107, 108, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 133, 134, 135, 138, 140, 142, 145, 148, 151, 152, 169-242 and 243-10 242; or comprising the amino acid sequence motif of SEQ ID NOs: 158 and / or 159.

[0379] 19. The synthetic peptide shuttle agent of clause 17 or 18, for use in delivering a polypeptide cargo from the extracellular space to the cytosol and / or nucleus of a target eukaryotic cell in vitro, wherein the synthetic peptide shuttle agent is used at a concentration sufficient to increase the transduction efficiency of the polypeptide cargo compared to the absence of the synthetic peptide shuttle agent.

[0380] 20. The synthetic peptide shuttle agent of clause 17 or 18, for use in delivering a polypeptide cargo from the extracellular space to the cytosol and / or nucleus of a target eukaryotic cell in vivo, wherein the synthetic peptide shuttle agent is used at a concentration sufficient to increase the transduction efficiency of the polypeptide cargo compared to the absence of the synthetic peptide shuttle agent.

[0381] 21. A composition comprising a shuttle agent as defined in any one of clauses 1 to 15, or a mixture of at least 2, at least 3, at least 4 or at least 5 different types of shuttle agents as defined in any one of clauses 1 to 15, and a polypeptide cargo to be delivered from the extracellular space to the cytosol and / or nucleus of a target eukaryotic cell.

[0382] 22. Use of a shuttle agent as defined in any one of clauses 1 to 15 or a synthetic peptide as defined in clause 18 for delivering a polypeptide cargo from the extracellular space to the cytosol and / or nucleus of a target eukaryotic cell, wherein the shuttle agent or synthetic peptide is used at a concentration sufficient to increase the transduction efficiency of the polypeptide cargo compared to the absence of the shuttle agent or synthetic peptide.

[0383] 23. A kit for delivering a polypeptide cargo from the extracellular space to the cytosol and / or nucleus of a target eukaryotic cell, the kit comprising a shuttle agent as defined in any one of clauses 1 to 15, or a synthetic peptide as defined in clause 18; and a suitable container.

[0384] 24. The method of any one of clauses 1 to 16, the synthetic peptide shuttle agent of any one of clauses 17 to 20, the composition of clause 21, the use of clause 22, or the kit of clause 23, wherein the polypeptide cargo lacks a cell penetrating domain.

[0385] 25. The method of any one of clauses 1 to 16, the synthetic peptide shuttle agent of any one of clauses 17 to 20, the composition of clause 21, the use of clause 22, or the kit of clause 23, wherein the polypeptide cargo comprises a cell penetrating domain.

[0386] 26. The method of any one of clauses 1 to 16, 24 or 25, the synthetic peptide shuttle agent of any one of clauses 17 to 20, 24 or 25, the composition of any one of clauses 21, 24 or 25, the use of any one of clauses 22 to 25, wherein the polypeptide cargo comprises a subcellular targeting domain.

[0387] 27. The method, synthetic peptide shuttle agent, composition, use or kit of clause 26, wherein the subcellular targeting domain is:

[0388] (a) Nuclear localization signal (NLS);

[0389] (b) nucleolar signal sequence;

[0390] (c) a mitochondrial signal sequence; or

[0391] (d) Peroxisome signal sequence.

[0392] 28. The method, synthetic peptide shuttle agent, composition, use or kit of clause 27, wherein:

[0393] (a) The NLS is from: E1a, T-Ag, c-myc, T-Ag, op-T-NLS, Vp3, nucleoplasmin, histone 2B, Xenopus N1, PARP, PDX-1, QKI-5, HCDA, H2B, v-Rel, Amida, RanBP3, Pho4p, LEF-1, TCF-1, BDV-P, TR2, SOX9 or Max;

[0394] (b) the nucleolar signal sequence is from BIRC5 or RECQL4;

[0395] (c) the mitochondrial signal sequence is derived from Tim9 or yeast cytochrome c oxidase subunit IV; or

[0396] (d) The peroxisome signal sequence is derived from PTS1.

[0397] 29. The method, synthetic peptide shuttle, composition, use or kit of any one of clauses 24 to 29, wherein the polypeptide cargo is complexed with a DNA and / or RNA molecule.

[0398] 30. The method, synthetic peptide shuttle, composition, use or kit of any one of clauses 24 to 29, wherein the polypeptide cargo is a transcription factor, a nuclease, a cytokine, a hormone, a growth factor, an antibody, a peptide cargo, an enzyme, an enzyme inhibitor or any combination thereof.

[0399] 31. The method, synthetic peptide shuttle agent, composition, use or kit of clause 30, wherein:

[0400] (a) the transcription factor is: HOXB4, NUP98-HOXA9, Oct3 / 4, Sox2, Sox9, Klf4, c-Myc, MyoD, Pdx1, Ngn3, MafA, Blimp-1, Eomes, T-bet, FOXO3A, NF-YA, SALL4, ISL1, FoxA1, Nanog, Esrrb, Lin28, HIF1-α, Hlf, Runx1t1, Pbx1, Lmo2, Zfp37, Prdm5, Bcl-6 or any combination thereof;

[0401] (b) the nuclease is catalytically active or catalytically dead: RNA-guided endonuclease, CRISPR endonuclease, type I CRISPR endonuclease, type II CRISPR endonuclease, type III CRISPR endonuclease, type IV CRISPR endonuclease, type V CRISPR endonuclease, type VI CRISPR endonuclease, CRISPR-associated protein 9 (Cas9), Cpf1, CasY, CasX, zinc finger nuclease (ZFN), transcription activator-like effector nuclease (TALEN), homing endonuclease, meganuclease, DNA-guided nuclease, NgAgo, or any combination thereof;

[0402] (c) the antibody recognizes an intracellular antigen; and / or

[0403] (d) The peptide payload recognizes an intracellular molecule.

[0404] 32. The method, synthetic peptide shuttle, composition, use or kit of any one of clauses 24 to 31 for use in cell therapy, genome editing, adoptive cell transfer and / or regenerative medicine.

[0405] 33. The method, synthetic peptide shuttle, composition, use or kit of any one of clauses 24 to 32, wherein the target eukaryotic cell is an animal cell, a mammalian cell, a human cell, a stem cell, a primary cell, an immune cell, a T cell, a NK cell or a dendritic cell.

[0406] 34. A eukaryotic cell comprising a shuttle agent as defined in any one of clauses 1 to 15, a synthetic peptide shuttle agent as defined in clause 18, or a composition as defined in clause 21.

[0407] 35. The eukaryotic cell of clause 34, which is an animal cell, a mammalian cell, a human cell, a stem cell, a primary cell, an immune cell, a T cell, a NK cell or a dendritic cell.

[0408] 36. A method for delivering one or more CRISPR-associated nucleases alone or together with one or more corresponding guide RNAs and / or linear DNA templates to a target eukaryotic cell, the method comprising contacting the target eukaryotic cell with the endonuclease in the presence of a shuttle agent, wherein the concentration of the shuttle agent is sufficient to increase the transduction efficiency of the endonuclease compared to the absence of the shuttle agent, wherein the shuttle agent is as defined in any one of clauses 1 to 15.

[0409] 37. The method of clause 36, which is an in vitro method or an in vivo method.

[0410] 38. The method of clause 36 or 37, wherein the one or more endonucleases are: a type I CRISPR endonuclease, a type II CRISPR endonuclease, a type III CRISPR endonuclease, a type IV CRISPR endonuclease, a type V CRISPR endonuclease, a type VI CRISPR endonuclease, or any combination thereof.

[0411] 39. The method of clause 36 or 37, wherein the one or more endonucleases are CRISPR-associated protein 9 (Cas9), Cpf1, CasX, CasY, or any combination thereof; or catalytically dead CRISPR-associated protein 9 (dCas9), dCpf1, dCasX, dCasY, or any combination thereof.

[0412] 40. The method of any one of clauses 36 to 39, wherein the target eukaryotic cell is an animal cell, a mammalian cell, a human cell, a stem cell, a primary cell, an immune cell, a T cell, a NK cell or a dendritic cell.

[0413] 41. The method of claim 58, wherein the one or more corresponding guide RNAs and / or linear DNA templates target one or more genes to reduce immunogenicity, improve cytotoxicity and / or otherwise improve the effectiveness of the target eukaryotic cells for cell-based therapy compared to corresponding parent eukaryotic cells not subjected to the method.

[0414] 42. The method of clause 41, wherein the cell-based therapy is a cell-based cancer immunotherapy.

[0415] 43. The method of any one of clauses 40 to 42, wherein the one or more corresponding guide RNAs and / or linear DNA templates target the CBLB gene, the c-CBL gene, the GSK3 gene, the ILT2 gene, the CISH gene, the NKG2a gene, the B2M gene or any combination thereof.

[0416] 44. A method for producing a synthetic peptide shuttle agent that delivers a polypeptide cargo from the extracellular space to the cytosol and / or nucleus of a target eukaryotic cell, the method comprising synthesizing the following peptide:

[0417] (1) A peptide of at least 20 amino acids in length comprising:

[0418] (2) an amphipathic α-helical motif with a positively charged hydrophilic outer surface, and

[0419] (3) Hydrophobic outer surface,

[0420] Among them, at least five of the following parameters (4) to (15) are involved:

[0421] (4) based on an open cylindrical representation of an α-helix with 3.6 residues per turn, the hydrophobic outer surface contains a highly hydrophobic core composed of spatially adjacent L, I, F, V, W, and / or M amino acids representing 12% to 50% of the amino acids of the peptide;

[0422] (5) The hydrophobic moment (μ) of the peptide is 3.5 to 11;

[0423] (6) the peptide has a predicted net charge of at least +4 at physiological pH;

[0424] (7) the isoelectric point (pI) of the peptide is between 8 and 13;

[0425] (8) The peptide consists of 35% to 65% of any combination of the amino acids A, C, G, I, L, M, F, P, W, Y, and V;

[0426] (9) The peptide consists of any combination of 0% to 30% of the amino acids: N, Q, S and T;

[0427] (10) The peptide consists of 35% to 85% of any combination of amino acids: A, L, K or R;

[0428] (11) a peptide consisting of 15% to 45% of any combination of amino acids: A and L, provided that at least 5% of L is present in the peptide;

[0429] (12) The peptide consists of 20% to 45% of any combination of amino acids: K and R;

[0430] (13) The peptide consists of 0% to 10% of any combination of amino acids: D and E;

[0431] (14) the difference between the percentage of A and L residues in the peptide (%A+L) and the percentage of K and R residues in the peptide (%K+R) is less than or equal to 10%; and

[0432] (15) The peptide consists of any combination of 10% to 45% of the amino acids: Q, Y, W, P, I, S, G, V, F, E, D, C, M, N, T and H.

[0433] 45. The method of clause 44, wherein the peptide is as defined in any one of clauses 2 to 15.

[0434] 46. ​​A method for identifying a shuttle agent that delivers a polypeptide cargo from the extracellular space to the cytosol and / or nucleus of a target eukaryotic cell, the method comprising:

[0435] (a) a synthetic peptide which is a peptide as defined in any one of clauses 1 to 15 or 18;

[0436] (b) contacting the target eukaryotic cells with the polypeptide cargo in the presence of the peptide;

[0437] (c) measuring the transduction efficiency of the polypeptide cargo in the target eukaryotic cells; and

[0438] (d) When an increase in the transduction efficiency of the polypeptide cargo in the target eukaryotic cells is observed, the peptide is identified as a shuttle agent that transduces the polypeptide cargo.

[0439] 47. The method of clause 46, wherein the polypeptide cargo is as defined in any one of clauses 24 to 31.

[0440] 48. A genome editing system comprising:

[0441] (a) a shuttling agent as defined in any one of clauses 1 to 15 or 18;

[0442] (b) one or more CRISPR-associated endonucleases; and

[0443] (c) one or more guide RNAs.

[0444] 49. The genome editing system of clause 48, further comprising a linear DNA template for controlling genome editing.

[0445] 50. The genome editing system of clause 48 or 49, wherein the one or more CRISPR-associated endonucleases are: type I CRISPR endonucleases, type II CRISPR endonucleases, type III CRISPR endonucleases, type IV CRISPR endonucleases, type V CRISPR endonucleases, type VI CRISPR endonucleases, CRISPR-associated protein 9 (Cas9), Cpf1, CasX, CasY or any combination thereof.

[0446] 51. A method for enriching eukaryotic cells transduced with a target polypeptide load, the method comprising:

[0447] (a) co-transducing a target eukaryotic cell population with a polypeptide cargo of interest and a marker protein; and

[0448] (b) separating or concentrating eukaryotic cells transduced with the marker protein, thereby enriching eukaryotic cells transduced with the polypeptide cargo of interest.

[0449] 52. The method of clause 51, wherein:

[0450] (i) the labeled protein is not covalently bound to the target polypeptide cargo, the labeled protein is covalently bound to the target polypeptide cargo, the labeled protein is non-covalently bound to the target polypeptide cargo, or the labeled protein is covalently bound to the target polypeptide cargo via a cleavable linker; and / or

[0451] (ii) The marker protein comprises a detectable label, or the marker protein is a fluorescent protein, a fluorescently labeled protein, a bioluminescent protein, an isotope-labeled protein or a magnetically labeled protein.

[0452] 53. The method of clause 51 or 52, wherein the intracellular concentration of the transduced marker protein is positively correlated with the intracellular concentration of the transduced target polypeptide load.

[0453] 54. The method of any one of clauses 51 to 53, wherein the eukaryotic cells transduced with the marker protein are isolated or concentrated using flow cytometry, fluorescence activated cell sorting (FACS) or magnetic activated cell sorting (MACS).

[0454] 55. The method of any one of clauses 51 to 54, wherein eukaryotic cells transduced with the marker protein are separated or sorted from cells lacking the marker protein, thereby generating a population of marker protein-positive cells and / or a population of marker protein-negative cells.

[0455] 56. The method of clause 55, further comprising repeating steps (a) and (b) one or more times on the marker protein negative cell population, on the marker protein positive cell population, or on both the marker protein negative and marker protein positive cell populations.

[0456] 57. The method of any one of clauses 51 to 56, wherein eukaryotic cells transduced with the marker protein are separated or sorted based on their intracellular concentration of the marker protein.

[0457] 58. The method of any one of clauses 51 to 57, wherein the marker protein is a protein that stimulates cell proliferation, a protein that stimulates cell differentiation, a protein that promotes cell survival, an anti-apoptotic protein, or a protein that has the biological activity of another protein.

[0458] 59. The method of any one of clauses 51 to 58, wherein the target polypeptide cargo and marker protein are co-transduced by contacting the target eukaryotic cells with the polypeptide cargo and marker protein in the presence of a peptide transduction agent, wherein the peptide transduction agent is present at a concentration sufficient to increase the transduction efficiency of the polypeptide cargo and marker protein compared to the absence of the peptide transduction agent.

[0459] 60. The method of clause 59, wherein:

[0460] (a) the peptide transduction agent is an endosomolytic peptide;

[0461] (b) the peptide transduction agent is or comprises a synthetic peptide shuttle agent as defined in clause 17 or 18;

[0462] (c) target eukaryotic cells include animal cells, mammalian cells, human cells, stem cells, primary cells, immune cells, T cells, NK cells or dendritic cells;

[0463] (d) the target polypeptide cargo is: (i) a polypeptide cargo as defined in any one of clauses 24 to 31; and / or (ii) one or more CRISPR-associated nucleases alone or together with one or more corresponding guide RNAs and / or linear DNA templates as defined in any one of clauses 38 to 43; or

[0464] (e) Any combination of (a) to (d).

[0465] Other objects, advantages and features of the present specification will become more apparent from a reading of the following non-restrictive description of certain embodiments of the invention, given by way of example only with reference to the accompanying drawings.

[0466] Example

[0467] Embodiment 1:

[0468] Materials and methods

[0469] 1.1 Materials

[0470] Unless otherwise stated, all chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA or Oakville, ON, Canada) or were of equivalent grade from BioShop Canada Inc. (Mississauga, ON, Canada) or VWR (Ville Mont-Royal, QC, Canada).

[0471] 1.2 Reagents

[0472] Table 1.1: Reagents

[0473]

[0474]

[0475] 1.3 Cell lines

[0476] HeLa, HEK293A, HEK293T, THP-1, CHO, NIH3T3, CA46, Balb3T3, HT2, KMS-12, DOHH2, REC-1, HCC-78, NCI-H196 and HT2 cells were obtained from the American Type Culture Collection (Manassas, VA, USA) and cultured according to the manufacturer's instructions. Myoblasts were primary human cells gifted by Professor JP Tremblay (Université Laval, Quebec, Canada).

[0477] Table 1.2: Cell lines and culture conditions

[0478]

[0479]

[0480] FBS: Fetal bovine serum

[0481] 1.4 Protein purification

[0482] The fusion protein was expressed in bacteria (Escherichia coli BL21DE3) using an isopropyl β-D-1-thiogalactopyranoside (IPTG)-inducible vector containing a T5 promoter under standard conditions. The culture medium contained 24 g yeast extract, 12 g tryptone, 4 ml glycerol, 2.3 g KH 2 PO 4 and 12.5 g K 2 HPO 4 The bacterial broth was incubated with appropriate antibiotics (e.g., ampicillin) at 37°C with stirring. Expression was induced at an optical density (600 nm) of 0.5-0.6 with a final concentration of 1 mM IPTG at 30°C for 3 hours. The bacteria were recovered after centrifugation at 5000 RPM and the bacterial pellet was stored at -20°C.

[0483] The bacterial pellet was resuspended in Tris buffer (Tris 25 mM pH 7.5, NaCl 100 mM, imidazole 5 mM) containing 1 mM phenylmethylsulfonyl fluoride (PMSF) and passed through a homogenizer Panda 2K at 1000 bar. TM The solution was centrifuged at 15000 RPM, 4°C for 30 minutes. The supernatant was collected and filtered using a 0.22 μM filter unit.

[0484] Using FPLC (AKTA Explorer 100R), the HisTrap ELISA kit was pre-equilibrated with 5 column volumes (CV) of Tris buffer. TM The dissolved protein was loaded onto the FF column using 30 column volumes (CV) of 5% Triton supplemented with 0.1% TM The column was washed with 30 CV of Tris buffer with 40 mM imidazole in X-114. The protein was eluted and collected with 5 CV of Tris buffer with 350 mM imidazole. The collected fractions corresponding to the specific protein were determined by standard denaturing SDS-PAGE.

[0485] The purified protein was diluted in Tris 20 mM at the desired pH according to the pI of the protein and loaded onto an appropriate ion exchange column (Q Sepharose TM or SP Sepharose TM ). The column was washed with 10 CV of 20 mM Tris, 30 mM NaCl and the protein was eluted with a NaCl gradient to 1 M over 15 CV. The collected fractions corresponding to the specific protein were determined by standard denaturing SDS-PAGE. The purified protein was then washed and eluted on an Amicon Ultra TM Concentrate on centrifugal filter 10,000 MWCO in PBS 1X. Estimate protein concentration using standard Bradford assay.

[0486] 1.5 Synthetic peptides and shuttle agents

[0487] All peptides used in this study were purchased from GLBiochem (Shanghai, China) and their purity was confirmed by HPLC and mass spectrometry. In some cases, the synthetic peptides were prepared to contain a C-terminal cysteine ​​residue to allow the preparation of peptide dimers. These dimeric peptides were synthesized directly with a disulfide bond between the C-terminal cysteines of the two monomers. The amino acid sequences and features of each of the synthetic peptides and shuttle agents tested in this example are summarized in Table 1.3, Table B1, and Table C1.

[0488] Table 1.3: Synthetic peptides and shuttle agents tested

[0489]

[0490]

[0491]

[0492]

[0493]

[0494] Using ExPASy TM ProtParam provided by Bioinformatics Resource Portal TM Online tool calculation results (http: / / web.expasy.org / protparam / )

[0495] MW: Molecular weight

[0496] pI: isoelectric point

[0497] Charge: The total number of positively (+) and negatively (-) charged residues

[0498] Embodiment 2:

[0499] Peptide shuttles promote the escape of endocytically trapped calcein

[0500] 2.1 Endosomal escape assay

[0501] Microscopy-based and flow cytometry-based fluorescence assays were developed to study endosomal leakage and determine whether the addition of shuttle agents promoted endosomal leakage of polypeptide cargo. These methods are described in Example 2 of PCT / CA2016 / 050403.

[0502] 2.1.1 Observation of endosomal leakage by microscopy

[0503] Calcein is a membrane-impermeable fluorescent molecule that can be easily internalized by cells when administered into the extracellular medium. Its fluorescence is pH-dependent and calcein self-quenches at higher concentrations. Once internalized, calcein is sequestered in high concentrations in endosomes and can be observed as a punctate pattern by fluorescence microscopy. Following endosomal leakage, calcein is released into the cytoplasm, and this release can be observed in a diffuse pattern by fluorescence microscopy.

[0504] The day before the calcein assay, cells in the exponential growth phase were collected and plated in 24-well plates (80,000 cells per well). As described in Example 1, cells were attached by incubation overnight in an appropriate growth medium. The next day, except for HEK293A (250 μg / mL, 400 μM), the culture medium was removed and replaced with 300 μL of fresh culture medium without FBS but containing 62.5 μg / mL (100 μM) calcein. At the same time, the shuttle agent to be tested was added at a predetermined concentration. The plate was incubated at 37°C for 30 minutes. The cells were washed with 1×PBS (37°C) and fresh culture medium containing FBS was added. The plate was incubated at 37°C for 2.5 hours. The cells were washed three times and observed by phase contrast microscopy and fluorescence microscopy (IX81 TM ,Olympus).

[0505] Figure 1A A typical result is shown, in which untreated HEK293A cells loaded with calcein ("100 μM Calcein") display a low-intensity punctate fluorescence pattern when viewed by fluorescence microscopy (upper left). In contrast, HeLa cells treated with a shuttle that promotes endosomal escape of calcein ("100 μM Calcein + CM18-TAT 5 μM") display a higher-intensity, more diffuse fluorescence pattern in a larger proportion of cells (upper right).

[0506] 2.1.2 Quantification of endosomal leakage by flow cytometry

[0507] In addition to microscopy, flow cytometry allows for a more quantitative analysis of endosomal leakage as the fluorescence intensity signal increases once calcein is released into the cytoplasm. Calcein fluorescence is optimal at physiological pH (e.g., in the cytoplasm) compared to the acidic environment of the endosome.

[0508] One day before the calcein assay, cells in the exponential growth phase were collected and plated in 96-well plates (20,000 cells per well). As described in Example 1, cells were attached by incubation overnight in appropriate growth medium. The next day, except for HEK293A (250 μg / mL, 400 μM), the medium in the wells was removed and replaced with 50 μL of fresh medium without serum but containing 62.5 μg / mL (100 μM) calcein. At the same time, the shuttle agent to be tested was added at a predetermined concentration. The plate was incubated at 37°C for 30 minutes. The cells were washed with 1×PBS (37°C) and fresh medium containing 5-10% serum was added. The plate was incubated at 37°C for 2.5 hours. The cells were washed with 1×PBS and separated by trypsinization. Trypsinization was terminated by adding appropriate growth medium, and flow cytometry was used to quantify calcein fluorescence (Accuri C6, Becton, Dickinsonand Company (BD)).

[0509] Untreated calcein-loaded cells are used as controls to distinguish cells with baseline fluorescence due to calcein captured by endosomes from cells with increased fluorescence due to calcein released from endosomes. Analyze the fluorescence signal mean value ("average count") for quantitative endosomal escape. In some cases, calculate the "average factor", which corresponds to the multiplication of the average count relative to the control (untreated calcein-loaded cells). In addition, analyze the events of the flow cytometry scan corresponding to the cells (size and granularity). Cell mortality is monitored with cell percentage in the total events scanned. When it becomes lower than the control, it is believed that the number of cell fragments increases due to toxicity and the assay is abandoned.

[0510] Figure 1B A typical result is shown, in which an increase in fluorescence intensity (right shift) is observed for calcein-loaded HeLa cells treated with a shuttle agent that promotes endosomal escape ("Calcein 100 μM + CM18-TAT 5 μM", right panel) compared to untreated calcein-loaded HeLa cells ("Calcein 100 μM", left panel). The increase in calcein fluorescence is caused by the increase in pH associated with the release of calcein from endosomes (acidic) to the cytoplasm (physiological).

[0511] 2.2 Results of endosomal escape assay

[0512] 2.2.1 HeLa cells

[0513] HeLa cells were cultured and tested in the endosomal escape assay as described in Example 2.1. The results of the flow cytometry analysis are summarized below. In each case, the flow cytometry results were also confirmed by fluorescence microscopy (data not shown).

[0514] Table 2.1: CM18-penetrating peptide-Cys ratio control in HeLa cells

[0515]

[0516] Table 2.2: CM18-TAT-Cys vs. Control in HeLa Cells

[0517]

[0518] The results in Table 2.1 and Table 2.2 show that compared to untreated control cells or cells treated with single domain peptides (CM18, TAT-Cys, penetrating peptide-Cys) used alone or used together (CM18+TAT-Cys, CM18+ penetrating peptide-Cys), the treatment of calcein-loaded HeLa cells with the shuttle agent CM18-penetrating peptide-Cys and CM18-TAT-Cys (having the domain structure ELD-CPD) resulted in an increase in the average cellular calcein fluorescence intensity. These results indicate that CM18-penetrating peptide-Cys and CM18-TAT-Cys promote the escape of calcein trapped in the endosomal, but single domain peptides (used alone or together) cannot.

[0519] Table 2.3: Dose response of CM18-TAT-Cys in HeLa cells, data from Figure 2

[0520]

[0521]

[0522] Table 2.4: Dose response of CM18-TAT-Cys in HeLa cells

[0523]

[0524] Table 2.5: Dose response of CM18-TAT-Cys and CM18-penetrating peptide-Cys in HeLa cells, data from Figure 3

[0525]

[0526] Table 2.3( Figure 2), 2.4 and 2.5( Figure 3 ) showed that CM18-TAT-Cys and CM18-penetrating peptide-Cys promoted the escape of endosome-trapped calcein in HeLa cells in a dose-dependent manner. In some cases, concentrations of CM18-TAT-Cys or CM18-penetrating peptide-Cys above 10 μM were associated with increased cytotoxicity in HeLa cells.

[0527] Table 2.6: Dimer to monomer ratio of CM18-TAT-Cys and CM18-penetrating peptide-Cys in HeLa cells

[0528]

[0529]

[0530] Table 2.7: Monomer to dimer ratio of CM18-TAT-Cys and CM18-penetrating peptide-Cys in HeLa cells

[0531]

[0532] The results in Tables 2.6 and 2.7 indicate that shuttle peptide dimers (which are molecules comprising more than one ELD and CPD) are able to promote endosomal escape of calcein at levels comparable to the corresponding monomers.

[0533] 2.2.3 HEK293A cells

[0534] To examine the effects of the shuttle agents on different cell lines, HEK293A cells were cultured and tested in an endosomal escape assay as described in Example 2.1. The results of the flow cytometric analysis are summarized in Tables 2.8 and Figure 1B .

[0535] Table 2.8: CM18-TAT-Cys in HEK293A cells

[0536] Table 2.8 and Figure 1B The results showed that treatment of calcein-loaded HEK293A cells with the shuttle agent CM18-TAT-Cys resulted in an increase in the mean cellular calcein fluorescence intensity compared to untreated control cells.

[0537] 2.2.2 Myoblasts

[0538] To test the effects of shuttle agents on primary cells, primary myoblasts were cultured and tested in the endosomal escape assay described in Example 2.1. The results of flow cytometry analysis are summarized in Tables 2.9 and 2.10 and Figure 4 In each case, flow cytometry results were also confirmed by fluorescence microscopy.

[0539] Table 2.9: Dose response of CM18-TAT-Cys in primary myoblasts, data from Figure 4

[0540]

[0541] Table 2.10: Dose response of CM18-TAT-Cys in primary myoblasts

[0542]

[0543]

[0544] Table 2.9( Figure 4 The results shown in Figure 2.10 and Table 2.10 indicate that CM18-TAT-Cys promotes the escape of endosomally trapped calcein in a dose-dependent manner in primary myoblasts. CM18-TAT-Cys concentrations above 10 μM are associated with increased cytotoxicity in myoblasts, as for HeLa cells.

[0545] Table 2.11: Monomer to dimer ratio of CM18-TAT-Cys and CM18-penetrating peptide-Cys in primary myoblasts

[0546]

[0547] Embodiment 3:

[0548] Peptide shuttle agents increase GFP transduction efficiency

[0549] 3.1 Protein transduction assay

[0550] One day before the transduction assay, cells in the exponential growth phase were harvested and seeded in 96-well plates (20,000 cells per well). The cells were incubated overnight in an appropriate growth medium containing FBS (see Example 1). The next day, in a separate sterile 1.5 mL test tube, the specified concentration of load protein was premixed (pre-incubated) at 37°C with the peptide (0.5 to 5 μM) as the test shuttle agent in 50 μL of fresh medium without serum (unless otherwise stated) for 1 or 10 minutes (depending on the protocol). The culture medium in the wells was removed and the cells were washed three times with freshly prepared phosphate buffered saline (PBS) pre-heated at 37°C. The cells were incubated with the load protein / shuttle agent mixture at 37°C for a specified time (e.g., 1, 5, or 60 minutes). After incubation, the cells were quickly washed three times with freshly prepared PBS and / or heparin (0.5 mg / mL) pre-heated at 37°C. Human THP-1 blood cells need to be washed with heparin to avoid unwanted background of cell membrane-bound proteins in subsequent analysis (microscopy and flow cytometry). Finally, cells were incubated in 50 μL of fresh medium containing serum at 37°C before analysis.

[0551] 3.1a Protocol A: Protein transduction assay in adherent cells

[0552] One day before the transduction assay, cells in the exponential growth phase were harvested and seeded in 96-well plates (20,000 cells per well). The cells were incubated overnight in an appropriate growth medium containing serum (see Example 1). The next day, in a separate sterile 1.5 mL tube, the peptide was diluted in sterile distilled water at room temperature (if the load is or contains a nucleic acid, water without nuclease is used). The carrier protein was then added to the peptide, and if necessary, sterile PBS or cell culture medium (serum-free) was added to obtain the desired concentration of shuttle agent and load, which had a final volume sufficient to cover the cells (e.g., 10 to 100 μL per well for a 96-well plate). The peptide / load mixture was then used immediately for the experiment. Each experiment included at least three controls, including: (1) peptide alone (e.g., at the highest concentration tested); (2) load only; and (3) without any load or shuttle agent. The culture medium in the wells was removed, the cells were washed once with PBS preheated at 37°C, and the cells were incubated with the load protein / peptide mixture at 37°C for the desired length of time. The peptide / load mixture was removed from the wells, the cells were washed once with PBS, and fresh complete medium was added. Prior to analysis, the cells were washed once a final time with PBS and fresh complete medium was added.

[0553] 3.1b Protocol B: Protein transduction assay in suspension cells

[0554] One day before the transduction assay, suspension cells in exponential growth phase were harvested and plated in 96-well plates (20,000 cells per well). The cells were incubated overnight in an appropriate growth medium containing serum (see Example 1). The next day, in a separate sterile 1.5 mL tube, the peptide was diluted in sterile distilled water at room temperature (nuclease-free water was used if the load was or contained a nucleic acid). The carrier protein was then added to the peptide, and if necessary, sterile PBS or cell culture medium (serum-free) was added to obtain the desired concentration of shuttle agent and load, which had a final volume sufficient to resuspend the cells (e.g., 10 to 100 μL per well in a 96-well plate). The shuttle agent / peptide was then used in the experiment immediately. Each experiment included at least three controls, including: (1) peptide alone (e.g., at the highest concentration tested); (2) load only; and (3) without any load or shuttle agent. The cells were centrifuged at 400 g for 2 minutes, and then the culture medium was removed and the cells were resuspended in PBS pre-heated at 37°C. The cells were centrifuged again at 400 g for 2 minutes, the PBS was removed, and the cells were resuspended with the carrier protein / peptide mixture at 37 ° C for the desired length of time. Afterwards, 200 μL of complete medium was added directly onto the cells. The cells were centrifuged at 400 g for 2 minutes and the medium was removed. The pellet was resuspended and washed in 200 μL of PBS previously warmed at 37 ° C. After centrifugation again, the PBS was removed, and the cells were resuspended in 50 μL of trypsin-EDTA solution for 2 minutes. 200 μl of complete medium was added directly, and the cells were centrifuged at 400 g for 2 minutes. The medium was removed and the cells were resuspended in 200 μL of complete medium.

[0555] 3.2 Fluorescence microscopy analysis

[0556] Using an Olympus IX70 equipped with a fluorescent lamp (model U-LH100HGAPO) and different filters TM The delivery of fluorescent protein cargo within the cytoplasmic and nuclear cell compartments was observed using an Olympus filter U-MF2 TM (C54942-Exc495 / Em510) to observe the fluorescence signals of GFP and FITC-labeled antibodies. Use Olympus filter HQ-TRTM (V-N41004-Exc555-60 / Em645-75) to observe mCherry TM and GFP antibody fluorescence signal. Olympus filter U-MWU2 TM (Exc330 / Em385) for observing DAPI or Blue Hoechst fluorescence signals. Cells incubated in 50 μL of fresh culture medium were directly observed by microscopy (bright field and fluorescence) at different power fields (4x to 40x). Using CoolSNAP-PRO TMCamera (series A02D874021) to observe cells, using Image-Proplus TM Software to acquire images.

[0557] 3.2a Cell immunolabeling

[0558] Adherent cells were plated on sterile glass tape in 24-well plates at 1.5×105 cells per well and incubated overnight at 37°C. For fixation, cells were incubated with 500 μL / well formaldehyde (3.7% v / v) at room temperature for 15 minutes and washed three times with PBS for 5 minutes. For permeabilization, cells were incubated with 500 μL / well Triton at room temperature for 5 minutes. TM X-100 (0.2%) was incubated for 10 minutes and washed 3 times for 5 minutes with PBS. For blocking, the cells were incubated at room temperature for 60 minutes with 500 μL of PBS containing 1% BSA (PBS / BSA) per well. Primary mouse monoclonal antibodies were diluted with PBS / BSA (1%). Cells were incubated overnight at 4°C in 30 μL of primary antibody. Cells were washed 3 times with PBS for 5 minutes each. Secondary antibodies were diluted in PBS / BSA (1%). Cells were incubated in 250 μL of secondary antibody at room temperature in the dark for 30 minutes. Cells were washed 3 times with PBS for 5 minutes each. The glass strips containing cells were mounted in a mounting medium Fluoroshield with 10 μL of DAPI. TM on a microscope slide.

[0559] 3.3 Flow cytometry analysis:

[0560] Flow cytometry (Accuri C6, Becton, Dickinson and Company (BD)) was used to quantify the fluorescence of GFP. Untreated cells were used to establish a baseline to quantify the increased fluorescence due to the internalization of the fluorescent protein in the treated cells. The percentage of cells with a fluorescent signal higher than the maximum fluorescence of untreated cells, "average %" or "positive cells (%)" were used to identify positive fluorescent cells. "Relative fluorescence intensity (FL1-A)" corresponds to the average of all fluorescence intensities from each cell with a fluorescent signal after the delivery of the fluorescent protein with a shuttle agent. In addition, the events of the flow cytometric scans corresponding to the cells (size and granularity) were analyzed. Cytotoxicity (% cell viability) was monitored by comparing the percentage of cells in the total events scanned by the treated cells relative to the untreated cells.

[0561] 3.3a ​​Vitality analysis

[0562] Where indicated, cell viability was assessed using the rezazurine test. Rezazurine is a sodium salt colorant that changes color from blue to pink by metabolically active mitochondrial enzymes in cells. This colorimetric conversion, which occurs only in viable cells, can be measured by spectroscopic analysis to quantify the percentage of viable cells. A rezazurine stock solution was prepared at 1 mg / 100 mL in water and stored at 4°C. 25 μL of the stock solution was added to each well of a 96-well plate and the cells were incubated at 37°C for 1 hour prior to spectroscopic analysis. The incubation time for the rezazurine enzymatic reaction depends on the number of cells and the volume of medium used in the wells.

[0563] 3.4 Construction and amino acid sequence of GFP

[0564] The gene encoding GFP was cloned into a T5 bacterial expression vector to express a GFP protein containing a 6x histidine tag and a serine / glycine-rich linker at the N-terminus and a serine / glycine-rich linker and a stop codon (-) at the C-terminus. The recombinant GFP protein was purified as described in Example 1.4. The sequence of the GFP construct is:

[0565]

[0566] (MW = 31.46 kDa; pI = 6.19)

[0567] Serine / glycine-rich linkers are in bold

[0568] GFP sequence is underlined

[0569] 3.5 HeLa cells transduced with GFP via CM18-TAT-Cys: fluorescence microscopy

[0570] HeLa cells were cultured and tested in a protein transduction assay as described in Example 3.1. Briefly, GFP recombinant protein was co-incubated with 0, 3 or 5 μM CM18-TAT and then exposed to HeLa cells for 1 hour. Cells were observed by bright field and fluorescence microscopy as described in Example 3.2. Figure 5 The results presented in show intracellular delivery of GFP to HeLa cells in the presence of the shuttle agent CM18-TAT.

[0571] 3.6 GFP transduction in HeLa cells via shuttle agents: dose response (CM18-TAT-Cys, dCM18-TAT-Cys, GFP) and cell viability

[0572] HeLa cells were cultured and tested in the protein transduction assay described in Examples 3.1-3.3. In brief, GFP recombinant protein was co-incubated with different concentrations of CM18-TAT-Cys or dimerized CM18-TAT-Cys (dCM18-TAT-Cys) and then exposed to HeLa cells for 1 hour. The results are shown in Table 3.1 and Figure 6.

[0573] Table 3.1: Dose response (CM18-TAT) and cell viability, data from Fig. 6A and 6B

[0574]

[0575] Table 3.1 and Fig. 6A The results of flow cytometric analysis of the fluorescence intensity of HeLa cells transduced with GFP (5 μM) with or without 5, 3, 1 and 0.5 μM CM18-TAT-Cys are shown. The corresponding cytotoxicity data are shown in Tables 3.1 and Figure 6B These results indicate that the shuttle agent CM18-TAT-Cys increases the transduction efficiency of GFP in a dose-dependent manner.

[0576] Table 3.2: Dose response (GFP), data from Fig. 7A and 7B

[0577]

[0578]

[0579] Table 3.2 and Figure 7 show the results of flow cytometric analysis of the fluorescence intensity of HeLa cells transduced with different concentrations of GFP (1-10 μM) with or without 5 μM of CM18-TAT-Cys ( Fig. 7A ) or 2.5 μM dCM18-TAT-Cys ( Figure 7B ).

[0580] 3.7 GFP transduction in HeLa cells: dose response of CM18-TAT-Cys, CM18-penetrant peptide-Cys and their dimers

[0581] HeLa cells were cultured and tested in the protein transduction assay as described in Example 3.1. Briefly, GFP recombinant protein (5 μM) was co-incubated with different concentrations of CM18-TAT-Cys, CM18-penetrating peptide-Cys and respective dimers (dCM18-TAT-Cys, dCM18-penetrating peptide-Cys) and then exposed to HeLa cells for 1 hour. Cells were analyzed by flow cytometry as described in Example 3.3. The results are shown in Tables 3.3 and Figure 8 As well as Table 3.4 and Fig. 9 middle.

[0582] Table 3.3: Figure 8 Data in

[0583]

[0584] Table 3.3 and Figure 8 The results showed that the transduction efficiency of GFP in HeLa cells was increased using the shuttle agents CM18-TAT-Cys and dCM18-TAT-Cys (see Figure 8 Although no intracellular delivery of GFP was observed using either CM18-penetrating peptide-Cys or dCM18-penetrating peptide-Cys alone (see Figure 8 3 or 4), but the combination of CM18-TAT-Cys and CM18-penetrating peptide-Cys (monomer or dimer) improved the delivery of GFP protein (see Figure 8 The four rightmost bars in the graph).

[0585] Table 3.4: Fig. 9 Data in

[0586]

[0587] Table 3.4 and Fig. 9 The results showed that the transduction efficiency of GFP in HeLa cells was increased using the shuttle agents CM18-TAT-Cys and dCM18-TAT-Cys (see Fig. 9 Although no intracellular delivery of GFP was observed using either CM18-penetrating peptide-Cys or dCM18-penetrating peptide-Cys alone (see Fig. 9 3 or 4), but the combination of CM18-TAT-Cys and CM18-penetrating peptide-Cys (monomer or dimer) improved the delivery of GFP protein (see Fig. 9 The four rightmost bars in the graph).

[0588] 3.8 GFP transduction in HeLa cells via shuttle agents: controls

[0589] HeLa cells were cultured and tested in the protein transduction assay as described in Example 3.1. In short, GFP recombinant protein (5 μM) was co-incubated with 5 μM of various following peptides: TAT-Cys; CM18; Penetrating peptide-Cys; TAT-Cys+CM18; Penetrating peptide-Cys+CM18 and CM18-TAT-Cys, and then exposed to HeLa cells for 1 hour. GFP fluorescence was observed by bright field and fluorescence microscopy. Microscopic examination results (data not shown) show that CM18-TAT-Cys is used to successfully deliver GFP in cells. However, using single domain peptides (CM18, TAT-Cys, Penetrating peptide-Cys) alone or together (CM18+TAT-Cys, CM18+ Penetrating peptide-Cys), GFP cannot be successfully delivered in cells. These results are consistent with those provided in Tables 2.1 and 2.2 for the calcein endosomal escape assay.

[0590] Embodiment 4:

[0591] Peptide shuttle agents increase TAT-GFP transduction efficiency

[0592] The experiments in Example 3 demonstrate the ability of shuttle agents to deliver GFP intracellularly. This example provides experiments demonstrating that shuttle agents can also increase the intracellular delivery of a GFP cargo protein fused to a CPD (TAT-GFP).

[0593] 4.1 Construction and amino acid sequence of TAT-GFP

[0594] In addition to cloning the TAT sequence between the 6x histidine tag and the GFP sequence, the construction was performed as described in Example 3.4. The 6x histidine tag, TAT, GFP, and the stop codon (-) were separated by a serine / glycine-rich linker. The recombinant TAT-GFP protein was purified as described in Example 1.4. The sequence of the TAT-GFP construct is:

[0595]

[0596]

[0597] [SEQ ID NO: 61]

[0598] (MW = 34.06 kDa; pI = 8.36)

[0599] The TAT sequence is underlined

[0600] Serine / glycine-rich linkers are in bold

[0601] 4.2 Transduction of TAT-GFP by CM18-TAT-Cys in HeLa cells: Observation by fluorescence microscopy

[0602] HeLa cells were cultured and tested in the protein transduction assay described in Example 3.1. Briefly, TAT-GFP recombinant protein (5 μM) was co-incubated with 3 μM CM18-TAT-Cys and then exposed to HeLa cells for 1 hour, and cells and GFP fluorescence were observed by bright field and fluorescence microscopy at 10x and 40x magnifications (as described in Example 3.2). Sample results are shown in Table 1. Fig.10 As shown. Microscope results show that in the absence of CM18-TAT-Cys, TAT-GFP shows low-intensity endosomal distribution as reported in the literature. On the contrary, TAT-GFP is delivered to the cytoplasm and nucleus in the presence of shuttle agent CM18-TAT-Cys. Not limited by theory, TAT peptide itself can be used as a nuclear localization signal (NLS) to explain the nuclear localization of TAT-GFP. These results show that CM18-TAT-Cys can increase the transduction efficiency of TAT-GFP and allow the TAT-GFP captured by the endosome to obtain access to the cytoplasm and nuclear compartments.

[0603] 4.3 TAT-GFP transduction by CM18-TAT-Cys in HeLa cells: dose response and viability of transduced cells

[0604] HeLa cells were cultured and tested in the protein transduction assay described in Example 3.1. Briefly, TAT-GFP-Cys recombinant protein (5 μM) was co-incubated with different concentrations of CM18-TAT-Cys (0, 0.5, 1, 3, or 5 μM) and then exposed to HeLa cells for 1 hour. Cells were analyzed by flow cytometry as described in Example 3.3. The results are shown in Tables 4.3 and Fig.11A shown. Fig. 11B The corresponding cytotoxicity data are given.

[0605] Table 4.3: From Fig.11A and 11B Data

[0606]

[0607] 1 As confirmed by fluorescence microscopy, the fluorescence was mainly endosomal.

[0608] 2 As confirmed by fluorescence microscopy, the fluorescence was more diffuse and also nuclear.

[0609] Embodiment 5:

[0610] Peptide shuttle agents increase GFP-NLS transduction efficiency and nuclear localization

[0611] The experiments in Examples 3 and 4 show the ability of shuttle agents to deliver GFP and TAT-GFP intracellularly. This example provides experiments showing that shuttle agents can facilitate nuclear delivery of a GFP protein cargo fused to a nuclear localization signal (NLS).

[0612] 5.1 Construction and amino acid sequence of GFP-NLS

[0613] The construction was performed as described in Example 3.4, except that the optimized NLS sequence was cloned between the GFP sequence and the stop codon (-). The NLS sequence was separated from the GFP sequence and the stop codon by two serine / glycine-rich linkers. The recombinant GFP-NLS protein was purified as described in Example 1.4. The sequence of the GFP-NLS construct is:

[0614]

[0615] (MW = 34.85 kDa; pI = 6.46)

[0616] NLS sequences are underlined

[0617] Serine / glycine-rich linkers are in bold

[0618] 5.2 Nuclear delivery of GFP-NLS by CM18-TAT-Cys in HeLa cells within 5 min: observation by fluorescence microscopy

[0619] HeLa cells were cultured and tested in the protein transduction assay described in Example 3.1. Briefly, GFP-NLS recombinant protein (5 μM) was co-incubated with 5 μM CM18-TAT-Cys and then exposed to HeLa cells. After 5 minutes, GFP fluorescence was observed by bright field and fluorescence microscopy at 10x, 20x, and 40x magnifications (as described in Example 3.2). Sample results are shown in Fig.12 Microscopic results showed that GFP-NLS was efficiently delivered to the nucleus in the presence of the shuttle agent CM18-TAT-Cys after only 5 min of incubation.

[0620] 5.3 GFP-NLS transduction by CM18-TAT-Cys in HeLa cells: dose response and viability of transfected cells

[0621] HeLa cells were cultured and tested in the protein transduction assay described in Example 3.1. GFP-NLS recombinant protein (5 μM) was co-incubated with 0, 0.5, 1, 3, or 5 μM of CM18-TAT-Cys and then exposed to HeLa cells for 1 hour. Cells were analyzed by flow cytometry as described in Example 3.3. The results are shown in Tables 5.1 and Fig.13A The corresponding cytotoxicity data are given in Fig. 13B .

[0622] Table 5.1: From Fig.13A and 13B Data

[0623]

[0624] These results indicate that CM18-TAT-Cys is able to increase the GFP-NLS transduction efficiency in HeLa cells in a dose-dependent manner.

[0625] 5.4 GFP-NLS transduction in HeLa cells by CM18-TAT-Cys, CM18-penetrating peptide-Cys and their dimers

[0626] HeLa cells were cultured and tested in the protein transduction assay described in Example 3.1. GFP-NLS recombinant protein (5 μM) was co-incubated with different concentrations of CM18-TAT-Cys, CM18-penetrating peptide-Cys and respective dimers (dCM18-TAT-Cys, dCM18-penetrating peptide-Cys) and then exposed to HeLa cells for 1 hour. Cells were analyzed by flow cytometry as described in Example 3.3. The results are shown in Tables 5.2 and 5.3 and Fig.14 and 15 middle.

[0627] Table 5.2: Fig.14 Data in

[0628]

[0629]

[0630] Table 5.3: Fig.15 Data in

[0631]

[0632] Tables 5.2 and 5.3 and Fig.14 and 15 The results in show that the use of the shuttle agents CM18-TAT-Cys and dCM18-TAT-Cys increased the transduction efficiency of GFP-NLS in HeLa cells (see Fig.14 and15 Although no intracellular delivery of GFP-NLS was observed using either CM18-penetrating peptide-Cys or dCM18-penetrating peptide-Cys alone (see Fig.14 and 15 ), but the combination of CM18-TAT-Cys and CM18-penetrating peptide-Cys (monomer or dimer) improved the intracellular delivery of GFP-NLS (see Fig.14 and 15 ).

[0633] 5.5 GFP-NLS transduction in HeLa cells via shuttle agent: incubation for 5 min vs. 1 h; with or without FBS

[0634] HeLa cells were cultured and tested in the protein transduction assay described in Example 3.1. GFP-NLS recombinant protein (5 μM) was co-incubated with CM18-TAT-Cys (3.5 μM) alone or with dCM18-penetrating peptide-Cys (1 μM). Cells were incubated in pure DMEM medium ("DMEM") or DMEM containing 10% FBS ("FBS") for 5 minutes or 1 hour before flow cytometry analysis as described in Example 3.3. The results are shown in Tables 5.4 and Fig.16 Cells not treated with a shuttle agent or GFP-NLS ("Control") and cells treated with GFP-NLS without a shuttle agent ("GFP-NLS 5 μM") were used as controls.

[0635] Table 5.4: Fig.16 Data in

[0636]

[0637] Table 5.4 and Fig.16 The results in show that even the addition of relatively low amounts of dimeric dCM18-penetrating peptide-Cys (1 μM; "dCM18pen") to CM18-TAT-Cys monomers improves GFP-NLS transduction efficiency. Interestingly, intracellular GFP-NLS delivery is achieved in as little as 5 minutes of incubation, and delivery is still achievable (although reduced) in the presence of FBS.

[0638] 5.6 GFP-NLS transduction in THP-1 suspension cells via shuttle agents

[0639] The ability of the shuttle agent to deliver GFP-NLS intracellularly was tested in THP-1 cells, an acute monocytic leukemia cell line grown in suspension. THP-1 cells (see Example 1) were cultured and tested in the protein transduction assay described in Example 3.1. GFP-NLS recombinant protein (5 μM) was co-incubated with or without 1 μM CM18-TAT-Cys and exposed to THP-1 cells for 5 minutes, followed by flow cytometry analysis as described in Example 3.3. The results are shown in Tables 5.5 and Fig.17A The corresponding cytotoxicity data are given in Fig. 17B .

[0640] Table 5.5: Fig.17A and 17B Data in

[0641]

[0642] The results in Table 5.5 and Figure 17 demonstrate the ability of the shuttle agents to deliver protein cargo intracellularly to a human monocytic cell line grown in suspension.

[0643] Embodiment 6:

[0644] Peptide shuttle agents increase the transduction efficiency of FITC-labeled anti-tubulin antibodies

[0645] The experiments in Examples 3-5 show the ability of shuttle agents to improve the transduction efficiency of GFP, TAT-GFP and GFP-NLS. The experiments provided in this Example show that shuttle agents can also deliver larger protein loads: FITC-labeled anti-tubulin antibodies. FITC-labeled anti-tubulin antibodies were purchased from (Abcam, ab64503) with an estimated molecular weight of 150 KDa. Delivery and microscopy protocols are described in Example 3.

[0646] 6.1 Transduction of functional antibodies in HeLa cells by CM18-TAT-Cys: microscopic observation

[0647] FITC-labeled anti-tubulin antibody (0.5 μM) was co-incubated with 5 μM CM18-TAT-Cys and exposed to HeLa cells for 1 hour. Antibody delivery was observed by bright field (20x) and fluorescence microscopy (20x and 40x). Fig.18 As shown, fluorescent tubulin fibers are visible in the cytoplasm, demonstrating the functionality of the antibody within the cell.

[0648] 6.2 Transduction of functional antibodies by CM18-TAT-Cys, CM18-penetrant peptide-Cys and dimers in HeLa: flow cytometry

[0649] HeLa cells were cultured and tested in the protein transduction assay described in Example 3.1. FITC-labeled anti-tubulin antibody (0.5 μM) was co-incubated with 3.5 μM CM18-TAT-Cys, CM18-penetrating peptide-Cys or dCM18-penetrating peptide-Cys or a combination of 3.5 μM CM18-TAT-Cys and 0.5 μM dCM18-penetrating peptide-Cys and exposed to HeLa cells for 1 hour. Cells were analyzed by flow cytometry as described in Example 3.3. The results are shown in Tables 6.1 and Fig.19A The corresponding cytotoxicity data are shown in Fig.19B .

[0650] Table 6.1: From Fig.19A and 19B Data in

[0651]

[0652]

[0653] Table 6.1 and Fig.18 The results in and 19 show that CM18-TAT-Cys and CM18-penetrating peptide-Cys promote the intracellular delivery of FITC-labeled anti-tubulin antibodies. Compared with the results of GFP, TAT-GFP and GFP-NLS in Examples 3-5, CM18-penetrating peptide-Cys is able to deliver antibody loads intracellularly when used alone (without CM18-TAT-Cys). However, compared with the use of CM18-TAT-Cys alone, the combination of CM18-TAT-Cys and dCM18-penetrating peptide-Cys allows higher intracellular delivery and has less cytotoxicity than CM18-penetrating peptide-Cys and dCM18-penetrating peptide-Cys (see Fig.19A and 19B ).

[0654] Embodiment 7:

[0655] CM18-TAT-Cys allows intracellular plasmid DNA delivery, but plasmid expression is poor

[0656] In this example, the ability of the CM18-TAT-Cys shuttle to deliver plasmid DNA intracellularly was tested using a plasmid encoding GFP on HEK293A cells.

[0657] 7.1 Transfection assay in HEK293A cells

[0658] One day before the transfection assay, mammalian cells (HEK293A) in exponential growth phase were harvested and seeded in 24-well plates (50,000 cells per well). The cells were incubated overnight in the appropriate growth medium containing FBS. The next day, in a separate sterile 1.5 mL tube, the Cy5 TM Fluorescent dye-labeled pEGFP and CM18-TAT-Cys (0.05, 0.5 or 5 μM) were mixed in fresh PBS at 37°C with a final 100 μL volume for 10 minutes. The culture medium in the well was removed, the cells were quickly washed three times with PBS, and 500 μL of warm culture medium without FBS was added. pEGFP and CM18-TAT-Cys solution were added to the cells and incubated at 37°C for 4 hours. After incubation, the cells were washed with PBS and fresh culture medium containing FBS was added. The cells were incubated at 37°C and then flow cytometry was performed, as described in Example 3.

[0659] 7.2 Plasmid DNA delivery using CM18-TAT-Cys

[0660] According to the manufacturer's instructions (Mirus Bio LLC), Cy5 TM Dye-labeled plasmid DNA (pEGFP). Cy5 TM Moiety did not affect transfection efficiency (data not shown). Flow cytometric analysis allowed quantification of Cy5 corresponding to DNA intracellular delivery and GFP emission, corresponding to successful nuclear delivery, DNA transcription, and protein expression. TM The results are shown in Table 7.1 and Fig. 20 shown.

[0661] Table 7.1: From Fig. 20 Data in

[0662]

[0663]

[0664] Table 7.1 and Fig. 20The results shown in show that, compared with cells incubated with DNA only, when used at 0.05, 0.5 and 5 μM concentrations, CM18-TAT-Cys can increase the intracellular delivery of plasmid DNA (" pEGFP-Cy5 "). However, the expression of GFP was not detected in cells, which shows that very little plasmid DNA obtains access to the cytoplasmic compartment, allowing nuclear localization. Not limited by theory, plasmid DNA may be sealed in endosomes in large quantities to prevent escape to the cytoplasmic compartment. Salomone et al., 2013 reported the use of CM18-TAT11 hybrid peptides to deliver plasmid DNA in cells. They use luciferase reporter gene assay to assess transfection efficiency, which may not be ideal for the efficiency of quantitative cytoplasm / nuclear delivery, because the ratio of plasmid DNA successfully released from endosomes and delivered to the core may be overestimated due to the effective activity of luciferase. In this regard, the authors of Salomone et al., 2013 even indicated that the expression of luciferase coincided with the massive capture of large numbers of (naked) DNA molecules in vesicles, which is consistent with Table 7.1 and Fig. 20 The results shown are consistent.

[0665] 7.3 Plasmid DNA delivery of peptides in HeLa cells

[0666] After the poor transfection efficiency observed for the peptide CM18-TAT-Cys (0.1%, see Table 7.1) in HEK293A cells, the experiments were repeated in another cell line (HeLa) with CM18-TAT-Cys and the other peptides listed in Table 1.3, Table B1 and Table C1.

[0667] One day before the transfection assay, HeLa cells in the exponential growth phase were harvested and seeded in 96-well plates (10,000 cells per well). The cells were incubated overnight in an appropriate growth medium containing FBS. The next day, in a separate sterile 1.5 mL tube, the peptide to be tested and the polynucleotide vector (pEGFP-C1) were mixed in a final volume of 50 μL in a serum-free medium at 37 ° C for 10 minutes. The culture medium in the well was removed and the cells were quickly washed once with PBS at 37 ° C. A mixture containing the peptide to be tested and the polynucleotide vector was added to the cells and incubated at 37 ° C for a specified time (e.g., 1 minute, 1 hour, or 4 hours). After incubation, the cells were washed once with PBS at 37 ° C, and fresh culture medium containing FBS was added. The cells were incubated at 37 ° C, and then flow cytometry analysis was performed as described in Example 3.2 to identify transfection efficiency (i.e., cells expressing EGFP) and viability. The results are shown in Table 7.2.

[0668] Table 7.2. DNA transfection in HeLa cells using peptides

[0669]

[0670]

[0671] All peptides tested in Table 7.2 showed transfection efficiencies less than 1%. In addition, the low transfection efficiency of CM18-TAT-Cys (0.08%) was confirmed in HeLa cells. These results show that peptides suitable for delivering polypeptide loads may not necessarily be suitable for delivering plasmid DNA. For example, the shuttle agent His-CM18-PTD4-His is shown herein to effectively transduce polypeptide loads (see, for example, Example 10), but the peptide only shows a DNA plasmid transfection efficiency of 0.34% (Table 7.2).

[0672] Embodiment 8:

[0673] Addition of a histidine-rich domain to the shuttle agent can further improve GFP-NLS transduction efficiency

[0674] 8.1 Transduction of GFP-NLS by His-CM18-TAT-Cys in HeLa cells: microscopic observation

[0675] GFP-NLS (5 μM; see Example 5) was co-incubated with 5 μM CM18-TAT-Cys or His-CM18-TAT and exposed to HeLa cells for 1 hour. Nuclear fluorescence of intracellularly delivered GFP-NLS was confirmed by fluorescence microscopy (data not shown), indicating that GFP-NLS was successfully delivered to the nucleus.

[0676] 8.2 Transduction of GFP-NLS by His-CM18-TAT in HeLa cells: flow cytometry

[0677] HeLa cells were cultured and tested in the protein transduction assay described in Example 3.1. GFP-NLS (5 μM) was co-incubated with 0, 1, 3, or 5 μM of CM18-TAT-Cys or His-CM18-TAT and exposed to HeLa cells for 1 hour. Cells were analyzed by flow cytometry as described in Example 3.3. The results are shown in Tables 8.1 and Fig.21A The corresponding cytotoxicity data are shown in Fig. 21B shown.

[0678] Table 8.1: From Fig.21A and 21B Data in

[0679]

[0680] Surprisingly, the results in Table 8.1 and Figure 21 show that His-CM18-TAT is able to increase the GFP-NLS protein transduction efficiency by about 2-fold at 3 μM and 5 μM concentrations compared to CM18-TAT-Cys. These results suggest that the addition of a histidine-rich domain to a shuttle agent comprising an ELD and a CPD can significantly increase its peptide cargo transduction efficiency. Alternatively or in parallel, combining a shuttle agent with another independent synthetic peptide containing a histidine-rich domain fused to a CPD (but lacking an ELD) can provide similar advantages for protein transduction, with the additional advantage of allowing the concentration of the histidine-rich domain to be varied or controlled independently of the concentration of the shuttle agent. Without being limited by theory, the histidine-rich domain may act as a proton sponge in the endosome, providing another mechanism for endosomal membrane destabilization.

[0681] Embodiment 9:

[0682] His-CM18-PTD4 increases GFP-NLS and mCherry TM -Transduction efficiency and nuclear delivery of NLS- and FITC-labeled anti-tubulin antibodies

[0683] 9.1 Protein transduction protocol

[0684] Protocol A: Protein transduction assay delivered in cell culture medium

[0685] The day before the transduction assay, cells in the exponential growth phase were harvested and plated in 96-well plates (20,000 cells per well). The cells were incubated overnight in an appropriate growth medium containing FBS (see Example 1). The next day, in a separate sterile 1.5-mL tube, the desired concentration of load protein was premixed (pre-incubated) with the expected concentration of shuttle agent in 50 μL fresh serum-free medium at 37 ° C for 10 minutes (unless otherwise indicated). The culture medium in the well was removed and the cells were washed 1-3 times (depending on the type of cells used) with PBS pre-heated at 37 ° C. The cells were incubated with the load protein / shuttle agent mixture at 37 ° C for the required length of time. After incubation, the cells were washed three times with PBS and / or heparin (0.5 mg / mL) pre-heated at 37 ° C. In subsequent analysis (microscope and flow cytometry), washing with heparin was used for human THP-1 blood cells to avoid undesirable cell membrane-bound protein background. Prior to analysis, cells were finally incubated at 37°C in 50 μL of fresh medium with serum.

[0686] Protocol B: Protein transduction assay in adherent cells in PBS

[0687] One day before the transduction assay, cells in the exponential growth phase were harvested and plated in 96-well plates (20,000 cells per well). The cells were incubated overnight in an appropriate growth medium containing serum (see Example 1). The next day, in a separate sterile 1.5-mL tube, the shuttle agent was diluted with sterile distilled water at room temperature (if the load is or contains a nucleic acid, nuclease-free water is used). The load protein was then added to the shuttle agent, and if necessary, sterile PBS was added to obtain the expected concentration of the shuttle agent and load in a final volume sufficient to cover the cells (e.g., 10 to 100 μL per well for a 96-well plate). The shuttle agent / load mixture was then used in the experiment immediately. Each experiment included at least three controls, including: (1) the shuttle agent alone (e.g., at the highest concentration tested); (2) the load alone; and (3) without any load or shuttle agent. The culture medium in the wells was removed, the cells were washed once with PBS previously heated at 37°C, and then the shuttle agent / load mixture was added to cover all cells for the desired length of time. Remove the shuttle / load mixture from the wells, wash the cells once with PBS, and add fresh complete medium. Prior to analysis, wash the cells once with PBS and add fresh complete medium.

[0688] Protocol C: Protein transduction assay with cells suspended in PBS

[0689] The day before the transduction assay, exponentially growing suspension cells were harvested and plated in 96-well plates (20,000 cells per well). The cells were incubated overnight in an appropriate growth medium containing serum (see Example 1). The next day, in a separate sterile 1.5-mL tube, the shuttle agent was diluted with sterile distilled water at room temperature (if the load is or contains nucleic acid, nuclease-free water is used). The load protein was then added to the shuttle agent, and if necessary, sterile PBS or cell culture medium (without serum) was added to obtain the expected concentration of shuttle agent and load in a final volume sufficient to resuspend the cells (e.g., 10 to 100 μL per well for 96-well plates). The shuttle agent / load mixture was then used in the experiment immediately. Each experiment included at least three controls, including: (1) the shuttle agent alone (e.g., at the highest concentration tested); (2) the load alone; and (3) without any load or shuttle agent. The cells were centrifuged at 400g for 2 minutes, and then the culture medium was removed and the cells were resuspended in PBS pre-heated at 37°C. Centrifuge the cells again at 400g for 2 minutes, remove the PBS, and resuspend the cells in the shuttle / load mixture. After the desired incubation time, add 100 μL of complete medium directly onto the cells. Centrifuge the cells at 400g for 2 minutes and remove the medium. Resuspend the pellet and wash in 200 μL of PBS pre-warmed to 37°C. After centrifugation again, remove the PBS and resuspend the cells in 100 μL of complete medium. Repeat the last two steps once before analysis.

[0690] 9.2 Transduction of GFP-NLS by His-CM18-PTD4 in HeLa cells using protocol A or B: flow cytometry

[0691] To compare the effects of different protocols on the transduction efficiency of the shuttle agent, HeLa cells were cultured and tested in the protein transduction assay of protocol A or B described in Example 9.1. Briefly, GFP-NLS recombinant protein (5 μM; see Example 5.1) was co-incubated with 10 μM His-CM18-PTD4 using protocol A and exposed to HeLa cells for 1 hour, or co-incubated with 35 μM His-CM18-PTD4 using protocol B and exposed to HeLa cells for 10 seconds. Cells were analyzed by flow cytometry as described in Example 3.3. The results are shown in Tables 9.1 and Fig.22A As shown. (“Positive cells (%)” is the percentage of cells emitting GFP signals).

[0692] Table 9.1: Comparison of protein transduction protocols A and B: from Fig.22A Data

[0693]

[0694] The above results indicate that higher protein transduction efficiency of the loaded GFP-NLS using the shuttle agent His-CM18-PTD4 was obtained using protocol B compared to protocol A.

[0695] 9.3 GFP-NLS transduction by His-CM18-PTD4 in HeLa cells using protocol B: flow cytometry

[0696] Dose response experiments were performed to evaluate the effect of His-CM18-PTD4 concentration on protein transduction efficiency. HeLa cells were cultured and tested in the protein transduction assay described in Protocol B of Example 9.1. Briefly, GFP-NLS recombinant protein (5 μM; see Example 5.1) was co-incubated with 0, 50, 35, 25, or 10 μM His-CM18-PTD4 and then exposed to HeLa cells for 10 seconds. Cells were analyzed by flow cytometry as described in Example 3.3. The results are shown in Tables 9.2 and Fig. 22B .

[0697] Table 9.2: Dose response of shuttle agents using regimen B: Fig. 22B Data

[0698]

[0699] The above results showed that His-CM18-PTD4 could increase the GFP-NLS transduction efficiency in HeLa cells in a dose-dependent manner.

[0700] 9.4 GFP-NLS transduction in HeLa cells via His-CM18-PTD4 using protocol B: Observation by microscopy

[0701] GFP-NLS recombinant protein (5 μM; see Example 5.1) was co-incubated with 35 μM His-CM18-PTD4 and then exposed to HeLa cells for 10 seconds as described in Example 9.1 using protocol B. Cells were then analyzed by fluorescence microscopy as described in Examples 3.2 and 3.2a.

[0702] For the sample results shown in Figures 23 and 24, GFP fluorescence of HeLa cells was observed by bright field and fluorescence microscopy at 4x, 20x and 40x magnifications immediately after the final wash step.

[0703] In Figure 23, the upper panels of A, B and C show nuclear markers (DAPI) at magnifications of 4x, 20x and 40x, respectively, while the lower panels show the corresponding GFP-NLS fluorescence. In Figure C, the white triangular window indicates an example of a co-labeled area between the nuclear (DAPI) and GFP-NLS signals. In Figure D, the upper and lower panels show sample bright field images of HeLa cells, and the middle panel shows the results of the corresponding FACS analysis (performed as described in Example 3.3), which indicates the percentage of cells with GFP signals in a 96-well plate. No significant GFP fluorescence was observed in the negative control sample (i.e., cells exposed to GFP-NLS without any shuttle agent; data not shown).

[0704] Figure 24 shows bright field (Panel A) and fluorescence images (Panel B). The inset of Panel B shows the results of the corresponding FACS analysis (performed as described in Example 3.3), which shows the percentage of cells in a 96-well plate with GFP signal. No significant GFP fluorescence was observed in the negative control samples (i.e., cells exposed to GFP-NLS without any shuttle agent; data not shown).

[0705] For the sample results shown in Figure 25, HeLa cells were fixed, permeabilized and immunolabeled as described in Example 3.2a before observation by fluorescence microscopy as described in Example 3.2. Primary mouse monoclonal anti-GFP antibody (Feldan, #A017) and goat anti-mouse Alexa Fluor 500 antibody were used. TM-594 secondary antibody (Abcam #150116) labeled GFP-NLS. The upper figure in Figure 25 shows the nuclear marker (DAPI), and the lower figure shows the corresponding labeling of GFP-NLS. Figures A and B show sample images at 20x and 40x magnification, respectively. White triangle windows represent examples of co-labeled areas between the nucleus and GFP-NLS. No significant GFP-NLS labeling was observed in the negative control samples (i.e., cells exposed to GFP-NLS without any shuttle agent; data not shown).

[0706] Fig.26 Shown are sample images of living cells captured with a confocal microscope at 63x magnification. Fig.26 Panel A shows a bright field image, while Panel B shows the corresponding fluorescent GFP-NLS. Panel C is an overlay between the images of Panels A and B. No significant GFP-NLS fluorescence was observed in the negative control samples (i.e., cells exposed to GFP-NLS without any shuttle agent; data not shown).

[0707] 9.4a Transduction of anti-tubulin antibody labeled with His-CM18-PTD4 in HeLa cells using protocol B: Observation by microscopy

[0708] FITC-labeled anti-tubulin antibody (0.5 μM; Abcam, ab64503) was co-incubated with 50 μM of His-CM18-PTD4 and then exposed to HeLa cells for 10 seconds using protocol B as described in Example 9.1. The cells were then subjected to fluorescence microscopy analysis as described in Examples 3.2 and 3.2a, where after the final wash step, the FITC fluorescence of the anti-tubulin antibody in HeLa cells was immediately visualized by bright field and fluorescence microscopy at 20x magnification. Sample results are shown in Fig.24C and 24D No significant FITC fluorescence was observed in the negative control samples (ie, cells exposed to FITC-labeled anti-tubulin antibody without any shuttling agent; data not shown).

[0709] In summary, the results of Examples 9.4 and 9.4a show that GFP-NLS and FITC-labeled anti-tubulin antibody cargo were successfully transduced and delivered to the nucleus and / or cytoplasm of HeLa cells in the presence of the shuttle agent His-CM18-PTD4.

[0710] 9.5 Kinetics of GFP-NLS transduction by His-CM18-PTD4 in HeLa cells: microscopic observation

[0711] The GFP-NLS recombinant protein (5 μM; see Example 5.1) was co-incubated with 50 μM of His-CM18-PTD4 and then exposed to HeLa cells for 10 seconds using protocol B as described in Example 9.1. After the washing step, the GFP fluorescence of the HeLa cells was immediately observed by fluorescence microscopy (Example 3.2) at 20x magnification after different time intervals. Typical results are shown in Figure 27, where fluorescence microscopy images were captured after 45, 75, 100 and 120 seconds (see Figures A, B, C and D, respectively).

[0712] like Fig.27A As shown, diffuse cellular GFP fluorescence was generally observed after 45 seconds, with areas of lower GFP fluorescence in the nucleus in many cells. These results indicate that GPF-NLS delivered intracellularly via the shuttle agent was predominantly cytoplasmic with low nuclear distribution after 45 seconds. Figures 27B-27D It is shown that after exposure to the His-CM18-PTD4 shuttle and GFP-GFP loading, GFP fluorescence gradually redistributes to the nucleus at 75 seconds (B), 100 seconds (C), and 120 seconds (D). No significant cellular GFP fluorescence was observed in the negative control samples (i.e., cells exposed to GFP-NLS without any shuttle; data not shown).

[0713] The results of Example 9.5 show that GFP-NLS was successfully delivered to the nucleus of HeLa cells in the presence of the shuttle agent His-CM18-PTD4 for 2 minutes.

[0714] 9.6 GFP-NLS and mCherry in HeLa cells via His-CM18-PTD4 TM -NLS co-transduction: microscopic observation

[0715] As described in Example 1.4, mCherry was constructed, expressed and purified from the bacterial expression system. TM -NLS recombinant protein. mCherry TM The sequence of the -NLS recombinant protein is:

[0716]

[0717] (MW = 34.71 kDa; pI = 6.68)

[0718] NLS sequences are underlined

[0719] Serine / glycine-rich linkers are in bold

[0720] GFP-NLS recombinant protein (5 μM; see Example 5.1) and mCherry TM-NLS recombinant protein (5 μM) was co-incubated with 35 μM His-CM18-PTD4 and then exposed to HeLa cells for 10 seconds using protocol B as described in Example 9.1. After the washing step, the cells were immediately observed by bright field and fluorescence microscopy at 20x magnification as described in Example 3.2. Sample results are shown in Figure 28, which shows bright field (Figure A), DAPI fluorescence (Figure B), GFP-NLS fluorescence (Figure C) and mmCherry TM -Corresponding image of NLS fluorescence (Figure D). The white triangle window indicates GFP-NLS and mCherry in the nucleus. TM Examples of co-labeled regions between fluorescent signals. TM No significant cellular GFP or mCherry expression was observed in the cells (data not shown) TM Fluorescence.

[0721] These results suggest that GFP-NLS and mCherry TM -NLS was successfully delivered into the nucleus of HeLa cells together with the presence of the shuttle agent His-CM18-PTD4.

[0722] 9.7 Transduction of GFP-NLS by His-CM18-PTD4 in THP-1 suspension cells: flow cytometry

[0723] The ability of His-CM18-PTD4 to deliver GFP-NLS in the nucleus of suspended cells was tested using THP-1 cells. THP-1 cells were cultured and tested using protocols A and C in the protein transduction assay described in Example 9.1. GFP-NLS (5 μM; see Example 5.1) was co-incubated with 1 μM His-CM18-PTD4 and exposed to THP-1 cells for 1 hour (Protocol A), or co-incubated with 5 μM His-CM18-PTD4 and exposed to THP-1 cells for 15 seconds (Protocol C). Cells were analyzed by flow cytometry as described in Example 3.3. The results are shown in Tables 9.3 and Fig.31 .

[0724] Table 9.3: From Fig.31 Data

[0725]

[0726] 9.8 GFP-NLS transduction via His-CM18-PTD4 in THP-1 cells: microscopic observation

[0727] GFP-NLS recombinant protein (5 μM; see Example 5.1) was co-incubated with 5 μM His-CM18-PTD4 and then exposed to THP-1 cells for 15 seconds using protocol C as described in Example 9.1. Cells were observed microscopically as described in Example 3.2.

[0728] For the sample results shown in Figure 32, the GFP fluorescence of HeLa cells was observed by bright field (upper figure) and fluorescence (lower figure) microscopes of 4x, 10x and 40x magnification (Figure A-C, respectively) immediately after the final washing step. The white triangle window in Figure C indicates an example of a region of co-labeling between bright field and fluorescence images. Figure D shows the typical results of corresponding FACS analysis (carried out as described in Example 3.3), which indicates the percentage of cells with GFP signals in 96-well plates. Other results are shown in Figure 33, where Figures A and B show bright field images, and Figures C and D show corresponding fluorescence images. The white triangle window indicates an example of a region of co-labeling between Figure A and Figure C and Figure B and Figure D. The rightmost figure shows the typical results of corresponding FACS analysis (carried out as described in Example 3.3), which indicates the percentage of cells with GFP signals in 96-well plates.

[0729] No significant cellular GFP fluorescence was observed in negative control samples (ie, cells exposed to GFP-NLS without any shuttling agent; data not shown).

[0730] The results of this example demonstrate that GFP-NLS was successfully delivered intracellularly in THP-1 cells in the presence of the shuttle agent His-CM18-PTD4.

[0731] Embodiment 10:

[0732] Different multi-domain shuttle agents (rather than single-domain peptides) successfully transduce GFP-NLS in HeLa and THP-1 cells

[0733] 10.1 GFP-NLS transduction in HeLa cells by different shuttle agents: flow cytometry

[0734] HeLa cells were cultured and tested in the protein transduction assay using protocol B described in Example 9.1. Briefly, GFP-NLS recombinant protein (5 μM; see Example 5.1) was co-incubated with 50 μM of different shuttle agents and exposed to HeLa cells for 10 seconds. Cells were analyzed by flow cytometry as described in Example 3.3. The results are shown in Tables 10.1 and Fig.29A "Positive cells (%)" is the average percentage of all cells emitting GFP signal. The negative control ("Control") corresponds to cells incubated with GFP-NLS recombinant protein (5 μM) without any shuttling agent.

[0735] Table 10.1: From Fig.29A Data

[0736]

[0737] *His-LAH4-PTD4: The intracellular GFP fluorescence pattern was punctate as observed by fluorescence microscopy, indicating that the GFP cargo was still trapped in the endosome.

[0738] 10.2 GFP-NLS transduction in HeLa using different shuttle agents and different incubation times: flow cytometry

[0739] HeLa cells were cultured and tested in the protein transduction assay using protocol B described in Example 9.1. Briefly, GFP-NLS recombinant protein (5 μM; see Example 5.1) was co-incubated with 10 μM of TAT-KALA, His-CM18-PTD4 or His-C(LLKK)3C-PTD4 for 1, 2 or 5 minutes. After the final wash step, cells were analyzed by flow cytometry as described in Example 3.3. The results are shown in Tables 10.2 and Fig.29B "Positive cells (%)" is the average percentage of all cells emitting GFP signal. The negative control ("Control") corresponds to cells co-incubated with GFP-NLS recombinant protein (5 μM) without any shuttling agent.

[0740] Table 10.2: From Fig.29B Data

[0741]

[0742]

[0743] 10.3 In HeLa cells, TAT-KALA, His-CM18-PTD4 and His-C(LLKK) 3 Transduction of C-PTD4 with GFP-NLS using different incubation times: flow cytometry

[0744] HeLa cells were cultured and tested in the protein transduction assay described in Example 9.1 using Protocol C. Briefly, GFP-NLS recombinant protein (5 μM; see Example 5.1) was co-cultured with 5 μM of TAT-KALA, His-CM18-PTD4 or His-C(LLKK) 3 C-PTD4 was co-incubated for 1, 2 or 5 minutes. After the final wash step, the cells were analyzed by flow cytometry as described in Example 3.3. The results are shown in Tables 10.3 and Fig.29CThe negative control ("Control") corresponds to cells incubated with GFP-NLS recombinant protein (5 μM) without any shuttling agent.

[0745] Table 10.3: From Fig.29C Data

[0746]

[0747] 10.4 GFP-NLS transduction in HeLa cells by different shuttle agents: flow cytometry

[0748] HeLa cells were cultured and tested in the protein transduction assay using protocol B described in Example 9.1. Briefly, GFP-NLS recombinant protein (5 μM; see Example 5.1) was co-incubated with 50 μM of different shuttle agents (amino acid sequences and properties see Table 1.3) and exposed to HeLa cells for 10 seconds. Cells were analyzed by flow cytometry as described in Example 3.3. The results are shown in Tables 10.3a and 10.3b and Fig.29E and 29F "Positive cells (%)" is the average percentage of all cells emitting GFP signal. The negative control ("Control") corresponds to cells co-incubated with GFP-NLS recombinant protein (5 μM) without any shuttling agent.

[0749] Table 10.3a: From Fig.29E Data

[0750]

[0751] *His-LAH4-PTD4: The intracellular GFP fluorescence pattern observed by fluorescence microscopy was punctate, indicating that the GFP cargo was still trapped in the endosome. ** Fig.29E Not shown in .

[0752] Table 10.3b: From Fig.29F Data

[0753]

[0754] HeLa cells were cultured and tested in the protein transduction assay using protocol B described in Example 9.1. Briefly, GFP-NLS recombinant protein (5 μM; see Example 5.1) was co-incubated with 10 μM of TAT-KALA, His-CM18-PTD4 or His-C(LLKK)3C-PTD4 for 1, 2 or 5 minutes. After the final wash step, cells were analyzed by flow cytometry as described in Example 3.3. The results are shown in Tables 10.3c and 10.3b and Figure 29G and 29H"Positive cells (%)" is the average percentage of all cells emitting GFP signal. The negative control ("Control") corresponds to cells incubated with GFP-NLS recombinant protein (5 μM) without any shuttling agent.

[0755] Table 10.3c: From Figure 29G Data

[0756]

[0757] Table 10.3d: From Fig.29H Data

[0758]

[0759]

[0760] The shuttle agent CM18-PTD4 was used as a model to demonstrate the modular nature of individual protein domains and their ability to be modified. More specifically, the presence or absence of an N-terminal cysteine ​​residue ("Cys"), different flexible linkers between the ELD and CPD domains ("L1": GGS; "L2": GGSGGGS; and "L3": GGSGGGSGGGS) and domain variants of varying length, position, and histidine enrichment were investigated.

[0761] HeLa cells were cultured and tested in the protein transduction assay using protocol B as described in Example 9.1. Briefly, GFP-NLS recombinant protein (5 μM; see Example 5.1) was co-incubated with 20 μM of the shuttle agent His-CM18-PTD4 of different shuttle peptide variants (amino acid sequences and properties see Table 1.3) for 1 minute. After the final washing step, the cells were analyzed by flow cytometry as described in Example 3.3. The results are shown in Tables 10.3e and Fig.29I "Positive cells (%)" is the average percentage of all cells emitting GFP signal. The negative control ("Control") corresponds to cells incubated with GFP-NLS recombinant protein (5 μM) without any shuttling agent.

[0762] Table 10.3e: From Fig.29I Data

[0763]

[0764]

[0765] These results indicate that changes in a given shuttle agent (e.g., CM18-PTD4) can be used to modulate the degree of transduction efficiency and cell viability of a given shuttle agent. More specifically, the addition of an N-terminal cysteine ​​residue to CM18-PTD4 (see Cys-CM18-PTD4) reduced GFP-NLS transduction efficiency by 11% (from 47.6% to 36.6%), but increased cell viability from 33.9% to 78.7%. The introduction of flexible linker domains of varying lengths (L1, L2, and L3) between the CM18 and PTD4 domains did not result in a significant loss of transduction efficiency, but rather increased cell viability (see CM18-L1-PTD4, CM18-L2-PTD4, and CM18-L3-PTD4). Finally, changes in the amino acid sequence and / or position of the histidine-rich domain did not result in a complete loss of transduction efficiency and cell viability of His-CM18-PTD4 (see 3His-CM18-PTD4, 12His-CM18-PTD4, HA-CM18-PTD4, 3HA-CM18-PTD4, CM18-His-PTD4, and His-CM18-PTD4-His). Notably, the addition of a second histidine-rich domain to the C-terminus of His-CM18-PTD4 (i.e., His-CM18-PTD4-His) increased transduction efficiency from 60% to 68%, with similar cell viability.

[0766] 10.5 Lack of GFP-NLS transduction by single domain peptides or His-CPD peptides in HeLa cells: flow cytometry

[0767] HeLa cells were cultured and tested in the protein transduction assay using protocol B as described in Example 9.1. Briefly, GFP-NLS recombinant protein (5 μM; see Example 5.1) was co-incubated with 50 μM of different single domain peptides (TAT; PTD4; penetratin; CM18; C(LLKK)3C; KALA) or the two-domain peptide His-PTD4 (lacking ELD) and exposed to HeLa cells for 10 seconds. After the final wash step, cells were analyzed by flow cytometry as described in Example 3.3. The results are shown in Tables 10.4 and Fig.29D "Positive cells (%)" is the average percentage of all cells emitting GFP signal. The negative control ("Control") corresponds to cells incubated with GFP-NLS recombinant protein (5 μM) without any single domain peptide or shuttle agent.

[0768] Table 10.4: From Fig.29D Data

[0769]

[0770] These results show that the single domain peptides TAT, PTD4, penetratin, CM18, C(LLKK)3C, KALA or the two domain peptide His-PTD4 (lacking the ELD) were unable to successfully transduce GFP-NLS in HeLa cells.

[0771] 10.6 In HeLa cells, TAT-KALA, His-CM18-PTD4, His-C(LLKK) 3 C-PTD4, PTD4-KALA, EB1-PTD4 and His-CM18-PTD4-His transduced with GFP-NLS: Observation by microscopy

[0772] GFP-NLS recombinant protein (5 μM; see Example 5.1) was co-incubated with 50 μM of the shuttle agent and then exposed to HeLa cells for 10 seconds as described in Example 9.1 using protocol B. After an incubation time of 2 minutes, the cells were observed by microscopy as described in Example 3.2.

[0773] For the sample results shown in Figure 30, GFP fluorescence of HeLa cells was observed immediately after the final wash step by bright field (lower row) and fluorescence (upper and middle row) microscopy at 20x or 40x magnification. Shuttle Agents TAT-KALA, His-CM18-PTD4 and His-C(LLKK) 3 The results for C-PTD4 are shown in Figures A, B and C, respectively. The results for the shuttle agents PTD4-KALA, EB1-PTD4 and His-CM18-PTD4-His are shown in Figures D, E and F, respectively. The inset in the bottom row shows the results of the corresponding FACS analysis (performed as described in Example 3.3), which represents the percentage of cells with GFP signal in a 96-well plate. No significant cellular GFP fluorescence was observed in the negative control samples (i.e., cells exposed to GFP-NLS without any shuttle agent; data not shown).

[0774] 10.7 Expression of TAT-KALA, His-CM18-PTD4 and His-C(LLKK) in THP-1 cells using different incubation times 3 C-PTD4 transduced GFP-NLS cells: flow cytometry

[0775] THP-1 cells were cultured and tested in a protein transduction assay using protocol C as described in Example 9.1. Briefly, GFP-NLS recombinant protein (5 μM; see Example 5.1) was co-cultured with 1 μM of TAT-KALA, His-CM18-PTD4 or His-C(LLKK) 3C-PTD4 was incubated for 15, 30, 60, or 120 seconds. After a final wash step, cells were analyzed by flow cytometry as described in Example 3.3. The average percentage of cells emitting GFP signal ("Positive cells (%)") is shown in Tables 10.4a and Fig.34A The average fluorescence intensity is shown in Table 10.5 and Fig.34B The negative control ("Control") corresponds to cells incubated with GFP-NLS recombinant protein (5 μM) without any shuttling agent.

[0776] Table 10.4a: From Fig.34A Data

[0777]

[0778] Table 10.5: From Fig.34B Data

[0779]

[0780] Embodiment 11:

[0781] Repeated daily treatment with low concentrations of the shuttle agent in the presence of serum results in GFP-NLS transduction in THP-1 cells

[0782] 11.1 Use of His-CM18-PTD4 or His-C(LLKK) in THP-1 cells 3 C-PTD4 transduction with GFP-NLS: flow cytometry

[0783] THP-1 cells were cultured and tested in a protein transduction assay using protocol A as described in Example 9.1, but with the following modifications. GFP-NLS recombinant protein (5, 2.5 or 1 μM; see Example 5.1) was co-cultured with 0.5 or 0.8 μM His-CM18-PTD4 or with 0.8 μM His-C(LLKK) 3 C-PTD4 was co-incubated and then exposed to THP-1 cells for 150 minutes daily in the presence of serum-containing cell culture medium. After repeated exposure to the shuttle agent / load for 1 or 3 days, the cells were washed and analyzed by flow cytometry as described in Example 3.3. The results are shown in Tables 11.1 and Fig.35A , B, C and F. The negative control ("Control") corresponds to cells incubated with GFP-NLS recombinant protein (5 μM) without any shuttling agent.

[0784] Table 11.1: From Fig.35A , B, C and F data

[0785]

[0786]

[0787] The viability of THP-1 cells repeatedly exposed to His-CM18-PTD4 and GFP-NLS was determined as described in Example 3.3a. The results are shown in Tables 11.2 and 11.3 and Fig.35D and 35E Table 11.2 and Fig.35D The results show the metabolic activity index of THP-1 cells after 1, 2, 4 and 24 h, Table 11.3 and Fig.35E The results in Figure 5 show the metabolic activity index of THP-1 cells after 1 to 4 days.

[0788] Table 11.2: From Fig.35D Data

[0789]

[0790] Table 11.3: From Fig.35E Data

[0791]

[0792]

[0793] The results in Example 11 show that repeated daily (or chronic) treatment with relatively low concentrations of His-CM18-PTD4 or His-C(LLKK)3C-PTD4 in the presence of serum results in intracellular delivery of GFP-NLS in THP-1 cells. The results also show that the doses of the shuttle agent and the cargo can be adjusted independently to improve the transduction efficiency of the cargo and / or cell viability.

[0794] Embodiment 12:

[0795] His-CM18-PTD4 increases transduction efficiency and nuclear delivery of GFP-NLS in multiple cell lines

[0796] 12.1 Transduction of GFP-NLS using His-CM18-PTD4 in different adherent and suspension cells: flow cytometry

[0797] The ability of the shuttle agent His-CM18-PTD4 to deliver GFP-NLS to the nuclei of different adherent and suspension cells using protocol B (adherent cells) or C (suspension cells) as described in Example 9.1 was examined. The cell lines tested included: HeLa, Balb3T3, HEK293T, CHO, NIH3T3, myoblasts, Jurkat, THP-1, CA46 and HT2 cells, cultured as described in Example 1. GFP-NLS (5 μM; see Example 5.1) was co-incubated with 35 μM His-CM18-PTD4 and exposed to adherent cells for 10 seconds (protocol B), or co-incubated with 5 μM His-CM18-PTD4 and exposed to suspension of suspension cells for 15 seconds (protocol C). The cells were washed and analyzed by flow cytometry as described in Example 3.3. The results are shown in Tables 12.1 and Fig.36 "Positive cells (%)" is the average percentage of all cells emitting GFP signal.

[0798] Table 12.1: From Fig.36 Data

[0799]

[0800]

[0801] 12.2 Transduction of GFP-NLS using His-CM18-PTD4 in several adherent and suspension cell lines: microscopic observation

[0802] The GFP-NLS recombinant protein (5 μM; see Example 5.1) was co-incubated with 35 μM of His-CM18-PTD4 and exposed to adherent cells for 10 seconds using protocol A, or co-incubated with 5 μM of His-CM18-PTD4 and exposed to suspended cells for 15 seconds using protocol B as described in Example 9.1. After washing the cells, GFP fluorescence was observed by bright field and fluorescence microscopy. Figure 37 shows sample images of (A) 293T, (B) Balb3T3, (C) CHO, (D) myoblasts, (E) Jurkat, (F) CA46, (G) HT2 and (H) NIH3T3 cells showing GFP fluorescence captured at 10x magnification. The inset shows the corresponding flow cytometry results performed as described in Example 3.3, indicating the percentage of GFP-NLS positive cells. No significant cellular GFP fluorescence was observed in the negative control samples (i.e., cells exposed to GFP-NLS without any shuttle agent; data not shown).

[0803] Nuclear localization of GFP-NLS was further confirmed in fixed and permeabilized myoblasts using cellular immunolabeling as described in Example 3.2a. Primary mouse monoclonal anti-GFP antibody (Feldan, #A017) and goat anti-mouse Alexa Fluor 504 were used. TM -594 secondary antibody (Abcam #150116) labeled GFP-NLS. Nuclei were labeled with DAPI. Sample results of primary human myoblasts are shown in Figure 38, where GFP immunolabeling is shown in Figure A, and the overlap of GFP immunolabeling and DAPI labeling is shown in Figure B. No significant cellular GFP labeling was observed in the negative control samples (i.e., cells exposed to GFP-NLS without any shuttle agent; data not shown).

[0804] Microscopic examination results showed that GFP-NLS was successfully delivered to the nucleus of all cells tested using the shuttle agent His-CM18-PTD4.

[0805] Embodiment 13:

[0806] His-CM18-PTD4 allows transduction of the CRISPR / Cas9-NLS system and genome editing in Hela cells

[0807] 13.1Cas9-NLS Recombinant Protein

[0808] As described in Example 1.4, the Cas9-NLS recombinant protein was constructed, expressed and purified from a bacterial expression system. The sequence of the produced Cas9-NLS recombinant protein is:

[0809]

[0810] (MW = 162.9 kDa; pI = 9.05)

[0811] NLS sequences are underlined

[0812] Serine / glycine-rich linkers are in bold

[0813] 13.2 Transfection Plasmid Alternative Assay

[0814] This assay allows for the visual identification of cells to which an active CRISPR / Cas9 complex has been successfully delivered. Fig.39A As shown, the assay involves the use of mCherry, a fluorescent protein encoding TM Cells were transfected with expression plasmid DNA of mCherry and GFP (with a stop codon separating their two open reading frames). TM expression, but no GFP expression ( Fig.39B). The CRISPR / Cas9 complex, which has been designed / programmed to cleave the plasmid DNA at the stop codon, is then delivered intracellularly to the transfected mCherry expressing TM Cells ( Fig.39D Successful transduction of an active CRISPR / Cas9 complex results in the CRISPR / Cas9 complex cleaving the plasmid DNA at the stop codon ( Fig.39C In a subset of cells, random nonhomologous DNA repair of the cleaved plasmid occurs and results in the removal of the stop codon, leading to the expression and fluorescence of GFP ( Fig.39E ).

[0815] On day 1 of the transfection plasmid replacement assay, dilute the DNA plasmids for different experimental conditions (250 ng) in DMEM (50 μL) in separate sterile 1.5-mL tubes, vortex, and briefly centrifuge. TM The transfection reagent was mixed in serum-free and antibiotic-free DMEM (50 μL) at a ratio of 3:1 (3 μL of Fastfect TM Dilute the transfection reagent to 1 μg of DNA) and vortex quickly and centrifuge briefly. TM The / DMEM mixture was added to the DNA mixture and vortexed briefly and centrifuged briefly. TM The / DMEM / DNA mixture was incubated at room temperature for 15-20 minutes and then added to the cells (100 μL per well). The cells were then incubated at 37°C and 5% CO2 for 5 hours. The medium was then replaced with complete medium (with serum) and further incubated at 37°C and 5% CO2 for 24-48 hours. The cells were then observed under a fluorescence microscope to observe mCherry TM Signal.

[0816] 13.3 His-CM18-PTD4-mediated CRISPR / Cas9-NLS system delivery and plasmid DNA cleavage

[0817] Design RNA (crRNA and tracrRNA) to target the nucleotide sequence of the EMX1 gene, mCherry in the plasmid of Example 13.2 TM There is a stop codon between the GFP coding sequence.

[0818] The sequences of crRNA and tracrRNA used are as follows:

[0819]

[0820] HeLa cells were cultured and subjected to the transfection plasmid replacement assay as described in Example 13.2. Fig.39A As shown, the mCherry TM On day 2, a mixture of Cas9-NLS recombinant protein (2 μM; see Example 13.1) and RNA (crRNA and tracrRNA; 2 μM; see above) was co-incubated with 50 μM His-CM18-PTD4, and the mixture (CRISPR / Cas9 complex) was exposed to HeLa cells for 10 seconds using protocol B as described in Example 9.1. TM The double-stranded plasmid DNA was cut at the stop codon between the GFP coding sequence ( Fig.39B ), and subsequent nonhomologous repair by the cell in some cases results in removal of the STOP codon ( Fig.39C ), thereby allowing mCherry TM and GFP fluorescent protein expression in the same cells on day 3 ( Fig.39D The white triangle windows in Figures D and E indicate mCherry TM Examples of co-labeled regions between GFP and GFP.

[0821] As a positive control for the CRISPR / Cas9-NLS system, HeLa cells were cultured and co-transfected with three plasmids: a plasmid replacement (as described in Example 13.2) and an additional expression plasmid encoding the Cas9-NLS protein (Example 13.1) and crRNA / tracrRNA (Example 13.3). Typical fluorescence microscopy results are shown in Figure 13. Fig.40A Panels A and B show cells 24 hours after transfection, while panels C and D show cells 72 hours after transfection.

[0822] Fig.40E -H show the results of a parallel transfection plasmid replacement assay using 35 μM of the shuttle agent His-CM18-PTD4, as described in Figure 39. Panels E and F show cells 24 hours after transduction, while panels G and H show cells 48 hours after transduction. Panels E and G show mCherry TM Fluorescence, Figures F and H show GFP fluorescence, which is generated by the removal of the stop codon by the transduced CRISPR / Cas9-NLS complex and subsequent non-homologous repair by the cell. No significant cellular GFP fluorescence was observed in the negative control samples (i.e., cells exposed to CRISPR / Cas9-NLS complexes without any shuttle agent; data not shown).

[0823] 13.4T7E1 assay

[0824] Use Edit-R TM Synthetic crRNA positive control (Dharmacon #U-007000-05) and T7 endonuclease I (NEB, Cat #M0302S) were used for T7E1 assay. After CRISPR / Cas9 complex delivery, cells were incubated in 100 μL Phusion TM High-fidelity DNA polymerase (NEB #M0530S) was lysed in the laboratory. The cells were incubated at 56°C for 15-30 minutes and then inactivated at 96°C for 5 minutes. The plate was briefly centrifuged to collect the liquid at the bottom of the well. A 50 μL PCR sample was set up for each sample to be analyzed. The PCR sample was heated to 95°C for 10 minutes and then slowly (>15 minutes) cooled to room temperature. The PCR products (~5 μL) were then separated on an agarose gel (2%) to confirm amplification. 15 μL of each reaction was incubated with T7E1 nuclease at 37°C for 25 minutes. The entire reaction volume was immediately run with an appropriate gel loading buffer on an agarose gel (2%).

[0825] 13.5His-CM18-PTD4 and His-C (LLKK) 3 C-PTD4-mediated delivery of the CRISPR / Cas9-NLS system and cleavage of genomic PPIB sequences

[0826] A mixture consisting of Cas9-NLS recombinant protein (25 nM; Example 13.1) targeting the PPIB gene nucleotide sequence and crRNA / tracrRNA (50 nM; see below) was added with 10 μM His-CM18-PTD4 or His-C(LLKK) 3 C-PTD4 was co-incubated and incubated with HeLa cells in serum-free medium for 16 hours as described in Protocol A in Example 9.1.

[0827] The sequences of the constructed crRNA and tracrRNA and their targets are:

[0828]

[0829] After 16 hours, HeLa cells were washed with PBS and incubated in medium with serum for 48 hours.HeLa cells were harvested for T7E1 protocol assay as described in Example 13.4.

[0830] Fig.41AAgarose gel showing PPIB DNA sequence after PCR amplification. Lane A shows the PPIB DNA sequence amplified in HeLa cells without any treatment (i.e. no shuttle or Cas9 / RNA complex). Lane B: The two bands framed in white box #1 are amplified in HeLa cells using the shuttle agent His-C (LLKK). 3 C-PTD4 delivery complex followed by cleavage products of the PPIB DNA sequence by the CRIPR / Cas9 complex. Lane C: These bands show the amplified PPIB DNA sequence after incubation of HeLa cells with the Cas9 / RNA complex in the absence of a shuttle agent (negative control). Lane D: The bands in white box #2 show the amplified PPIB DNA sequence after incubation of HeLa cells with the Cas9 / RNA complex in the presence of a lipid transfection agent (DharmaFect TM Amplified PPIB DNA sequence after incubation in the presence of transfection reagent #T-20XX-01) (positive control). Similar results were obtained using the shuttle agent His-CM18-PTD4 (data not shown).

[0831] Fig.41B An agarose gel with the PPIB DNA sequence after PCR amplification is shown. The left panel shows the cleavage products of the PPIB DNA sequence amplified by the CRIPR / Cas9 complex after delivery of the complex with the shuttle His-CM18-PTD4 in HeLa cells. The right panel shows the DNA sequence amplified before the T7E1 digestion step as a negative control.

[0832] Fig.41C The left image shows an agarose gel with PPIB DNA sequence after PCR amplification. The left image shows HeLa cells with Cas9 / RNA complex in a lipid transfection reagent (DharmaFect TM Amplified PPIB DNA sequence after incubation in the presence of transfection reagent #T-20XX-01) (positive control). The right panel shows the amplified DNA sequence before the T7E1 digestion step as a negative control.

[0833] These results suggest that the shuttle agents His-CM18-PTD4 and His-C(LLKK) 3 C-PTD4 successfully delivered functional CRISPR / Cas9 complexes to the nucleus of HeLa cells, and this delivery resulted in CRISPR / Cas9-mediated cleavage of genomic DNA.

[0834] 13.6 Delivery of the CRISPR / Cas9-NLS system via different shuttle agents and cleavage of genomic HPTR sequences in HeLa and Jurkat cells

[0835] A mixture consisting of Cas9-NLS recombinant protein (2.5 μM; Example 13.1) and crRNA / tracrRNA (2 μM; see below) targeting the nucleotide sequence of the HPTR gene was incubated with 35 μM of His-CM18-PTD4, His-CM18-PTD4-His, His-C(LLKK) 3 C-PTD4 or EB1-PTD4 were co-incubated and incubated with HeLa or Jurkat cells in PBS for 2 minutes using protocol B as described in Example 9.1.

[0836] The sequences of the constructed crRNA and tracrRNA and their targets are:

[0837]

[0838] After 2 minutes, the cells were washed with PBS and incubated in medium with serum for 48 hours. The cells were harvested for T7E1 protocol assay as described in Example 13.4. Figure 46 shows an agarose gel with HPTR DNA sequence after PCR amplification and cleavage products of the amplified HPTR DNA sequence by CRISPR / Cas9 complex after delivery of the complex with different shuttle agents. Panel A shows the results in HeLa cells using the following shuttle agents: His-CM18-PTD4, His-CM18-PTD4-His and His-C(LLKK) 3 C-PTD4. Panel B shows the results of using His-CM18-PTD4 and His-CM18-L2-PTD4 in Jurkat cells. After incubation of cells with CRISPR / Cas9 complex in the absence of shuttle agent, the negative control (lane 4) shows amplified HPTR DNA sequence. RNAiMAX TM After incubation of cells with Cas9 / RNA complexes in the presence of transfection reagent ThermoFisher Product No. 13778100), the positive control (lane 5 in panels A and B) showed amplified HPTR DNA sequences.

[0839] These results indicate that the different polypeptide shuttle agents of the present invention can successfully deliver functional CRISPR / Cas9 complexes to the nuclei of HeLa and Jurkat cells, and that this delivery results in CRISPR / Cas9-mediated cleavage of genomic DNA.

[0840] Embodiment 14:

[0841] His-CM18-PTD4 allows transduction of the transcription factor HOXB4 in THP-1 cells

[0842] 14.1HOXB4-WT recombinant protein

[0843] As described in Example 1.4, human HOXB4 recombinant protein was constructed, expressed and purified from a bacterial expression system. The sequence of the resulting HOXB4-WT recombinant protein is:

[0844]

[0845] (MW = 28.54 kDa; pI = 9.89)

[0846] The starting methionine and 6x histidine tag are shown in bold.

[0847] 14.2 Real-time polymerase chain reaction (rt-PCR)

[0848] Transfer control and treated cells to separate sterile 1.5-mL tubes and centrifuge at 300 g for 5 min. Resuspend the cell pellet in an appropriate buffer to cleave the cells. Then add RNase-free 70% ethanol followed by mixing by pipetting. Transfer the cleavage to RNeasy TM Mini spin columns and centrifuge at 13000RPM for 30 seconds. After several washes with appropriate buffers and centrifugation steps, the eluate was collected in a sterile 1.5-mL test tube on ice, and the amount of RNA in each test tube was quantified using a spectrophotometer. For DNase treatment, 2 μg of RNA was diluted in 15 μL of RNase-free water. Then 1.75 μL of 10X DNase buffer and 0.75 μL of DNase were added, followed by incubation at 37°C for 15 minutes. For reverse transcriptase treatment, 0.88 μL of EDTA (50 nM) was added, followed by incubation at 75°C for 5 minutes. In a PCR tube, 0.5 μg of DNase-treated RNA was mixed with 4 μL of iScript TM Reverse transcription supermix (5X) and 20 μL of nuclease-free water were mixed. The mixture was incubated in a PCR machine with the following program: 5 minutes at 25°C, 30 minutes at 42°C, and 5 minutes at 85°C. The newly synthesized cDNA was transferred to a sterile 1.5-mL tube and diluted with 2 μL of nuclease-free water. Then 18 μL of each well was added to the qPCR machine (CFX-96 TM ) mixture was added to the PCR plate for analysis.

[0849] 14.3 HOXB4-WT transduction by His-CM18-PTD4 in THP-1 cells: dose response and viability

[0850] THP-1 cells were cultured and tested in a protein transduction assay using protocol A as described in Example 9.1. Briefly, THP-1 cells were seeded at 30,000 cells / well one day before transduction. HOXB4-WT recombinant protein (0.3, 0.9 or 1.5 μM; Example 14.1) was co-incubated with different concentrations of His-CM18-PTD4 (0, 0.5, 7.5, 0.8 or 1 μM) and then exposed to THP-1 cells for 2.5 hours in the presence of serum. The cells were subjected to real-time PCR analysis as described in Example 14.2 to measure the mRNA levels of target genes as markers of HOXB4 activity, which were then normalized to the target gene mRNA levels detected in negative control cells (no treatment) to obtain a "fold over control" value. Total RNA levels (ng / μL) were also measured as a marker of cell viability. The results are shown in Tables 14.1 and Fig.42 .

[0851] Table 14.1: From Fig.42 Data

[0852]

[0853]

[0854] These results indicate that exposure of THP-1 cells to a mixture of the shuttle agent His-CM18-PTD4 and the transcription factor HOXB4-WT for 2.5 h in the presence of serum resulted in a dose-dependent increase in mRNA transcription of the target gene. These results suggest that HOXB4-WT is successfully delivered to the nucleus of THP-1 cells in an active form, where it can mediate transcriptional activation.

[0855] 14.4 HOXB4-WT transduction in THP-1 cells by His-CM18-PTD4: time course and viability (0 to 48 hours)

[0856] THP-1 cells were cultured and tested in a protein transduction assay using protocol A as described in Example 9.1. Briefly, THP-1 cells were seeded at 30,000 cells / well one day before the first time course experiment. HOXB4-WT recombinant protein (1.5 μM; Example 14.1) was co-incubated with His-CM18-PTD4 (0.8 μM) and then exposed to THP-1 cells in the presence of serum for 0, 2.5, 4, 24, or 48 hours. The cells were subjected to real-time PCR analysis as described in Example 14.2 to measure the mRNA levels of target genes as markers of HOXB4 activity, which were then normalized to the target gene mRNA levels detected in negative control cells (no treatment) to obtain a "fold over control" value. Total RNA levels (ng / μL) were also measured as a marker of cell viability. The results are shown in Tables 14.2 and Fig.43 shown.

[0857] Table 14.2: From Fig.43 Data

[0858]

[0859]

[0860] 14.5 HOXB4-WT transduction in THP-1 cells by His-CM18-PTD4: time course and viability (0-4 hours)

[0861] THP-1 cells were cultured and tested in a protein transduction assay using protocol A as described in Example 9.1. Briefly, THP-1 cells were seeded at 30,000 cells / well one day before the first time course experiment. HOXB4-WT recombinant protein (0.3 μM; Example 14.1) was co-incubated with His-CM18-PTD4 (0.8 μM) and then exposed to THP-1 cells in the presence of serum for 0, 0.5, 1, 2, 2.5, 3, or 4 hours. The cells were subjected to real-time PCR analysis as described in Example 14.2 to measure the mRNA levels of target genes as markers of HOXB4 activity, which were then normalized to the target gene mRNA levels detected in negative control cells (no treatment) to obtain a "fold over control" value. Total RNA levels (ng / μL) were also measured as a marker of cell viability. The results are shown in Tables 14.3 and Fig.44 .

[0862] Table 14.3: From Fig.44 Data

[0863]

[0864] 14.6 HOXB4-WT transduction in HeLa cells by His-CM18-PTD4: immunolabeling and microscopy

[0865] As described in Example 9.1, recombinant HOXB4-WT transcription factor (25 μM; Example 14.1) was co-incubated with 35 μM His-CM18-PTD4 and exposed to HeLa cells for 10 seconds using protocol B. After 30 minutes of incubation to allow transduced HOXB4-WT to accumulate in the nucleus, cells were fixed, permeabilized, and immunolabeled as described in Example 3.2a. Mouse anti-HOXB4 monoclonal primary antibody (Novus Bio #NBP2-37257) was diluted 1 / 500 and anti-mouse secondary antibody Alexa Fluor was diluted 1 / 1000. TM -594 (Abcam #150116) labeled HOXB4-WT. The nucleus was labeled with DAPI. As described in Example 3.2, cells were observed by bright field and fluorescence microscopy at magnifications of 20x and 40x, and sample results are shown in Figure 45. Colocalization was observed between nuclear markers (Figures A and C) and HOXB4-WT markers (Figures B and D), indicating that HOXB4-WT was successfully delivered to the nucleus after 30 minutes in the presence of the shuttle agent His-CM18-PTD4. White triangular windows show examples of colocalized areas between cell nuclei (DAPI) and HOXB4-WT immunolabeling.

[0866] 14.7 HOXB4-WT transduction in THP-1 cells by different shuttle agents: dose response and viability

[0867] THP-1 cells were cultured and tested in the protein transduction assay using protocol A as described in Example 9.1. Briefly, THP-1 cells were seeded at 30 000 cells / well one day before the first time course experiment. HOXB4-WT recombinant protein (1.5 μM; Example 14.1) was incubated with the shuttle agents His-CM18-PTD4, TAT-KALA, EB1-PTD4, His-C(LLKK) 3 C-PTD4 and His-CM18-PTD4-His were co-incubated at 0.8 μM and then exposed to THP-1 cells in the presence of serum for 2.5 hours. The cells were subjected to real-time PCR analysis as described in Example 14.2 to measure the mRNA levels of the target genes as markers of HOXB4 activity, which were then normalized to the target gene mRNA levels detected in negative control cells (no treatment) to obtain a "fold over control" value. Total RNA levels (ng / μL) were also measured as a marker of cell viability. The results are shown in Tables 14.4 and Fig.47 shown.

[0868] Table 14.4: From Fig.47 Data

[0869]

[0870] Embodiment 15:

[0871] In vivo delivery of GFP-NLS in the rat parietal cortex by His-CM18-PTD4

[0872] The shuttle agent His-CM18-PTD4 was tested for its ability to deliver GFP-NLS in vivo in the nucleus of rat brain cells.

[0873] In a separate sterile 1.5-mL tube, the shuttle agent His-CM18-PTD4 was diluted in sterile distilled water at room temperature. GFP-NLS, used as the load protein, was then added to the shuttle agent, and if necessary, sterile PBS was added to obtain the desired concentration of shuttle agent and load in a final volume sufficient for injection in the rat brain (e.g., 5 μL per brain injection site). The shuttle agent / load mixture was used immediately in the experiment. A negative control was included in the experiment, which corresponds to the injection of GFP-NLS alone.

[0874] Bilateral injections were performed in the parietal cortex of three rats. In the left parietal cortex (ipsilateral), a mixture consisting of the shuttle agent (20 μM) and GFP-NLS (20 μM) was injected, while in the right parietal cortex (contralateral), only GFP-NLS (20 μM) was injected as a negative control. For surgical procedures, mice were anesthetized with isoflurane. The animals were then placed in a stereotaxic frame, and the skull surface was exposed. Two holes were drilled at appropriate sites to allow bilateral infusion of the shuttle agent / load mixture or GFP-NLS alone (20 μM) using a 5 μL Hamilton syringe. Anterior-posterior (AP), lateral (L), and dorsal-ventral (DV) coordinates are relative to bregma: (a) AP + 0.48 mm, L ± 3 mm, V – 5 mm; (b) AP – 2 mm, L ± 1.3 mm, V – 1.5 mm; (c) AP – 2.6 mm, L ± 1.5 mm, V – 1.5 mm. The volume of the shuttle / load mixture or load alone was 5 μL per injection site and the injection was performed over 10 minutes. Afterwards, the experimenter waited for 1 minute before removing the needle from the brain. All measures were performed before, during and after the surgery to reduce pain and discomfort to the animals. The animals were sacrificed 2 h after the surgery by perfusion with paraformaldehyde (4%) and the brains were collected and prepared for microscopic analysis. The experimental procedures were approved by the Animal Care Committee in accordance with the guidelines of the Canadian Council on Animal Care.

[0875] Dorsal-ventral rat brain sections were collected and analyzed by fluorescence microscopy. Fig.48Shown at (A) 4x, (C) 10x and (D) 20x magnification. The injection site is located in the deepest layer of the parietal cortex (PCx). In the presence of the shuttle agent His-CM18-PTD4, GFP-NLS diffuses in the nuclei of PCx, corpus callosum (Cc) and striatum (Str) (white curves indicate restrictions between brain structures). Figure B shows the stereotactic coordinates of the injection site (black arrow) from the rat brain atlas of Franklin and Paxinos. Injection of GFP-NLS in the presence of His-CM18-PTD4 was performed in the left part of the brain, and the negative control (injection of GFP-NLS only) was performed in the contralateral part. The black circles and black lines on Figure B show the areas observed in the fluorescent photos (A, C and D).

[0876] This experiment demonstrates the delivery of cells loaded with GFP-NLS after stereotaxic injection in the parietal cortex of rats in the presence of the shuttle agent His-CM18-PTD4. The results show that GFP-NLS is delivered in the nuclei at the dorsal level from the deep layers of the top cortex (injection site) to the corpus callosum and striatum (putamen). In contrast, GFP-NLS was only locally detected around the injection site in the negative control. This experiment shows that the shuttle agent induces nuclear delivery of the injection site (parietal cortex) load and diffuses through adjacent brain regions (corpus callosum and striatum rat brain).

[0877] Embodiment A:

[0878] Physicochemical properties of domain-based peptide shuttles

[0879] Initially, a variety of different peptides were screened with the goal of identifying polypeptide-based shuttle agents that could deliver independent polypeptide cargo intracellularly to the cytosol / nucleus of eukaryotic cells. On the one hand, these large-scale screening efforts led to the discovery of domain-based peptide shuttle agents (see Examples 1-15), which comprise an endosome leakage domain (ELD) operably linked to a cell-penetrating domain (CPD), and optionally one or more histidine-rich domains that can increase the transduction efficiency of independent polypeptide cargo in eukaryotic cells, allowing the cargo to enter the cytosol / nuclear compartment. On the contrary, these screening efforts revealed that some peptides had no or low polypeptide cargo transduction capacity, excessive toxicity and / or other undesirable properties (e.g., poor solubility and / or stability).

[0880] Based on these empirical data, the physiochemical properties of successful, less successful, and failed peptides were compared to better understand the common features of the more successful shuttle agents. The method involves manually stratifying different peptides according to their transduction performance, taking into account: (1) their solubility / stability / ease of synthesis; (2) their ability to promote calcein endosomal escape (e.g., see Example 2); (3) their ability to deliver one or more types of independent polypeptide cargo intracellularly, as assessed by flow cytometry in different types of cells and cell lines (e.g., primary, immortalized, adherent, suspension, etc.) and under different transduction protocols (e.g., see Examples 3-6 and 8-15); and (4) the ability to deliver polypeptide cargo to the cytosol and / or nucleus under different transduction protocols, increased transcriptional activity (e.g., transcription factor cargo) or genome editing ability (e.g., for nuclease cargo, such as CRISPR / Cas9 or CRISPR / Cpf1), and toxicity to different types of cells and cell lines (e.g., primary, immortalized, adherent, suspension, etc.), as assessed by fluorescence microscopy (e.g., fluorescently labeled cargo) (e.g., see Examples 3-6 and 8-15).

[0881] In parallel with the manual processing described above, for a given fluorescently labeled payload (GFP, GFP-NLS or fluorescently labeled antibody) and cell line, the transduction capacity and cytotoxicity of each peptide were combined into a single "transduction score" as a further screening tool, which was calculated as follows: [(highest percent transduction efficiency of a given peptide in a cell type observed by flow cytometry) x (percent viability of the peptide in the tested cell line)] / 1000, giving a total transduction score for a given cell type and peptide payload between 0 and 10. These analyses identified domain-based peptides with transduction scores ranging from approximately 8 (e.g., for successful domain-based peptide shuttles) to as low as 0.067 (e.g., for single-domain negative control peptides).

[0882] The manual control and "transduction score" based analysis described above revealed many parameters that are common to many successful domain-based shuttles. Some of these parameters are listed in Table A1. An example of a "transduction score" based analysis in HeLa cells using GFP as a polypeptide cargo is shown in Table A2. Other transduction score based analyses using cell lines other than HeLa and polypeptide cargoes other than GFP were also performed, but are not shown here for the sake of brevity.

[0883] No successful shuttle agents were found to be less than 20 amino acid residues in length (see parameter 1 in Tables A1 and A2). The four amino acids alanine, leucine, lysine and arginine are the main and most recurrent residues in most successful shuttle agents (35-85% of the residues of the peptide; see parameter 10). These residues determine the α-helical structure and amphipathic properties of these peptide sequences (parameters 2-5). There is usually a balance between the percentage of A / L residues (15-45%) and K / R residues (20-45%) in the shuttle agents (parameters 11, 12 and 14), and the percentage of negatively charged residues is often found to be no greater than 10% (parameter 14). In contrast, the 16 other amino acid residues (besides A, L, K and R) usually represent 10-45% of the shuttle agents (parameter 15). Successful shuttling agents typically have a predicted isoelectric point (pI) between 8-13 (parameter 7) and a predicted net charge greater than or equal to +4 (parameter 6), with dCM18-TAT-Cys having a predicted net charge as high as +26. Hydrophobic residues (A, C, G, I, L, M, F, P, W, Y, V) typically comprise 35-65% of the shuttling agent and neutral hydrophilic residues (N, Q, S, T) typically represent 0-30% (parameters 8 and 9).

[0884] As shown in Table A2, the most successful shuttle agents (e.g., transduction scores above 5.0) generally have few parameters outside the ranges listed in Table A1. However, significant increases in transduction efficiency were also observed for shuttle agents that did not meet several parameters, depending on, for example, the extent to which the unmet parameters fell outside the recommended ranges, and / or whether other parameters were close to the intermediate recommended ranges. Thus, shuttle agents with several parameters falling within the "optimal" range can compensate for other parameters that fall outside the recommended ranges. As described above, peptides shorter than 20 amino acids did not show any significant transduction ability (e.g., transduction scores less than 0.4), regardless of how many other parameters were met. Among peptides greater than 20 amino acids in length and having transduction scores less than 0.4, VSVG-PTD4 (score 0.35) failed to meet six parameters, while JST-PTD4 (score 0.083) failed to meet ten parameters. KALA (score of 0.12) failed to meet four parameters, with parameters 11 and 14 far outside the recommended ranges, reflecting the excess of A / L residues and the large imbalance between the percentages of A / L and L / R residues. It should be understood that the transduction score ranges presented in Table A2 are arbitrarily selected, and other ranges may be selected and are within the scope of the present specification.

[0885] Table A1. General physicochemical properties of successful domain-based peptide shuttles

[0886]

[0887]

[0888] Table A2. Physicochemical properties of domain-based peptides stratified by transduction score (in HeLa cells using GFP and GFP-NLS as cargo)

[0889]

[0890]

[0891] Y = yes; N = no; Unit = value falls within the parameter range listed in Table A1; Unit=values ​​fall outside the parameter ranges listed in Table A1. His-LAH4-PTD4 produced a transduction score higher than 5.0, but was excluded from this analysis because the intracellular GFP fluorescence pattern was observed as punctate by fluorescence microscopy, indicating that the GFP cargo remained trapped in the endosomes. However, it is worth noting that His-LAH4-PTD4 has several parameters that fall outside the ranges shown in Table A1 in terms of parameters 2, 3, 11, 12, 14 and 15.

[0892] Embodiment B:

[0893] Rational design of synthetic peptide shuttle agents

[0894] The parameters listed in Table A1 and empirical knowledge gained (eg, from Examples 1-15) were used to manually design the peptides listed in Table Bl to assess whether the parameters could be used to design successful peptide shuttles.

[0895] The ability of the peptides listed in Table B1 to transduce GFP-NLS load (see Example 3.4) in HeLa cells was tested using a protein transduction assay as generally described in Example 3.1a. GFP-NLS recombinant protein (10 μM) was co-incubated with 10 μM peptide and then exposed to HeLa cells for 1 minute. Flow cytometry analysis was performed on cells as described in Example 3.3. The results are shown in Tables B2 and B3. As discussed in Example A, an analysis based on "transduction score" was also performed, and the results are shown in Table B4. As described in Example 3.2, successful nuclear delivery of the transduced GFP-NLS was confirmed by fluorescence microscopy (usually only 1 minute after exposure to the peptide) (data not shown).

[0896] Peptides FSD1-FSD5 were originally designed based on the successful domain-based shuttle His CM18 PTD4-His, where peptides FSD1-FSD4 were designed to intentionally not involve one or more parameters listed in Table A1, and FSD5 was designed to involve all fifteen parameters. As can be seen in Table B2, peptides FSD1-FSD4 showed transduction efficiencies ranging from 2.45% to 37.6%. In contrast, peptide FSD5 showed high transduction efficiency (70.5%) and low toxicity (cell viability was 86%).

[0897] The α-helical conformation of FSD5 was predicted by three-dimensional modeling using PEP-FOLD, an online resource for de novo peptide structure prediction (see Fig.49C ; http: / / bioserv.rpbs.univ-paris-diderot.fr / services / PEP-FOLD / ). In contrast, the peptide VSVG-PTD4 (see Table 10.3a), which was predicted to show only 3.5% transduction efficiency, adopted a different structure, including shorter α-helices, short β-sheets (white arrows) and random coils (white invisible lines).

[0898] Fig.49A and 49B The helical wheel projection and side open cylindrical representation of FSD5 and VSVG-PTD4 shown (adapted from: http: / / rzlab.ucr.edu / scripts / wheel / wheel.cgi) illustrate the amphipathic nature of FSD5 compared to VSVG-PTD4. The geometry of each amino acid residue corresponds to its biochemical property (i.e., hydrophobicity, charge, or hydrophilicity) based on the residue side chain. One of the major differences between the two open cylindrical representations of FSD5 and VSVG-PTD4 is the presence of a highly hydrophobic core in FSD5 ( Fig.49A left and right), which is absent in VSVG PTD4. Fig.49A and 49B The cylinders in the lower middle panel represent a simplified form of the open cylindrical representation in the right panel, where: “H” represents a high hydrophobic surface area; “h” represents a low hydrophobic surface area; “+” represents a positively charged residue; and “h” represents a hydrophilic residue.

[0899] Given the high transduction efficiency of FSD5, we used this shuttle agent as a model to design peptides FSD6-FSD26. As shown in Table B2, a relatively high degree of amino acid substitutions can be made without complete loss of transduction ability as long as most of the design parameters listed in Table A1 are involved. The only peptide among FSD6-FSD26 that showed almost complete loss of transduction efficiency was FSD6, which is not expected to adopt an amphipathic α-helical structure. Interestingly, peptide FSD18 showed high toxicity in HeLa cells when used at 10 μM, but showed high transduction efficiency and relatively low toxicity when used in other types of cells (see Examples E and G), indicating that peptide toxicity can vary depending on the type of cell. Three-dimensional modeling of cells using PEP-FOLD predicted two separate α-helices for FSD18 (see Fig.49D ).

[0900] Peptides FSN1-FSN8 were designed to explore the effect on transduction efficiency without involving one or more of the design parameters listed in Table A1. For example, FSN7 showed only 3.56% transduction efficiency and was predicted by PEP-FOLD to form two β-sheets and no α-helix ( Fig.49F ).

[0901] Table B1. Manually designed synthetic peptides and shuttle agents

[0902]

[0903]

[0904] Using the command from ExPASy TM ProtParam available from the Bioinformatics Resource Portal (http: / / web.expasy.org / protparam / ) TM Online tool calculation results; pI: isoelectric point; charge: the total number of positive (+) and negative (-) charges

[0905] Table B2. Transduction of GFP-NLS in HeLa cells

[0906]

[0907]

[0908] "-" = No parameter exceeds the limits shown in Table A1.

[0909] Table B3. Transduction of GFP-NLS in HeLa cells

[0910]

[0911] Table B4. Physicochemical properties of peptides stratified by transduction score

[0912] (In HeLa cells using GFP-NLS as cargo)

[0913]

[0914]

[0915] Y = yes; N = no; Unit = value falls within the parameter range listed in Table A1; Unit = value falls outside the parameter range listed in Table A1.

[0916] The primary amino acid sequences of peptides FSD5, FSD16, FSD18, FSD19, FSD20, FSD22 and FSD23 are related as shown in the alignment below.

[0917]

[0918] Example C:

[0919] Computer-aided design of synthetic peptide shuttles

[0920] C.1 Machine Learning Assisted Design Methods

[0921] The peptides listed in Table C1 were designed using the algorithm described in the article by Sébastien Giguère et al. entitled "Machine learning-assisted design of highly active peptides for drug discovery" (Giguère et al., 2014). This computational prediction method is based on the use of algorithms based on kernel and machine learning methods (Shawe-Taylor J. and Cristianini N., 2004). These algorithms are designed to sort peptides with the greatest biological activity according to the biological effect of interest. Here, we considered all peptides tested in protein transduction assays to date and divided them into three different groups. The composition of the groups is based on the "transduction score" calculated as described in Example A. Group 1 consists of peptides that demonstrate effective cell delivery and have low toxicity; Group 2 consists of peptides that show effective cell delivery but increased toxicity; Group 3 consists of peptides that do not show any significant polypeptide load transduction ability.

[0922] The score of the peptide in each group is used as the starting data point for generating other peptide variants. The algorithm is programmed to use the peptide sequence and the score of the first group of peptides as a positive reference for predicting peptide variants with effective transduction ability. The sequences and scores of the second and third groups are included in the algorithm as negative controls to describe the search area. The peptide variants generated by the algorithm are limited to peptide variants with a length of 35 amino acids. After running, the prediction method generates 16 sequences (FSD27 to FSD42). After analyzing the sequences of these 16 sequences according to the design parameters listed in Table A1, only peptides FSD27, FSD34 and FSD40 meet all design parameters (see Table C2). Other peptide variants have one or more parameters outside those listed in Table A1.

[0923] Table C1. Synthetic peptides and shuttle agents tested by machine design

[0924]

[0925] Using the command from ExPASy TM ProtParam available from the Bioinformatics Resource Portal (http: / / web.expasy.org / protparam / ) TM Online tool calculation results; pI: isoelectric point; charge: the total number of positive (+) and negative (-) charges

[0926] Table C2: FSD27 to FSD42 sequences and properties

[0927]

[0928]

[0929] HeLa cells were cultured and tested in the protein transduction assay described in Example 3.1a. GFP-NLS recombinant protein (10 μM) was co-incubated with 10 μM peptide and then exposed to HeLa cells for 1 minute. Cells were analyzed by flow cytometry as described in Example 3.3. The results are shown in Table C3.

[0930] Table C3. Transduction of GFP-NLS in HeLa cells by synthetic peptides designed by the machine

[0931]

[0932] *Peptides demonstrating transduction efficiency greater than 10% are shown in bold.

[0933] Interestingly, the three peptides (i.e., FSD27, FSD34, and FSD40) generated using the algorithm that respected all the design parameters listed in Table A1 each exhibited a transduction efficiency of 25-33%, with cell viability ranging from 83.9%-98%. The other peptides generally exhibited a transduction efficiency below 12%, with the exception of FSD41, which had a transduction efficiency of 37% (although toxicity was higher than that of FSD27, FSD34, and FSD40). Despite using only a single parameter (i.e., the efficiency score) to program the algorithm, the results for FSD27, FSD34, and FSD40 validated the usefulness of the design parameters listed in Table A1.

[0934] C.2 Computer-assisted generation of peptide variants

[0935] A computer-aided design approach was employed to demonstrate the feasibility of designing and generating peptide variants that address most or all of the design parameters listed in Table A1. First, this approach involved manual consideration and comparison of the primary amino acid sequences of structurally diverse but successful peptide shuttles to identify a general consensus sequence that resulted in structural parameters (2), (3), and (4) (i.e., amphipathic α-helix formation, a positively charged face, and a 12%-50% highly hydrophobic core). Second, the approach involved computer-assisted random peptide sequence generation, followed by descriptor filtering to achieve a consensus sequence, as well as one or more of the design parameters (1) and (5)-(15) to generate a list of peptide variants that covered nearly all of the design parameters. This will be discussed in more detail below.

[0936] First, the primary amino acid sequences of the peptides with relatively high transduction efficiency scores shown in this article were compared using online multiple sequence alignment tools including CLUSTALW 2.1 (http: / / www.genome.jp / tools-bin / clustalw); Multiple sequence comparison by Log-Expectation (MUSCLE) (https: / / www.ebi.ac.uk / Tools / msa / muscle / ); and PRALINE (http: / / www.ibi.vu.nl / programs / pralinewww / ). The peptides selected for comparison included the following 11 peptides: His-CM18-PTD4; EB1-PTD4; His-C(LLKK) 3 C-PTD4; FSD5; FSD10; FSD19; FSD20; FSD21; FSD44; FSD46; and FSD63, but the analysis was not limited to these 11 peptides. Figure 49G11 exemplary peptides are aligned using PRALINE, where the "identity" score at the bottom of each aligned residue position represents the degree of conservation of that residue position (0 being the least conserved and 10 being the most conserved). For example, relative to the alanine (A) at position 29, Figure 49G is conserved in all 11 peptides shown in , and this was assigned an "identity" score of 10. This multiple sequence analysis of the peptide libraries described herein (and others) revealed the following general structure:

[0937] (a) [X1]-[X2]-[Linker]-[X3]-[X4] (Formula 1);

[0938] (b) [X1]-[X2]-[Linker]-[X4]-[X3] (Formula 2);

[0939] (c) [X2]-[X1]-[Linker]-[X3]-[X4] (Formula 3);

[0940] (d) [X2]-[X1]-[Linker]-[X4]-[X3] (Formula 4);

[0941] (e) [X3]-[X4]-[Linker]-[X1]-[X2] (Formula 5);

[0942] (f) [X3]-[X4]-[Linker]-[X2]-[X1] (Formula 6);

[0943] (g) [X4]-[X3]-[Linker]-[X1]-[X2] (Formula 7); or

[0944] (h) [X4]-[X3]-[Linker]-[X2]-[X1] (Formula 8),

[0945] Where [X1], [X2], [X3], [X4] and [Connector] are defined as follows:

[0946] Table C4

[0947]

[0948]

[0949] Secondly, a script was designed and constructed in the programming language Python to randomly generate and filter sequences with respect to all parameters (except the predicted isoelectric point (pI, parameter 7) because the source code for calculating this parameter was not available at the time of preparation of this example). The structural parameters 2, 3, 4 (amphipathic α-helix, positively charged surface and highly hydrophobic core) described in Table A1 were involved in the code by inputting Formulas 1 to 8 and the consensus sequence shown in Table C4 (appropriate alternation of hydrophobic, cationic, hydrophilic, Ala and Gly amino acids in the sequence), and the biochemical parameters (1), (5), (6) and (8)-(15) described in Table A1 were included separately in the code to generate 10,000 variant peptide sequences. These variant peptide sequences correspond to SEQ ID NOs: 243-10 242.

[0950] Embodiment D:

[0951] Rationally designed peptides promote the escape of endosome-trapped calcein

[0952] Calcein endosomal escape assays were performed as generally described in Example 2 and characterized by fluorescence microscopy (data not shown) and flow cytometry (results for FSD5 are shown below). FSD18 showed similar results to FSD5 (data not shown).

[0953] Table D1: Calcein endosomal escape assay

[0954]

[0955] Results from fluorescence microscopy and flow cytometry experiments demonstrated that the rationally designed peptide shuttles promoted the escape of endosomally trapped calcein in a dose-dependent manner, similar to domain-based peptide shuttles.

[0956] Embodiment E:

[0957] Rationally designed peptides increase transduction efficiency in different cell types

[0958] Prior to characterization by flow cytometry (Example 3.3) and fluorescence microscopy (Example 3.2), protein transduction assays of different cell types were performed as generally described in Example 3.1a (adherent cells) or Example 3.1b (suspension cells) using the indicated concentrations of rationally designed peptides, 10 μM GFP-NLS as a load, and at the indicated times. The results of flow cytometry are shown in the table below. Successful delivery of GFP-NLS to the nucleus was verified by fluorescence microscopy (data not shown).

[0959] Table E1: GFP-NLS transduction in HeLa cells

[0960]

[0961]

[0962] Table E2: GFP-NLS transduction in HCC-78 cells (human non-small cell lung cancer)

[0963]

[0964] Table E3: GFP-NLS transduction in NCI-H196 cells (human small cell lung cancer)

[0965]

[0966] Table E4: GFP-NLS transduction in THP-1 cells

[0967]

[0968]

[0969] Table E5. GFP-NLS transduction in various suspension cells

[0970]

[0971] * Quantification of negative controls ("no peptide") was similar for all cell lines tested. Therefore, data (*) represent the mean of "no peptide" controls for all cell lines tested.

[0972] Example F:

[0973] Rationally designed peptide shuttles enable transduction of antibodies

[0974] F.1 Transduction of fluorescently labeled antibodies in HeLa cells via FSD5

[0975] Protein transduction assays were performed as generally described in Example 3.1, using peptide FSD5 and antibodies as loading, and after incubation for 1 minute, were then characterized by fluorescence microscopy (Example 3.2). Figure 50 shows goat anti-mouse IgG H&L (Alexa Fluor 500, 100 μM) delivered in HeLa cells by peptide FSD5 (8 μM). 488) and goat anti-rabbit IgG H&L (Alexa The results of cytoplasmic transduction of AlexaFluor 594Ab ( Fig.50A ); for Alexa Fluor488Ab, the magnifications were 10x and 20x (respectively Fig.50B and 50C). Bright field and fluorescence images of living cells are shown in the upper and lower panels, respectively.

[0976] The following experiments demonstrate that other FSD peptides can also deliver functional antibodies: an anti-NUP98 antibody that labels the nuclear membrane, and two anti-active caspase 3 antibodies that bind and inactivate the pro-apoptotic caspase 3 protein. The delivery, microscopy, and cell immunolabeling protocols are described in Example 3.

[0977] F.2 Transduction of anti-NUP98 antibodies in HeLa cells via FSD19

[0978] Anti-NUP98 antibody (10 μg) was co-incubated with 7.5 μM FSD19 and exposed to HeLa cells for 4 h. The cells were washed, fixed with 4% paraformaldehyde, and stained with 0.1% Triton TM Permeabilization and fluorescently labeled (Alexa TM Fluor 488) goat anti-rat antibody labeling. Antibodies bound to the nuclear membrane and nucleus were observed by fluorescence microscopy at 20x (upper panel) and 40x (lower panel). Fig.50D As shown, green fluorescence signals emanate from the nuclear membrane (left panel) and overlap with Hoechst staining (right panel), demonstrating that the anti-NUP98 antibody retains its functionality within cells after its transduction.

[0979] F.3 Transduction of two functional anti-active caspase 3 antibodies by FSD23 in THP-1 and Jurkat cells: quantification by cleaved PARP assay by ELISA

[0980] Monoclonal (mAb) and polyclonal (pAb) anti-active caspase 3 antibodies (2 μg) were co-incubated with THP-1 and Jurkat cells in the presence of 7.5 μM FSD23 for 5 minutes. The anti-apoptotic effect of each antibody was assessed by the level of caspase 3-activated apoptosis using an ELISA cleaved PARP assay and quantified by spectrometry as described below.

[0981] On the day of the experiment, cells in the exponential growth phase were harvested, centrifuged (400 g, 3 minutes) and resuspended in serum-free RPMI (500,000 cells per well in 150 μL) in a 96-well plate. The cells were centrifuged and incubated for 5 minutes with a mixture consisting of the peptide to be tested (7.5 μM) and 2 μg of the antibody to be transduced. The cells were centrifuged and resuspended in RPMI containing serum in a 24-well plate at 37°C for 1 hour. Actinomycin D (2 μg / mL), a cytotoxic inducer of apoptosis, was incubated with the cells for 4 hours. The cells were washed with cold PBS and tested using the PARP (cleaved) [214 / 215] Human ELISA kit (ThermoFisher) according to the manufacturer's instructions and then analyzed spectroscopically. The results are shown in Table F1.

[0982] Table F1. Cleaved PARP ELISA after transduction of anti-TNF or anti-active caspase 3 antibodies in THP 1 and Jurkat cells by FSD23

[0983] Determination

[0984]

[0985] Results in THP-1 and Jurkat cells showed that FSD23 successfully transduced functional anti-active caspase 3 antibodies. Anti-TNF antibodies were used as nonspecific negative controls and actinomycin D was used as a cytotoxic inducer of apoptosis. In the absence of actinomycin D ("-"), delivery of each anti-active caspase 3 mAb and pAb resulted in a reduction in basal levels of apoptosis compared to the "anti-TNF" control, with no discernible effect of delivering anti-TNF antibodies on cell viability. In the presence of actinomycin D ("+"), after delivery of both anti-active caspase 3 antibodies with FSD23, the resulting apoptosis was reduced compared to the "anti-TNF" control.

[0986] Example G:

[0987] Rationally designed peptide shuttles enable transduction of CRISPR-based genome editing complexes

[0988] We tested the ability of rationally designed peptide shuttles to deliver functional CRISPR-based genome editing complexes to the eukaryotic nucleus using standard DNA cleavage assays. These assays were used to measure CRISPR / Cas9- and CRISPR / Cpf1...

Claims

1. A synthetic peptide shuttle agent, which is: (1) A peptide soluble in aqueous solution, having a minimum length of 20 amino acids and a maximum length of 150 amino acids, the peptide comprising (2) an amphipathic α-helical motif having (3) a positively charged hydrophilic outer surface, based on an α-helix with a rotation angle of 100 degrees between consecutive amino acids and / or an α-helix with 3.6 residues per turn, wherein the positively charged hydrophilic outer surface comprises (a) at least two adjacent positively charged K and / or R residues when projected in the helical wheel; and (b) a six-adjacent stretch of three to five K and / or R residues when projected in the helical wheel; (4) a hydrophobic outer surface, based on an open cylindrical representation of an alpha-helix with 3.6 residues per turn, comprising a highly hydrophobic core consisting of spatially adjacent L, I, F, V, W and / or M amino acids representing 12% to 50% of the amino acids of the peptide, wherein based on an alpha-helix with a rotation angle of 100 degrees between consecutive amino acids and / or an alpha-helix with 3.6 residues per turn, the hydrophobic outer surface comprises: (a) at least two adjacent L residues when projected on the helical wheel; and / or (b) a stretch of ten adjacent residues when projected on the helical wheel comprising at least five hydrophobic residues selected from the group consisting of L, I, F, V, W and M; At least six of the following parameters (5) to (15) must be met: (5) The hydrophobic moment (μ) of the peptide is 3.5 to 11; (6) the peptide has a predicted net charge of at least +4 at physiological pH; (7) the isoelectric point (pI) of the peptide is 8 to 13; (8) The peptide consists of 35% to 65% of any combination of amino acids A, C, G, I, L, M, F, P, W, Y and V; (9) The peptide consists of any combination of 0% to 30% of the amino acids N, Q, S and T; (10) The peptide consists of 35% to 85% of any combination of amino acids A, L, K or R; (11) The peptide consists of any combination of 15% to 45% of amino acids A and L, provided that at least 5% of L is present in the peptide; (12) The peptide consists of 20% to 45% of any combination of amino acids K and R; (13) The peptide consists of any combination of amino acids D and E at 0% to 10%; (14) the difference between the percentage of A and L residues in the peptide (%A+L) and the percentage of K and R residues in the peptide (%K+R) is less than or equal to 10%; and (15) The peptide consists of 10% to 45% of any combination of amino acids Q, Y, W, P, I, S, G, V, F, E, D, C, M, N, T and H, and wherein the synthetic peptide shuttle agent has at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95% identity to the amino acid sequence of any one of SEQ ID NOs: 113, 104, 105, 107, 108, 110, 111, 112, 114-131, 133-135, 138, 140, 142, 145, 148, 151, 152, 169-242 and 243-10242.

2. The synthetic peptide shuttle agent according to claim 1, wherein the synthetic peptide shuttle agent involves at least seven, at least eight, at least nine, at least ten, or all of the parameters (5) to (15).

3. The synthetic peptide shuttle agent according to claim 1 or 2, wherein: (i) the shuttle agent is a peptide having a minimum length of 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acids and a maximum length of 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 60, 65, 70, 80, 90, 100, 110, 120, 130, 140, or 150 amino acids; (ii) the hydrophobic moment (μ) of the amphipathic α-helical motif is 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0 and 9.5, 9.6, 9.7, 9.8, 9.9, 10.0, 10.1, 10.2, 10.3, 10.4, 10.5, 10.6, 10.7, 10.8, 10.9 or 11.0; (iii) the amphipathic α-helical motif comprises a positively charged hydrophilic outer surface, the hydrophilic outer surface comprising: (a) at least three or four adjacent positively charged K and / or R residues in helical wheel projection; (iv) the amphipathic α-helical motif comprises a hydrophobic outer surface, based on an α-helix with a rotation angle of 100 degrees between consecutive amino acids and / or an α-helix with 3.6 residues per turn, wherein the hydrophobic outer surface comprises: (a) at least two adjacent L residues when projected on the helical wheel; and / or (b) a stretch of ten adjacent residues when projected on the helical wheel comprising at least five hydrophobic residues selected from the group consisting of: L, I, F, V, W and M; (v) the hydrophobic outer surface comprises a highly hydrophobic core composed of spatially adjacent L, I, F, V, W and / or M amino acids representing 12.5%, 13%, 13.5%, 14%, 14.5%, 15%, 15.5%, 16%, 16.5%, 17%, 17.5%, 18%, 18.5%, 19%, 19.5% or 20% to 25%, 30%, 35%, 40% or 45% of the amino acids of the peptide; (vi) the hydrophobic moment (μ) of the peptide is between 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0 on the lower limit and 9.5, 9.6, 9.7, 9.8, 9.9, 10.0, 10.1, 10.2, 10.3, 10.4, 10.5 on the upper limit; (vii) the peptide has a predicted net charge of between +4, +5, +6, +7, +8, +9, to +10, +11, +12, +13, +14, or +15; (viii) the peptide has a predicted pi of 10-13; or (ix) Any combination of (i) to (viii).

4. The synthetic peptide shuttle agent according to any one of claims 1 to 3, wherein the synthetic peptide shuttle agent satisfies at least one, at least two, at least three, at least four, at least five, at least six or all of the following parameters: (8) The peptide consists of any combination of amino acids A, C, G, I, L, M, F, P, W, Y, and V, 36% to 64%, 37% to 63%, 38% to 62%, 39% to 61%, or 40% to 60%; (9) the peptide consists of any combination of amino acids N, Q, S and T from 1% to 29%, 2% to 28%, 3% to 27%, 4% to 26%, 5% to 25%, 6% to 24%, 7% to 23%, 8% to 22%, 9% to 21% or 10% to 20%; (10) The peptide consists of any combination of 36% to 80%, 37% to 75%, 38% to 70%, 39% to 65%, or 40% to 60% of amino acids A, L, K, or R; (11) The peptide consists of any combination of amino acids A and L from 15% to 40%, 20% to 40%, 20% to 35%, or 20% to 30%; (12) The peptide consists of any combination of amino acids K and R from 20% to 40%, 20% to 35%, or 20% to 30%; (13) The peptide consists of 5% to 10% of any combination of amino acids D and E; (14) the difference between the percentage of A and L residues in the peptide (%A+L) and the percentage of K and R residues in the peptide (%K+R) is less than or equal to 9%, 8%, 7%, 6% or 5%; and (15) The peptide consists of any combination of 15% to 40%, 20% to 35% or 20% to 30% of amino acids Q, Y, W, P, I, S, G, V, F, E, D, C, M, N, T and H. 5 . The synthetic peptide shuttle agent according to any one of claims 1 to 4 , wherein the synthetic peptide shuttle agent further comprises a flexible linker domain enriched in serine and / or glycine residues.

6. The synthetic peptide shuttle agent of any one of claims 1 to 4, wherein the synthetic peptide shuttle agent comprises the amino acid sequence of any one of SEQ ID NO: 113, 104, 105, 107, 108, 110, 111, 112, 114-131, 133-135, 138, 140, 142, 145, 148, 151, 152, 169-242 and 243-10242.

7. A synthetic peptide shuttle agent comprising, or consisting of, an amino acid sequence having at least 80%, 85%, 90% or 95% identity to the amino acid sequence of any one of SEQ ID NOs: 113, 104, 105, 107, 108, 110, 111, 112, 114-131, 133-135, 138, 140, 142, 145, 148, 151, 152, 169-242, and 243-10242.

8. The synthetic peptide shuttle agent of claim 7, wherein the synthetic peptide shuttle agent comprises or consists of the amino acid sequence of any one of SEQ ID NO: 113, 104, 105, 107, 108, 110, 111, 112, 114-131, 133-135, 138, 140, 142, 145, 148, 151, 152, 169-242, and 243-10242.

9. A composition comprising a synthetic peptide shuttle as defined in any one of claims 1 to 8, and a polypeptide cargo for delivery from the extracellular space to the cytosol and / or nucleus of a target mammalian cell.

10. Use of a synthetic peptide shuttle agent as defined in any one of claims 1 to 8 in the preparation of a medicament for delivering a polypeptide cargo from the extracellular space to the cytosol and / or nucleus of a target mammalian cell in vitro or in vivo, wherein the synthetic peptide shuttle agent is used at a concentration of at least 2.5 μM, and wherein the synthetic peptide shuttle agent is used at a concentration sufficient to increase the transduction efficiency of the polypeptide cargo to the cytosol and / or nucleus of a target mammalian cell compared to the absence of the synthetic peptide shuttle agent.

11. A mammalian cell comprising the synthetic peptide shuttle agent according to any one of claims 1 to 8.